



VALENCIAN ONCOLOGY
INSTITUTE FOUNDATION

ACTIVITY REPORT 2025



www.ivo.es

ACTIVITY REPORT 2025



FUNDACIÓN
INSTITUTO VALENCIANO
DE ONCOLOGÍA

INDEX

1. PRESENTATION	05	Neurosurgery	84
Board Of Trustees Of The Foundation	09	Ear, Nose And Throat (Ent)	85
Organisational Chart	11	Medical Physics And Radiation Protection	87
Hospital Committee	13	Radiology	89
		Oncology Well-being Unit	91
2. CLINICAL ACTIVITY REPORT	21	Physical Activity	92
Early Diagnosis Unit Ii Marqués Del Turia	23	Physiotherapy	93
Early Diagnosis Of Breast Cancer	23	Nutrition	94
Early Diagnosis Of Gynaecological Cancer	24	Mental Health Unit	95
I-ELCAP Early Detection Unit	25	Clinical Documentation And Admissions Unit (CDAU)	96
Early Diagnosis Of Prostate Cancer(Opportunistic Screening)	26	Emergency Department (ED)	100
Cancer Care	27	Urology	101
Distribution Of Conditions	28	Nursing	103
Outpatient Activity	32	Quality	104
Day Hospital Activity	34		
Hospitalisation	35	4. SCIENTIFIC REPORT	105
Surgical Activity	37	Pathology	107
Global Activity Indicators	38	Anaesthesia, Resuscitation, And Pain Management	115
		Molecular Biology	117
3. CLINICAL ACTIVITY BY SERVICE	39	General Surgery	121
Pathology	41	Thoracic Surgery	125
Anaesthesia, Resuscitation, And Pain Management	43	Dermatology	127
Molecular Biology	47	Pharmacy	142
Cardiology	49	Gynaecology	143
General And Gastrointestinal Surgery	51	Gastroenterology Unit	144
Thoracic Surgery	53	Clinical Laboratory And Microbiology	145
Dermatology	55	Internal Medicine	149
Gastroenterology Unit	57	Nuclear Medicine	151
Pharmacy	58	Neurology	152
Gynaecology	65	Medical Oncology	153
Clinical Laboratory And Microbiology	67	Hospital At Home	182
Internal Medicine	69	Haematology	185
Nuclear Medicine	70	Radiation Oncology	188
Neurology	72	Ear, Nose And Throat (ENT)	191
Medical Oncology	73	Medical Physics And Protection	193
Hospital At Home	75	Radiology	197
Haematology And Autologous Haematopoietic Stem Cell Transplant Unit	77	Clinical Documentation And Admissions Unit (CDAU)	201
Radiation Oncology	79	Emergencies	203
Radiation Oncology In Alcoy	81	Urology	204
Radiation Oncology In Cuenca	82	Nursing	209
Radiation Oncology In Valencia	83	Oncology Well-being Unit	210



PRESENTATION

1.



FUNDACIÓN
INSTITUTO VALENCIANO
DE ONCOLOGÍA

GENERAL MANAGER

I hereby present the Activity Report of the Valencian Institute of Oncology Foundation (IVO) for 2025.

This year has been marked by significant advances that reinforce our commitment to excellence in healthcare, research, and training, but also by moments of remembrance and tribute. Among these, we were deeply saddened by the passing of Mr Manuel Llombart Bosch, the IVO's first Director General and one of its founding members. His humanity, dedication, commitment, and strategic vision, aimed at creating an integrated and pioneering cancer centre, were decisive in laying the foundations of our institution.

As this document shows, in 2025, the IVO treated more than 32,500 patients, of whom nearly 8,000 were newly diagnosed cases. These figures reflect our activity's sustained growth and, above all, demonstrate the trust placed in this institution by the people of Valencia, year after year. That trust is what drives us to keep improving every day, offering the best possible care, both human and professional.

We are closing out a year in which we have once again been recognised, for the sixth consecutive year, as one of the world's best cancer hospitals by *Newsweek* magazine. Furthermore, we have obtained EBU certification as a benchmark training centre for bladder and prostate tumours, and high-level certification under the Spanish National Security Framework (ENS), which confirms our commitment to the highest standards of patient data protection.

Alongside these milestones, in 2025:

- Significant improvements have been made, such as the refurbishment and relocation of the Medical Oncology Department, the comprehensive refurbishment of the Pathology Laboratory with the incorporation of advanced technology, and the expansion of the Well-being Unit, thereby strengthening comprehensive patient care.
- We have performed over 5,400 surgical procedures. Of these, 671 were carried out using robotic surgery with the Da Vinci Xi system, representing 15% more than in 2024.


Looking ahead, 2026 promises to be a particularly exciting year. We will begin a new phase of expansion for the hospital complex, a strategic project that will bring all healthcare facilities together in a single location, optimise flows and resources, and enhance the quality and efficiency of care for our patients.

Furthermore, 2026 will mark the 50th anniversary of the Valencian Institute of Oncology. In this half century, the IVO has evolved from a centre founded to 'help patients die with dignity'—for those affected by a disease with few treatment options—into a national and international benchmark in comprehensive and specialised care for cancer patients.

To mark this milestone, we will be unveiling our new brand identity and a slogan that will accompany us throughout the year: '50 years fighting cancer with our heart and soul'. It serves as a tribute to the professionals who have driven this institution forward for half a century. This team, across every unit and department, helps this project to flourish and has embraced the founding values of dedication, commitment, and a vocation to serving cancer patients in Valencia and their families.

I conclude with my deepest gratitude: to the professionals at the IVO for their tireless dedication, to the patients and their families for the trust they place in us every day, and to the Valencian institutions, with whom we share the responsibility of providing the best medical oncology service to society.

Manuel Llombart Fuertes
General Manager of the IVO Foundation



BOARD OF TRUSTEES OF THE FOUNDATION

PRESIDENT

Dr. Antonio Llombart Bosch

VICE-PRESIDENT

Tomás Trénor y Puig, Marquis of Turia

SECRETARY

Jaime Olleros Izard

TREASURER

Santiago Bauzá Anglada

VICE-SECRETARY

Vicente Fontestad Ballester

PATRONS OF HONOUR

Antonio Llombart Rodríguez †

Joaquín Colomer Sala †


Carlos Climent González †

Vicente Iborra Martínez †

Vicente López Merino †

Antonio Noblejas Sánchez-Migallón †

ORGANISATIONAL CHART



HOSPITAL COMMITTEES

MANAGEMENT AND MONITORING COMMITTEE

	NAME	POSITION
President	Manuel Llombart Fuertes	General Manager
Secretary	Belén Bolás Calduch	Director of Communication
Spokespersons	M. ^a José Ortega García	Deputy General Manager
	Tomás Quirós Morató	Medical Director
	Gonzalo Anaya Fernández-Albor	Chief Financial Officer (CFO)
	Ignacio Galve Castillo	Information Systems Director
	Pedro A. Gómez Gómez	Human Resources Director
	Nuria Casani Turégano	Head Nurse
	Carlos J. Andrés Blasco	Head of the Pharmacy Service
	Rodrigo Muñoz Balada	Head of the UDCA Service
	Marcos Guaita Martínez	Head of the Clinical Analysis and Microbiology Service
	Ana Calatrava Fons	Head of the Pathology Service
	M. ^a Ángeles Martínez Navarrete	Head of the Anaesthesia, Resuscitation and Pain Management Service
	Carlos Alberto Fuster Diana	Head of the General and Gastrointestinal Surgery Service
	Juan Carlos Peñalver Cuesta	Head of the Thoracic Surgery Service
	Onofre Sanmartín Jiménez	Head of the Dermatology Service
	Óscar C. Piñero Sánchez	Head of the Gynaecology Service
	Joaquín Gavilá Gregori	Head of the Medical Oncology Service
	Leoncio Arribas Alpuente	Head of the Radiation Oncology Service
	Juan Bosco Vendrell Marqués	Head of the Ear, Nose and Throat (ENT) Service
	Eugenio Sánchez Aparisi	Head of the Urology Service
	Juan L. Casanova Ramón-Borja	Head of the Radiology Service
	Vicente Enrique Miró Palau	Head of the Cardiology Service
	Vicente Crispín Contreras	Head of the Medical Physics and Radiation Protection Service
	Antonio Mancheño Álvaro	Hospital at Home Coordinator
	Marcos Tajahuerce Romera	Head of the Nuclear Medicine Service
	Francisco José Pascual Plá	Emergency Department Coordinator
	Carmen Martínez Lapiedra	Clinical Lead for Gastroenterology
	Adoración Egido González	Clinical Lead for Internal Medicine
	Nuria Nácher Alonso	Clinical Lead for the Early Diagnosis Unit
	Elena Oliete Ramírez	Well-being Unit Coordinator
Luis Bataller Alberola	Clinical Lead for Neurology	
José Antonio López Guerrero	Head of the Molecular Biology Service	

	María del Cerro Arastey	Attending Psychiatrist
	Elisa Bañuls Sendra	Physiotherapy Service
	Rocío Romero Retes	Psycho-Oncology Unit Psychologist
	Javier García Latorre	Head of Orderlies
	Ana Pérez Balaguer, María Cruz Navarro López, Isabel Gimeno Pérez, M. ^a Dolores Solís Moreno, and Amparo Devís Gamir	Employees' Council

TRANSFUSION COMMITTEE

	NAME	POSITION
President	Claudia Juliana Salazar Lozada	Head of the Transfusion Service
Secretary	Pablo López García	Legal Advisory
Spokespersons	Amparo Avaria Navalón	Attending Physician, Haematology Unit
	Tomás Quirós Morató	Medical Director
	Francisco José Pascual Plá	Attending Physician, UDCA
	Rocío Ramírez Belloch	Attending Medical Oncologist
	M. ^a Ángeles Martínez Navarrete	Head of the Anaesthesia, Resuscitation, and Pain Management Service
	Adoración Egido González	Attending Internal Medicine Physician
	Josefa Samper Hiraldo	Attending Physician, Emergency Department
	María José Juan Fita	Attending Medical Oncologist
	Nuria Casani Turégano	Head Nurse
	Amparo Fernández Martínez	ICU Nurse
	Elena Oliete Ramírez	Attending Physician, Continuing Care
	Gemma Maestre García	Laboratory Nurse Supervisor

EQUALITY COMMISSION

	NAME	POSITION
Workers' Representation	Amparo Devís Gamir	CC.OO.
	María Dolores Solís Moreno	CSIF
	Rosario Valero Valero	CC.OO.
	Tamara López Chicano	Staff Delegate in Cuenca CC.OO.
	Ramón Sanz Vidal	Staff Delegate in Alcoy CC.OO.
Company Representation	M. ^a José Ortega García	Deputy General Manager
	Pedro A. Gómez Gómez	Human Resources Director
	Pablo López García	Legal Advisory

ETHICS COMMITTEE ON RESEARCH INVOLVING MEDICINAL PRODUCTS

	NAME	POSITION
President	Esteban Morcillo Sánchez	Clinical Pharmacologist
Vice-President	Joaquín Gavilá Gregori	Specialist in Medical Oncology
Technical Secretary	Carlos J. Andrés Blasco	Pharmacist Specialising in Hospital Pharmacy
Technical Secretariat Coordinator	Bernat Navarro Aguir	Pharmacist
Spokespersons	Ismael P. Pastor Climente	Pharmacist Specialising in Hospital Pharmacy
	Ángel L. Guerrero Zotano	Specialist in Medical Oncology
	Marcos Melián Sosa	Specialist in Medical Oncology
	Sergio Sandiego Contreras	Specialist in Medical Oncology
	Lourdes Bello Luna	Graduate in Law
	M. ^a José Ortega García	Graduate in Law
	Josefa Guillem Flores	Degree in Nursing
	Elena Oliete Ramírez	Medical Specialist in Family and Community Medicine
	Julio Tudela Cuenca	Pharmacist Specialising in Clinical Analysis
	Emilia Montagud Penadés	Primary Care Pharmacist
	Luis Gómez de Membrillera Quesada	Medical Specialist in Family and Community Medicine
	David Hervás Marín	Degree in Biostatistics
	Josefina Balaguer Cusí	Lay Member
	Antonio José Revert Ventura	Medical Specialist in Radiology
	Miguel Ángel Sanz Alonso	Specialist in Haematology
	Vicente Enrique Miró Palau	Medical Specialist in Cardiology
Luis Bataller Alberola	Medical Specialist in Neurology	
Ana Fayos Fernández	Degree in Pharmacy	

BIOBANK

NAME	POSITION
Manuel Llombart Fuertes	General Manager
Ana Calatrava Fons	Head of the Pathology Service
José Antonio López Guerrero	Scientific Director of the Biobank and Head of the Molecular Biology Service
Nuria López Pérez-Madero	Documentation Technician
María Isabel Cortell Granero	Quality Technical Coordinator

HEALTH AND SAFETY COMMITTEE

	NAME	POSITION
Company Representatives	Tomás Quirós Morató	Medical Director
	M. ^a José Ortega García	Deputy General Manager
	Álvaro Minguet Calas	Head of the Maintenance Department
	Vicente Crispín Contreras	Head of the Medical Physics and Radiation Protection Service
Prevention Delegates	Josefina Larrosa Moya	Nurse
	Lucas Valero Corraliza	Histopathology Technician
	María Cruz Navarro López	Histopathology Technician
	Amparo Devís Gamir	Administrative Officer

TEACHING COMMITTEE

	NAME	POSITION
President	Onofre Sanmartín Jiménez	Head of the Dermatology Service
Secretary	Lourdes Bello Luna	Graduate in Law
Spokespersons	Marcos Melián Sosa	Tutor and Attending Medical Oncologist
	Sergio Sandiego Contreras	Tutor and Attending Medical Oncologist
	Paula Santamaría García	Tutor and Attending Radiation Oncologist
	Fátima Mayo Martínez	Tutor and Attending Dermatologist
	Vicente Crispín Contreras	Head of the Medical Physics and Radiation Protection Service
	Carlos J. Andrés Blasco	Head of the Pharmacy Service
	Ismael P. Pastor Climente	Tutor and Pharmacist Specialising in Hospital Pharmacy
	Sandra Bernabéu Castellá	Tutor and Pharmacist Specialising in Hospital Pharmacy
	Carlos Alberto Fuster Diana	Head of the General and Gastrointestinal Surgery Service
	Francisco Manchón Adsuar	Tutor and Attending Nuclear Medicine Physician
	Pilar Ferrer Peñaranda	Conselleria de Sanitat Representative
Lucía Morales López	Trainee Representative	

COMMITTEE ON PHARMACOTHERAPY IN HEALTHCARE AND CLINICAL TRIALS

	NAME	POSITION
President	Carlos J. Andrés Blasco	Pharmacist Specialising in Hospital Pharmacy
Secretary	Bernat Navarro Aguir	Degree in Pharmacy. Coordinator of the IVO Foundation's Technical Secretariat of the CEIM
Spokespersons	Ismael P. Pastor Climente	Pharmacist Specialising in Hospital Pharmacy
	Sergio Sandiego Contreras	Specialist in Medical Oncology
	David Lorente Estellés	Specialist in Medical Oncology
	Elena Oliete Ramírez	Medical Specialist in Family and Community Medicine
	Lourdes Bello Luna	Graduate in Law
	Belén Vázquez Blanco	Degree in Nursing. Coordinator of the Research Unit of the IVO Foundation
	Pablo López García	Graduate in Law
	Pilar Martínez Albaladejo	Pharmacist Specialising in Hospital Pharmacy
	Beatriz Llatas Serrano	Administrative Officer of the IVO Foundation's Technical Secretariat of the CEIM

INFECTION AND PROPHYLAXIS COMMISSION

	NAME	POSITION
President	Carlos J. Andrés Blasco	Head of the Pharmacy Service
Vice-President	Adoración Egido González	Clinical Lead for Internal Medicine
Secretary	Pablo López García	Legal Advisor
Spokespersons	M. ^a Ángeles Martínez Navarrete	Head of the Anaesthesia, Resuscitation and Pain Management Service
	Roberto Olmos Arenas	Hospital Pharmacist, Laboratory
	Ismael P. Pastor Climente	Pharmacist Specialising in Hospital Pharmacy
	Nuria Casani Turégano	Head Nurse

QUALITY AND PATIENT SAFETY COMMISSION

	NAME	POSITION
President	Tomás Quirós Morató	Medical Director
Secretary	Catalina Trenor Escuín	Quality Technician
Spokespersons	Rodrigo Muñoz Balada	Head of the UDCA Service
	Claudia J. Salazar Lozada	Attending Physician, Haematology Unit
	Nuria Casani Turégano	Head Nurse
	Carlos J. Andrés Blasco	Head of the Pharmacy Service

MEDICAL RECORDS COMMISSION

	NAME	POSITION
President	Francisco José Pascual Plá	Attending Physician, UDCA
Secretary	Catalina Trenor Escuín	Quality Technician
Spokespersons	Tomás Quirós Morató	Medical Director
	Nuria Casani Turégano	Head Nurse
	Janet Angelina Contreras Samamé	Attending Physician, Emergency Department
	Giovanni F. Vento Maggio	Attending General and Digestive Surgeon
	Eugenio Sánchez Aparisi	Head of the Radiology Service
	Raimundo Novella Cañadas	Information Systems
	Yasmina Murria Pérez	Attending Radiation Oncologist
	Joaquín Gavilá Gregori	Head of the Medical Oncology Service
	Antonio Mancheño Álvaro	Hospital at Home Coordinator
	M. ^a José Castro Boix	Head of Clinical Documentation
	Aránzazu Llavata Mayordomo	Head of Admissions
	Vicente Crispín Contreras	Head of the Medical Physics and Radiation Protection Service
	Rodrigo Muñoz Balada	Head of the UDCA Service
Pablo López García	Legal Advisor	
Laura Parra Gómez	Attending Internal Medicine Physician	

EMPLOYEES' COUNCIL

NAME	POSITION
Amparo Devís Gamir	Administrative Officer
Juana Escribá Fornés	Nurse
María Cruz Navarro López	Histopathology Technician
Ana Ferrer Rafael	Diagnostic Radiographer
Ana Pérez Balaguer	Administrative Officer
Rosario Valero Valero	Therapeutic Radiographer
Amparo Alcina Núñez	Auxiliary Nursing Care Technician
Isabel Catalá Navarro	Administrative Officer
Carlos Alberto Fuster Diana	Head of the General and Gastrointestinal Surgery Service
María Dolores Solís Moreno	Auxiliary Nursing Care Technician
Yolanda Pinar Montiel	Auxiliary Nursing Care Technician
Josefina Larrosa Moya	Nurse
María Ángeles Mayordomo Sánchez	Nurse
Lucas Valero Corraliza	Histopathology Technician
Rafael Martínez Dolz	Histopathology Technician
Estanislao Arana Fernández de Moya	Clinical Lead for Radiology
Isabel Gimeno Pérez	Auxiliary Nursing Care Technician
Tamara López Chicano	Nurse. Staff Delegate in Cuenca
Ramón Sanz Vidal	Maintenance. Staff Delegate in Alcoy



CLINICAL ACTIVITY REPORT

2.



FUNDACIÓN
INSTITUTO VALENCIANO
DE ONCOLOGÍA

EARLY DIAGNOSIS UNIT II MARQUÉS DEL TURIA

HUMAN RESOURCES

COORDINATOR

Nuria Nácher Alonso

ATTENDING PHYSICIAN

Esther García Gimeno

EARLY DIAGNOSIS OF BREAST CANCER

ACTIVITY INDICATORS


	2025	2024	Diff.	Dev. %
Women seen	15,944	16,383	-439	-3%
Cancers detected	201	164	34	21%

EARLY DIAGNOSIS OF GYNAECOLOGICAL CANCER

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Women seen	3,838	4,094	-256	-6%
Women with pathological findings	296	304	-8	-3%
Cancers detected	21	26	-5	-19%

BREAST AND GYNAECOLOGICAL PATHOLOGY



I-ELCAP EARLY DETECTION UNIT

DIAGNOSIS OF ASYMPTOMATIC LUNG CANCER

PRINCIPAL INVESTIGATOR

Eugenio Sánchez Aparisi

COORDINATOR

Esteban Mesas Plaza

PULMONOLOGIST

Encarnación Martínez Pérez

TARGET POPULATION

The lung cancer screening programme is aimed at healthy male and female subjects aged 55 years or older, with a smoking history of at least 30 pack-years, or 20–30 pack-years with additional risk factors, or former smokers who quit less than 15 years ago.

WHAT THE CONSULTATION CONSISTS OF

The consultation consists of taking a medical history and performing a low-dose CT scan without contrast. Respiratory tests are performed in the first consultation, all under the express acceptance of the subject (informed consent). This examination could be extended with additional tests if there is a suspected diagnosis.

ACTIVITY

	Cumulative from the start of activity in June 2008 to December 2025
Number of patients included	9,482
Number of follow-up visits	53,314
Number of CT scans	57,733
Number of lung cancers detected	250
Other cancers detected	567

EARLY DIAGNOSIS OF PROSTATE CANCER (OPPORTUNISTIC SCREENING)

TARGET POPULATION

Men between the ages of 50 and 75 with no history, or men aged 40 and older with a family history of prostate cancer who have a life expectancy of more than 10 years.

WHAT THE CONSULTATION CONSISTS OF

- This is a simple examination, such as a digital rectal examination,
- together with a conventional blood test for PSA. If the result is > 4 ng/ml, the patient is referred to the IVO for urinalysis and a culture. If a urinary tract infection is ruled out, a second PSA test is performed, and if it is still above 4 ng/ml, a multiparametric MRI is performed.

Based on the results of these procedures, the appropriateness of performing a transrectal or transperineal prostate biopsy with ultrasound/MRI fusion software or a mapping biopsy is discussed in the uro-radiology committee.

ACTIVITY

	Activity from July 2010 to December 2025
Number of patients included	11,982
Number of follow-up visits	41,621
Number of cancers detected	540

CANCER CARE


NUMBER OF PATIENTS TREATED

	2025	2024	Diff.	Dev. %
New patients	7,948	8,146	-198	-2%
Prevalent patients	24,576	23,518	1,058	4%
TOTAL	32,524	31,664	860	3%

NEW PATIENTS' ORIGIN


	2025	% Total
ALICANTE	1,340	17%
CASTELLÓN	164	2%
VALENCIA	6,148	77%
VALENCIAN C. TOTAL	7,652	96%
OTHER	296	4%
TOTAL	7,948	100%

NEW PATIENTS




DISTRIBUTION OF CONDITIONS

DISTRIBUTION OF CONDITIONS



TRENDS IN MALIGNANT CONDITIONS (1978-2025)



MALIGNANT CONDITIONS BY TOPOGRAPHY

	2025	2024	Diff.	Dev. %
MALIGNANT TUMOURS OF THE HEAD AND NECK				
C00 - LIP	9	7	2	29%
C01 - C02 - TONGUE	65	52	13	25%
C03 - GUM	15	15	0	0%
C04 - C05 - MOUTH	8	8	0	0%
C06 - OTHER PARTS OF THE MOUTH	18	17	1	6%
C07 - C08 - SALIVARY GLANDS	26	38	-12	-32%
C09 - C10 - OROPHARYNX AND TONSILS	59	56	3	5%
C11 - NASOPHARYNX AND CAVUM	17	19	-2	-11%
C12 - C13 - HYPOPHARYNX	19	14	5	36%
C14 - OTHER AND ILL-DEFINED SITES	14	5	9	180%
SUBTOTAL	250	231	19	8%
MALIGNANT TUMOURS OF THE DIGESTIVE SYSTEM				
C15 - OESOPHAGUS	45	41	4	10%
C16 - STOMACH	54	61	-7	-11%
C17 - SMALL INTESTINE	5	10	-5	-50%
C18 - LARGE INTESTINE	247	209	38	18%
C19 - C20 - C21 - RECTUM AND RECTOSIGMOID JUNCTION	167	191	-24	-13%
C22 - LIVER AND INTRAHEPATIC BILE DUCTS	39	25	14	56%
C23 - C24 - GALLBLADDER AND EXTRAHEPATIC BILE DUCTS	12	13	-1	-8%
C25 - PANCREAS	128	149	-21	-14%
C26 - OTHER DIGESTIVE ORGANS	1	1	0	0%
SUBTOTAL	698	700	-2	0%
MALIGNANT TUMOURS OF THE RESPIRATORY SYSTEM				
C30 - C31 - NOSE, NASAL CAVITIES, MIDDLE EAR AND SINUSES	15	17	-2	-12%
C32 - LARYNX	111	109	2	2%
C34 - TRACHEA, BRONCHI AND LUNG	734	726	8	1%
C37 - THYMUS AND MEDIASTINUM	17	5	12	240%
C38 - PLEURA	8	13	-5	-38%
SUBTOTAL	885	870	15	2%
BONE SARCOMAS				
C40 - C41 - BONE	10	7	3	43%
SUBTOTAL	10	7	3	43%
SKIN AND MELANOMAS				
C43 - MELANOMA	271	260	11	4%
C44 - SKIN	950	1,110	-160	-14%
SUBTOTAL	1,221	1,370	-149	-11%

BREAST				
C50 · BREAST	1,337	1,236	101	8%
SUBTOTAL	1,337	1,236	101	8%
SOFT TISSUE SARCOMAS				
C4A · MERKEL CELL CARCINOMA	9	8	1	13%
C45 · MESOTHELIOMA	4	3	1	33%
C46 · KAPOSII SARCOMA	10	3	7	233%
C47 · PERIPHERAL NERVES	1		1	0%
C48 · PERITONEUM AND RETROPERITONEUM	5	4	1	25%
C49 · CONNECTIVE TISSUE	33	35	-2	-6%
SUBTOTAL	62	53	9	17%
FEMALE GENITAL APPARATUS				
C51 · C52 · VULVA AND VAGINA	14	30	-16	-53%
C53 · CERVIX UTERI	64	83	-19	-23%
C54 · CORPUS UTERI	113	113	0	0%
C55 · UTERUS, PART UNSPECIFIED	19	12	7	58%
C56-C57 · OVARY AND FALLOPIAN TUBE	65	65	0	0%
SUBTOTAL	275	303	-28	-9%
URINARY TRACT AND MALE GENITAL SYSTEM				
C60 · PENIS	10	14	-4	-29%
C61 · PROSTATE	1097	1116	-19	-2%
C62 · TESTIS	14	17	-3	-18%
C63 · OTHER AND UNSPECIFIED MALE GENITAL ORGANS	0	0	0	0%
C64 · KIDNEY	142	150	-8	-5%
C65-C66 · RENAL PELVIS AND URETER	22	22	0	0%
C67 · BLADDER	314	369	-55	-15%
C68 · OTHER AND UNSPECIFIED URINARY ORGANS	0	7	-7	-100%
SUBTOTAL	1,599	1,695	-96	-6%
NERVOUS SYSTEM AND ENDOCRINE GLANDS				
C69 · EYE	1	1	0	0%
C70 · MENINGES	0	2	-2	-100%
C71 · BRAIN	22	44	-22	-50%
C72 · SPINAL CORD AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM	0	5	-5	-100%
C73 · THYROID	51	42	9	21%
C74 · C75 · ADRENAL AND OTHER ENDOCRINE GLANDS	4	5	-1	-20%
SUBTOTAL	78	99	-21	-21%
METASTASIS OF UNKNOWN ORIGIN				
C76 · OTHER AND ILL-DEFINED SITES	11	10	1	10%
C77 · LYMPH NODE METASTASES OF UNKNOWN PRIMARY	12	8	4	50%
C78 – RESPIRATORY AND DIGESTIVE SYSTEM METASTASES OF UNKNOWN PRIMARY	22	40	-18	-45%


C79 · OTHER METASTASES OF UNKNOWN PRIMARY	38	38	0	0%
C80 · METASTASIS OF UNSPECIFIED SITE	19	9	10	111%
SUBTOTAL	102	105	-3	-3%
HAEMOPOIETIC ORGANS				
C81 · HODGKIN	17	14	3	21%
C82-C83-C84-C86-C88 · OTHER LYMPHOMATOUS TUMOURS	61	32	29	91%
C85 · NON-HODGKIN'S LYMPHOMA	5	11	-6	-55%
C90 · MYELOMA	13	9	4	44%
C91 · LYMPHOID LEUKAEMIA	3	2	1	50%
C92 · MYELOID LEUKAEMIA	1	1	0	0%
C93 · MONOCYTIC LEUKAEMIA	0	1	-1	-100%
C95 · C96 · LEUKAEMIA OF UNSPECIFIED CELL TYPE	1	1	0	0%
SUBTOTAL	101	71	30	42%
BENIGN NEOPLASM OF THE BRAIN AND OTHER PARTS OF THE CNS				
C7A-D3A · NEUROENDOCRINE TUMOURS	1	1	0	0%
D32-D33 · BENIGN NEOPLASM OF BRAIN	15	13	2	15%
SUBTOTAL	16	14	2	14%
CARCINOMA "IN SITU"				
D00 · FLOOR OF MOUTH	0		0	0%
D01 · DIGESTIVE ORGANS	1	1	0	0%
D02 · RESPIRATORY SYSTEM			0	0%
D03-D04 · MELANOMA AND SKIN	26	28	-2	-7%
D05-D06-D07-D09 · BREAST AND GENITOURINARY SYSTEM	15	27	-12	-44%
D09.19 · CARCINOMA IN SITU OF OTHER SITES	1	5	-4	-80%
SUBTOTAL	43	61	-18	-30%
TUMOUR WITH UNCERTAIN EVOLUTION				
D37-D38 · DIGESTIVE AND RESPIRATORY SYSTEMS	184	226	-42	-19%
D39-D40-D41 · GENITOURINARY ORGANS	334	362	-28	-8%
D42-D43 · MENINGES AND CNS	2	6	-4	-67%
D44 · ENDOCRINE GLANDS	29	35	-6	-17%
D46-D47 · MYELODYSPLASTIC SYNDROMES AND OTHERS	7	5	2	40%
D48 · OTHER AND UNSPECIFIED SITES	158	200	-42	-21%
D49 · UNCERTAIN OR UNKNOWN BEHAVIOUR	7	8	-1	-13%
R97 · ABNORMAL TUMOUR MARKERS	191	120	71	59%
OTHER	61			
SUBTOTAL	973	962	11	1%
TOTAL DISTRIBUTION OF PATHOLOGY	7,650	7,777	-127	-2%

OUTPATIENT ACTIVITY

OUTPATIENT ACTIVITY

	2025			2024			Diff.	Dev. %
	First visits	Follow-up visits	Total	First visits	Follow-up visits	Total		
Physical Activity and Oncology	467	2,043	2,510				2,510	
Anaesthesia and Resuscitation	4,579	760	5,339	4,252	883	5,135	204	4%
Cardiology	662	850	1,512	538	858	1,396	116	8%
General and Gastrointestinal Surgery	461	2,224	2,685	420	2,238	2,658	27	1%
Breast Surgery	752	6,011	6,763	728	5,466	6,194	569	9%
Plastic Surgery	52	592	644	45	578	623	21	3%
Thoracic Surgery	225	1,026	1,251	231	1,015	1,246	5	0%
Genetic Counselling	460	202	662	354	191	545	117	21%
Orthopaedic Surgery and Traumatology	257	614	871	212	575	787	84	11%
Continuing Care	301	1,683	1,984	234	902	1,136	848	75%
Dermatology	1,545	12,247	13,792	1,485	11,338	12,823	969	8%
Gastroenterology	443	2,630	3,073	503	2,738	3,241	-168	-5%
Physiotherapy	678	4,609	5,287	181	4,303	4,484	803	18%
Gynaecology	768	7,003	7,771	615	7,015	7,630	141	2%
Haematology	295	2,860	3,155	289	2,755	3,044	111	4%
Internal Medicine	274	1,472	1,746	260	1,341	1,601	145	9%
Nuclear Medicine	3	61	64	0	75	75	-11	-15%
Pulmonology	258	855	1,113	230	785	1,015	98	10%
Neurosurgery	36	104	140	11	36	47	93	198%
Neurology	308	700	1,008	119	355	474	534	113%
Nutrition	920	1,701	2,621	323	645	968	1,653	171%
Medical Oncology	2,024	38,696	40,720	1,867	36,442	38,309	2,411	6%
Radiation Oncology	3,553	15,177	18,730	3,413	14,748	18,161	569	3%
Ear, Nose and Throat (ENT)	497	4,297	4,794	468	4,142	4,610	184	4%
Psycho-Oncology	717	2,594	3,311	454	2,324	2,778	533	19%
Psychiatry	299	548	847				847	
Pain Management	84	286	370	64	221	285	85	30%
Urology	1,482	15,253	16,735	1,381	15,364	16,745	-10	0%
Totals	22,400	127,098	149,498	18,677	117,333	136,010	13,488	10%

OUTPATIENT CLINICS




DAY HOSPITAL ACTIVITY

DAY HOSPITAL

	2025	2024	Diff.	Dev. %
Medical Oncology	22,991	21,157	1,834	9%
Haematology	835	732	103	14%
Urology	2,937	2,310	627	27%
TOTAL	26,763	24,199	2,564	11%

DAY HOSPITAL



EMERGENCY DEPARTMENT ACTIVITY

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Number of emergency visits	8,602	8,139	463	6%
Emergency admissions	2,024	1,944	80	4%


HOSPITALISATION

INPATIENT STAYS

	2025	2024	Diff.	Dev. %
ANAESTHESIA AND RESUSCITATION: PAIN UNIT	190	301	-111	-37%
GENERAL AND GASTROINTESTINAL SURGERY	2,962	3,344	-382	-11%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	46	24	22	92%
THORACIC SURGERY	635	656	-21	-3%
DERMATOLOGY	15	18	-3	-17%
GASTROENTEROLOGY	60	78	-18	-23%
GYNAECOLOGY	540	411	129	31%
HAEMATOLOGY	187	204	-17	-8%
INTERNAL MEDICINE	5,249	4,064	1,185	29%
NUCLEAR MEDICINE	101	49	52	106%
NEUROSURGERY	36			
MEDICAL ONCOLOGY	8,132	9,519	-1,387	-15%
EAR, NOSE AND THROAT (ENT)	1,037	969	68	7%
RADIOTHERAPY	1,493	1,359	134	10%
INTENSIVE CARE UNIT	2,846	2,850	-4	0%
UROLOGY	4,938	4,933	5	0%
TOTAL HOSPITAL	28,467	28,785	-318	-1%
DAY HOSPITAL UNIT	22,431	24,154	-1,723	-7%

NUMBER OF DISCHARGES


	2025	2024	Diff.	Dev. %
ANAESTHESIA AND RESUSCITATION: PAIN UNIT	56	46	10	22%
GENERAL AND GASTROINTESTINAL SURGERY	1,189	1,208	-19	-2%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	26	13	13	100%
THORACIC SURGERY	223	211	12	6%
DERMATOLOGY	11	8	3	38%
GASTROENTEROLOGY	48	30	18	60%
GYNAECOLOGY	452	421	31	7%
HAEMATOLOGY	34	36	-2	-6%
INTERNAL MEDICINE	741	730	11	2%
NUCLEAR MEDICINE	50	31	19	61%
NEUROSURGERY	4			
NEUROLOGY	1			
MEDICAL ONCOLOGY	1,206	1,099	107	10%
EAR, NOSE AND THROAT (ENT)	312	246	66	27%
RADIOTHERAPY	270	354	-84	-24%
INTENSIVE CARE UNIT	1,280	1,305	-25	-2%
UROLOGY	2,103	1,989	114	6%
TOTAL HOSPITAL	8,006	7,727	279	4%
DAY HOSPITAL UNIT	527	555	-28	-5%



SURGICAL ACTIVITY

NUMBER OF SURGICAL PROCEDURES

	2025	2024	Diff.	Dev. %
ANAESTHESIA AND RESUSCITATION: PAIN UNIT	132	84	48	57%
GENERAL AND GASTROINTESTINAL SURGERY	1,243	1,238	5	0%
PLASTIC SURGERY	128	110	18	16%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	35	33	2	6%
THORACIC SURGERY	158	152	6	4%
DERMATOLOGY	908	783	125	16%
GYNAECOLOGY	450	409	41	10%
NEUROSURGERY	6			
EAR, NOSE AND THROAT (ENT)	295	257	38	15%
RADIOTHERAPY - BRACHYTHERAPY	201	243	-42	-17%
UROLOGY	1,890	1,798	92	5%
TOTAL	5,446	5,107	339	7%
ROBOTIC SURGERY	671	585	86	15%



GLOBAL ACTIVITY INDICATORS

HOSPITAL-WIDE INDICATORS

	2025	2024	Diff.	Dev. %
Occupancy rate	78.3%	79.8%	-1.5%	-2%
Turnover rate	80.6	78.6	2.00	3%
Average length of stay	3.6	3.7	-0.10	-3%

AVERAGE LENGTH OF STAY BY SERVICE

	2025	2024	Diff.	Dev. %
ANAESTHESIA AND RESUSCITATION: PAIN UNIT	3.4	5.2	-1.8	-35%
GENERAL AND GASTROINTESTINAL SURGERY	2.5	2.8	-0.3	-11%
ORTHOPAEDIC SURGERY AND TRAUMATOLOGY	1.8	2	-0.2	-10%
THORACIC SURGERY	2.8	3.1	-0.3	-10%
DERMATOLOGY	1.4	2	-0.6	-30%
GASTROENTEROLOGY	1.3	2.3	-1.0	-43%
GYNAECOLOGY	1.2	1	0.2	20%
HAEMATOLOGY	5.5	5.2	0.3	6%
INTERNAL MEDICINE	7.1	7.8	-0.7	-9%
NUCLEAR MEDICINE	2	1.6	0.4	25%
NEUROSURGERY	9			
MEDICAL ONCOLOGY	6.7	7.5	-0.8	-11%
EAR, NOSE AND THROAT (ENT)	3.3	3.8	-0.5	-13%
RADIOTHERAPY	5.5	4	1.5	38%
INTENSIVE CARE UNIT	2.2	2.2	0.0	0%
UROLOGY	2.3	2.5	-0.2	-8%
TOTAL HOSPITAL	3.6	3.7	-0.1	-2.7%
DAY HOSPITAL UNIT	42.6	43.5	-0.9	-2%



CLINICAL ACTIVITY BY SERVICE

3.



FUNDACIÓN
INSTITUTO VALENCIANO
DE ONCOLOGÍA

PATHOLOGY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Ana Calatrava Fons

CLINICAL LEADS

Isidro Machado Puerto

Víctor Traves Zapata

ATTENDING PHYSICIANS

Jessica Aliaga Patiño

Susana López Agulló

María Elena Mengual García

Jaime José Padilla Esquivel

Nayara Pérez Sánchez

ACTIVITY INDICATORS

BIOPSIES

	2025	2024	Diff.	Dev. %
Number of patients	9,926	9,376	550	6%
Number of biopsies	39,490	32,413	7,077	22%

CYTOLOGY

	2025	2024	Diff.	Dev. %	
I.V.O.	Gynaecological	1,750	1,496	254	17%
	Non-gynaecological	1,752	1,669	83	5%
Early Diagnosis Unit	3,120	3,498	-378	-11%	
TOTAL	6,622	6,663	-41	-1%	

IMMUNOHISTOCHEMISTRY

	2025	2024	Diff.	Dev. %
Number	23,983	24,046	-63	0%

SILVER-ENHANCED IN SITU HYBRIDISATION (SISH)

	2025	2024	Diff.	Dev. %
Number	138	87	51	59%

OSNA (One-Step Nucleic Acid Amplification)

	2025	2024	Diff.	Dev. %
Number	762	959	-197	-21%

AUTOPSIES

	2025	2024	Diff.	Dev. %
Number	4	1	3	300%

ANAESTHESIA, RESUSCITATION, AND PAIN MANAGEMENT

HUMAN RESOURCES

HEAD OF DEPARTMENT

M.^a Ángeles Martínez Navarrete

CLINICAL LEADS

Enrique García Galiana

Celia López de Briñas Monfort

Victorio Sanchís Gil

María Pilar Vicent Martí

ATTENDING PHYSICIANS

Miriam Coret Moya

Rafael Fraga Rodríguez

Romina Kaplan Rubinstein

Rosa Alba Martínez Albaladejo

Irene Oliver Toquero

Javier Ortega Giménez

M.^a Begoña Perolada Beaus

Paula Saiz Gil

Jorge Uncio Veyrat

Carolina Zaragoza Peñalver

CRITICAL CARE AND RESUSCITATION UNIT

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Average number of beds	12	11.2	0.8	7%
Number of discharges	1,280	1,305	-25	-2%
Inpatient stays	2,846	2,850	-4	0%
Average length of stay	2.2	2.2	0	0%
Occupancy rate	65.10%	69.60%	-0.045	-6%
Turnover rate	106.9	116.5	-9.6	-8%
Number of deaths	27	21	6	29%

ANAESTHESIA OUTPATIENT CLINIC

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %	
Outpatient consultations	First visits	4,579	4,252	327	8%
	Follow-up visits	760	883	-123	-14%
Hospital interconsultations	183	180	3	2%	
TOTAL	5,522	5,315	207	4%	
ECG	3,653	3,413	240	7%	

ANAESTHESIA IN THE OPERATING THEATRE AND OUTSIDE THE SURGICAL AREA

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Anaesthesia in operating theatres	5,446	5,107	339	7%
Sedation (outpatient clinics, CT, MRI, PET, RT, etc.)	10	57	-47	-82%
Interventional radiology	86	100	-14	-14%
TOTAL	5,542	5,264	278	5%

PAIN UNIT

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Outpatient consultations	370	285	85	30%
Inpatient interconsultations	6	6	0	0%
Operating theatre	132	84	48	57%

SURGICAL TECHNIQUES

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Epidural block or injection	37	4	33	825%
Peripheral nerve blocks or injections, joint blocks, hydrodissections	35	30	5	17%
Botulinum toxin injections	1	15	-14	-93%
Intrathecal pump refill and epidural implant	2	12	-10	-83%
Spinal cord programming	21		21	
Intrathecal pump refill and epidural implant	42	9	33	367%
Spinal cord stimulators and intrathecal pumps implants	11	4	7	175%
Multiple radiofrequency. Pulstrode	6	7	-1	-14%
Cryoneurolysis	2		2	
TOTAL	157	81	76	94%

MOLECULAR BIOLOGY

HUMAN RESOURCES

HEAD OF SERVICE

José Antonio López Guerrero

MEDICAL PHYSICISTS

Reyes Claramunt Alonso

Antonio Fernández Serra

Zaida García Casado

RESEARCH STAFF

Zoraida Andreu Martínez

NUMBER OF SAMPLES ANALYSED PER PROCESS

TYPE OF ANALYSIS	2025	2024	Diff.	Dev. %
BCR-ABL QUANTITATIVE DETERMINATION	32	33	-1	-3%
MICROSATELLITE INSTABILITY (MSI) STUDY	178	177	1	1%
COVID-19 RNA EXTRACTION	278	135	143	106%
RNA EXTRACTION	1,934	1,661	273	16%
DNA EXTRACTION	568	369	199	54%
cfDNA EXTRACTION	588	692	-104	-15%
FISH (Fluorescence In Situ Hybridization)	8	4	4	100%
FACTOR II (PROTHROMBIN)	4	4	0	0%
FACTOR V LEIDEN	45	69	-24	-35%
HPV FRAGMENTS	2	8	-6	-75%
HAEMOCHROMATOSIS	93	103	-10	-10%
HYPERMETHYLATION OF THE MLH1 GENE PROMOTER	6	0	6	
MLPA (BRCA1, BRCA2, CKEK2)	14	25	-11	-44%
JAK2 QUALITATIVE PCR	11	14	-3	-21%
QUANTITATIVE PCR (EGFR, BRAF, KRAS, NRAS, PI3KCA)	786	641	145	23%
QUALITATIVE PCR FOR POLYOMAVIRUS	2	0	2	
HCS PANEL (70 genes)	337	288	49	17%
HRS PANEL (16 genes)	0	9	-9	-100%
STS PANEL (42 genes)	751	582	169	29%
DPYD POLYMORPHISMS	210	179	31	17%
IGH REARRANGEMENTS	49	39	10	26%
TCR REARRANGEMENTS	44	40	4	10%
SANGER SEQUENCING	273	214	59	28%
NGS FUSIONS	212	91	121	133%
UGT1A1 POLYMORPHISM	140	110	30	27%
TARGETED STUDY ON LIQUID BIOPSY BY DIGITAL PCR	104	21	83	395%
EPSTEIN-BARR VIRUS (EBV)	16	2	14	700%
TESTS PERFORMED	6,685	5,510	1,175	21%

CARDIOLOGY

HUMAN RESOURCES

HEAD OF SERVICE

Vicente Enrique Miró Palau

ACTIVITY INDICATORS

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
First visits	662	538	124	23%
Follow-up visits	850	858	·8	·1%
Subtotal	1,512	1,396	116	8%
Interconsultations	107	201	·94	·47%
TOTAL	1,619	1,597	22	1%

Electrocardiograms	553	637	·84	·13%
Pacemaker follow-up	146	166	·20	·12%
Doppler echocardiography with/without contrast	1,154	1,136	18	2%
Holter	77	67	10	15%
Cardiac nuclear medicine	1	2	·1	·50%
TOTAL	1,931	2,008	·77	·4%

GENERAL AND GASTROINTESTINAL SURGERY

HUMAN RESOURCES

HEAD OF SERVICE

Carlos Alberto Fuster Diana

CLINICAL LEADS

Jorge Campos Máñez

Fernando Carbonell Castelló

ATTENDING PHYSICIANS

Maria Caballero Soto

Ana Izquierdo Moreno

Vincenzo Maisto

Teresa Pérez Pérez

Alberto Ríos Agudo

Marta G. Trallero Anoro

Giovanni F. Vento Maggio

PLASTIC SURGEON

Ernesto E. Sanz Navarro

CONSULTANT IN VASCULAR SURGERY

Jorge Molina Martínez

CONSULTANT IN ORTHOPAEDIC AND TRAUMA SURGERY

Julio Ribes Iborra

ACTIVITY INDICATORS

			2025	2024	Diff.	Dev. %
Outpatient consultations	General and gastrointestinal surgery	First visits	461	420	41	10%
		Follow-up visits	2,224	2,238	-14	-1%
	Breast surgery	First visits	752	728	24	3%
		Follow-up visits	6,011	5,466	545	10%
	Plastic surgery	First visits	52	45	7	16%
		Follow-up visits	592	578	14	2%
	Orthopaedic surgery and traumatology	First visits	257	212	45	21%
		Follow-up visits	614	575	39	7%
		Interconsultations	55	75	-20	-27%
Number of procedures		General and gastrointestinal surgery	1,243	1,238	5	0%
		Plastic surgery	128	110	18	16%
		Orthopaedic surgery and traumatology	35	33	2	6%
Hospitalisation	General, gastrointestinal, and plastic surgery	Average number of available beds	21.8	22	-0.2	-1%
		Number of discharges	1,189	1,208	-19	-2%
		Inpatient stays	2,962	3,344	-382	-11%
		Average length of stay	2.5	2.8	-0.3	-11%
		Occupancy rate	37.2%	41.4%	-4%	-10%
		Turnover rate	54.6	54.9	-0.3	-1%
	Orthopaedic surgery and traumatology	Number of discharges	26	13	13	100%
		Inpatient stays	46	24	22	92%
		Average length of stay	1.8	2	-0.2	-10%

THORACIC SURGERY

HUMAN RESOURCES

HEAD OF SERVICE

Juan Carlos Peñalver Cuesta

ATTENDING PHYSICIANS

Karol de Aguiar Quevedo

Miguel Arrarás Martínez

PULMONOLOGIST

Encarnación Martínez Pérez

ACTIVITY INDICATORS

			2025	2024	Diff.	Dev. %
Outpatient consultations	Thoracic surgery	First visits	225	231	-6	-3%
		Follow-up visits	1,026	1,015	11	1%
		Interconsultations	72	55	17	31%
		Forced spirometry	9	5	4	80%
	Pulmonology	First visits	258	230	28	12%
		Follow-up visits	855	785	70	9%
		Interconsultations	314	325	-11	-3%
		Forced spirometry	3	0	3	
Number of procedures			158	152	6	4%
Hospitalisation	Number of discharges		223	211	12	6%
	Inpatient stays		365	656	-21	-3%
	Average length of stay		2.8	3.1	-0.3	-10%

DERMATOLOGY

HUMAN RESOURCES

HEAD OF SERVICE

Onofre Sanmartín Jiménez

CLINICAL LEADS

Beatriz Llombart Cussac

Eduardo Nagore Enguïdanos

Celia Requena Caballero

ATTENDING PHYSICIANS

Matilde E. Manrique Silva

Fátima M. Mayo Martínez

Ruggero Moro

M^a Pilar Pérez García

Carlos Serra Guillén

RESIDENT PHYSICIANS

Beatriz Córcoles Jannone

Andrea Díez Santandreu

Javier Lorenz Dolz

Diego Pérez Rodríguez

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	1,545	1,485	60	4%
	Follow-up visits	12,247	11,385	862	7.6%
	Photodynamic therapy	345	383	-38	-10%
	PUVA	76	226	-150	-66%
	Laser treatment	132	144	-12	-8%
	Digital dermoscopy	1,185	1,135	50	4%
Number of surgical procedures		908	783	125	16%
Hospitalisation	Number of discharges	11	8	3	38%
	Inpatient stays	15	18	-3	-17%
	Average length of stay	1.4	2	-0.6	-30%

GASTROENTEROLOGY UNIT

HUMAN RESOURCES

CLINICAL LEAD

Carmen Martínez Lapiedra

ATTENDING PHYSICIANS

Fernanda Maia de Alcántara

Fernando Martínez de Juan

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	443	503	-60	-12%
	Follow-up visits	2,630	2,738	-108	-4%
Endoscopy	Gastroscopy	579	567	12	2%
	Colonoscopy	1,321	1,265	56	4%
	Endoscopic ultrasound	67	61	6	10%
Hospitalisation	Number of discharges	48	30	18	60%
	Inpatient stays	60	78	-18	-23%
	Average length of stay	1.3	2.3	-1	-43%

PHARMACY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Carlos J. Andrés Blasco

HOSPITAL PHARMACISTS


Isabel Benet Giménez
Sandra Bernabéu Castellá
Yolanda Colomer Nieves
Álvaro Gómez Perales
Antoni Llopis Alemany
Pilar Martínez Albaladejo
Marta Monroy Ruíz
Ismael P. Pastor Climente

EQUIPMENT


- Two vertical Kardex automated warehouse cabinets.
- Two vertical laminar flow cabinets.
- Strocar solids repackager type HF-200-A.
- CDx 90/ Indiko.
- Pharmacotechnical material.
- Nahita centrifuge model 2698.
- Clean room with two vertical laminar flow cabinets.
- Two Cobos scales: standard and precision.
- Radio frequency warehouse.

UNIT DOSE DISPENSING AREA


MEDICINAL PRODUCT CONSUMPTION BY WARD




MOST CONSUMED MEDICINAL PRODUCTS BY WARDS



NUMBER OF VALIDATIONS



NUMBER OF PATIENTS ON UNIT DOSE DISPENSING



INTRAVENOUS ADMIXTURE UNIT

	2025	2024	Diff.	Dev. %
Number of chemotherapy prescriptions requiring pharmacy preparation for inpatients on unit dose dispensing	380	281	99	35%
Number of chemotherapy preparations for inpatients on unit dose dispensing	590	438	152	35%
Number of prescriptions for Day Hospital treatment	23,363	20,859	2,504	12%
Number of preparations for the Day Hospital	31,379	28,911	2,468	9%
Intravesical chemotherapy	2,042	1,620	422	26%

NUTRITION

	2025	2024	Diff.	Dev. %
Standard parenteral nutrition	1,782	1,695	87	5%
Enteral nutrition and supplements	10,821	10,497	324	3%

CLINICAL TRIALS WITH DRUG DISPENSING

	2025	2024	Diff.	Dev. %
Lung	15	13	2	15%
Prostate	15	15	0	0%
Gynaecological	6	9	-3	-33%
Renal	3	6	-3	-50%
Colorectal	7	5	2	40%
Melanoma	2	5	-3	-60%
Head and neck	2	1	1	100%
Breast	24	23	1	4%
Bladder	4	6	-2	-33%
Gastric	1	1	0	0%
Skin	4	1	3	300%
Liver	1		1	
Haematological	1		1	
Miscellaneous	5	10	-5	-50%
TOTAL	90	95	-5	-5%

Number of clinical trial dispensations: 1,964

PHARMACY COMPOUNDING UNIT

	2025	2024	Diff.	Dev. %
IV preparations (External pharmacy)	317	324	-7	-2%
Topical preparations (External pharmacy)	12	0	12	
Topical preparations (Hospital pharmacy)	624	542	82	15%
Oral preparations (External pharmacy)	63	37	26	70%

ONCOLOGY OUTPATIENT PHARMACY UNIT

	2025	2024	Diff.	Dev. %
Patients treated and provided with specific information	3,000	2,686	314	12%
Total outpatient visits	20,780	18,378	2,402	13%
Clinical dispensations	46,972	39,731	7,241	18%

PHARMACOKINETICS

DRUG LEVEL MEASUREMENTS BY ACTIVE SUBSTANCE AND RESULT

	Toxic level	Subtherapeutic level	Within therapeutic range	TOTAL
Digoxin	1		1	2
Gentamicin	1		2	3
Amikacin	1		1	2
Methotrexate			10	10
Vancomycin	1	2	1	4
TOTAL	4	2	15	21

ACTIVITY BY INPATIENT UNIT

Inpatient Unit	Patients	Reports	Drug level measurements
INTERNAL MEDICINE	2	4	4
ONCOLOGY	1	10	10
UROLOGY	5	6	6
TOTAL	8	20	20

DRUG INFORMATION

			2025
Drug information bulletin			Bimonthly
Drug-related problems identified			296
Pharmaceutical interventions			296
Communication channel	Oral/Telephone		127
	Documented in writing		3
	Electronic		2
	Resolved without communication		164
Statistics	Acceptance rate	Accepted with explicit change	55
		Accepted with implicit change	35
		Rejected with justification	42

GYNAECOLOGY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Óscar C. Piñero Sánchez

CLINICAL LEAD

Josep Sanchís Plá

ATTENDING PHYSICIANS

Paloma G. Badía Agustí

Cristina Díaz Sierra

Enrique E. Garrigós Llabata

Deborah Herrero Roselló

Rafael V. Martínez Gomá

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	768	615	153	25%
	Follow-up visits	7,003	7,015	-12	0%
Nursing care		295	219	76	35%
Number of patients operated on		450	409	41	10%
Colposcopies		423	390	33	8%
Diagnostic hysteroscopy		156	240	-84	-35%
Hospitalisation	Avg. no. of available beds	5.7	5.5	0.2	4%
	Number of discharges	452	421	31	7%
	Inpatient stays	450	411	129	31%
	Average length of stay	1.2	1	0.2	20%
	Occupancy rate	26.0%	20.5%	6%	27%
	Turnover rate	81.6	78.2	3.4	4%

CLINICAL LABORATORY AND MICROBIOLOGY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Marcos Guaita Martínez

CLINICAL ANALYSES

Sonia C. Cervantes García

Pilar Pérez Ballester

Marina Sánchez Yepes

MICROBIOLOGY AND PARASITOLOGY

Roberto Olmos Arena

Isabel Valero García

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
BIOCHEMISTRY	Requests	81,745	77,582	4,163	5%
	Tests performed	3,044,920	2,868,800	176,120	6%
MICROBIOLOGY	Bacteriology	45,258	35,653	9,605	27%
	Serology	8,086	6,379	1,707	27%
HAEMATOLOGY	Requests	69,059	66,001	3,058	5%
	Tests performed	1,380,590	1,320,107	60,483	5%
HAEMOSTASIS	Requests	22,775	20,627	2,148	10%
	Tests performed	91,650	82,998	8,652	10%
BLOOD BANK	Red blood cells	1,983	2,159	-176	-8%
	Plasma	40	35	5	14%
	Platelets	166	159	7	4%
TUMOUR MARKERS		49,944	45,930	4,014	9%
IMMUNOLOGY TESTS		75,612	64,456	11,156	17%

INTERNAL MEDICINE

HUMAN RESOURCES

CLINICAL LEAD

Adoración Egido González

ATTENDING PHYSICIANS

María Yurena Cañado Gómez

Laura Parra Gómez

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	274	260	14	5%
	Follow-up visits	1,472	1,341	131	10%
Hospitalisation	Average number of beds	6.1	7.4	-1.3	-18%
	Number of discharges	741	730	11	2%
	Inpatient stays	5,249	4,064	1,185	29%
	Average length of stay	7.1	7.8	-0.7	-9%
	Occupancy rate	235.8%	148.7%	87%	59%
	Turnover rate	104.6	69.6	35	50%

NUCLEAR MEDICINE

HUMAN RESOURCES

HEAD OF DEPARTMENT

Marcos Tajahuerce Romera

CLINICAL LEAD

Francisco Manchón Adsuar

ATTENDING PHYSICIANS

Laura Asensio Valero

Víctor M. Cardona Cardona

ACTIVITY INDICATORS

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
VENTRICULAR EJECTION FRACTION	14	5	9	180%
SENTINEL LYMPH NODE	587	452	135	30%
BONE SCANS	1,076	931	145	16%
OTHER	6	49	-43	-88%
SPECT	69	165	-96	-58%
PET	3,272	2,566	706	28%
TOTAL	5,024	4,168	856	21%

METABOLIC THERAPY

	2025	2024	Diff.	Dev. %
Discharges	50	31	19	61%
Inpatient stays	101	49	52	106%
Average length of stay	2	1.6	0.4	25%

NEUROLOGY

HUMAN RESOURCES

CLINICAL LEAD

Luis Bataller Alberola

CONSULTANT IN NEUROPHYSIOLOGY

Victoria Martín Alda

ACTIVITY INDICATORS

CLINICAL ACTIVITY INDICATORS - NEUROLOGY

	2025	2024	Diff.	Dev. %
First visits	308	119	189	159%
Follow-up visits	700	355	345	97%
Subtotal	1,008	474	534	113%
Interconsultations	24	23	1	4%
TOTAL	1,032	497	535	108%

ACTIVITY INDICATORS - NEUROPHYSIOLOGY

	2025
Electroencephalogram Electroencephalography (EEG)	40
Electromyography (EMG)	38
Nerve conduction studies	32
Somatosensory evoked potentials (SSEPs)	3
Repetitive nerve stimulation	4
TOTAL	117

MEDICAL ONCOLOGY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Joaquín Gavilá Gregori

CLINICAL LEADS

Miguel A. Climent Durán

Ángel L. Guerrero Zotano

ATTENDING PHYSICIANS

Héctor A. Aguilar Andino

Salvador Blanch Tormo

Cristina Hernando Meliá

M.^a José Juan Fita

David Lorente Estellés

Marcos Melián Sosa

Elena Oliete Ramírez

Rocío Ramírez Benlloch

Ignacio Romero Noguera

Vicente Ruiz Cordero

Sergio Sandiego Contreras

Ricardo Yaya Tur

RESIDENT PHYSICIANS

Tomás Gómez Laverde

Llum M.^a Nacher Arroyo

Ana Navarro López

Carlota Ramos López

Emilio Roda Auñón

Tatiana Ugalde Catarinella

ACTIVITY INDICATORS

ACTIVITY INDICATORS

			2025	2024	Diff.	Dev. %
Outpatient consultations	Medical oncology	First visits	2,024	1,867	157	8%
		Follow-up visits	38,696	36,442	2,254	6%
	Genetic counselling	First visits	460	354	106	30%
		Follow-up visits	202	191	11	6%
	Continuing care	First visits	301	234	67	29%
		Follow-up visits	1,683	902	781	87%
	Haematology	First visits	295	289	6	2%
		Follow-up visits	2,860	2,755	105	4%
Day Hospital chemotherapy activity	Medical oncology		22,991	21,157	1,834	9%
	Haematology		835	732	103	14%
Hospitalisation	Medical oncology	Avg. no. of available beds	22.3	22.7	0	-2%
		Number of discharges	1,206	1,099	107	10%
		Inpatient stays	8,132	9,519	-1,387	-15%
		Average length of stay	6.7	7.5	-0.8	-11%
		Occupancy rate	99.9%	114.2%	-14%	-13%
		Turnover rate	58.3	56.1	2.2	4%
	Haematology	Number of discharges	34	36	-2	-6%
		Inpatient stays	187	204	-17	-8%
		Average length of stay	5.5	5.2	0.3	6%

HOSPITAL AT HOME

HUMAN RESOURCES

HEAD OF DEPARTMENT

Joaquín Gavilá Gregori

UNIT COORDINATOR

Antonio Mancheño Álvaro

ATTENDING PHYSICIANS

Laura Bragado Martínez

Julia Pardo Seré

Patricia Ruiz Ortega

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Number of assigned patients	Surgical	20	20	0	0%
	Oncology	70	70	0	0%
Number of patients treated		325	392	-67	-17%
Home visits	Physicians	4,566	5,368	-802	-15%
	Nursing staff	5,159	6,246	-1,087	-17%
Inpatient care	Bed days	22,431	24,154	-1,723	-7%
	Discharges	527	555	-28	-5%
	Average length of stay	42.6	43.5	-0.9	-2%
	Occupancy rate	68.3%	73.1%	-4.80%	-7%

HAEMATOLOGY AND AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT UNIT

HUMAN RESOURCES

ATTENDING PHYSICIANS

Amparo M.^a Avaria Navalón

Claudia J. Salazar Lozada

HAEMATOLOGY / BLOOD BANK

	2025	2024	Diff.	Dev. %
Red blood cell concentrates	1,991	2,197	-206	-9%
Platelets	166	161	5	3%
Fresh frozen plasma (FFP)	40	42	-2	-5%
Irregular antibody screening	1,973	2,091	-118	-6%
Direct antiglobulin test	16	29	-13	-45%
Identified antibodies	4	18	-14	-78%
ABO and Rh typing	1,987	2,106	-119	-6%

DIAGNOSTIC ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Bone marrow studies (aspirates/biopsies)	76	77	-1	-1%
Peripheral blood smear	299	411	-112	-27%
Haematopoietic stem cell apheresis	8	7	1	14%
Autologous haematopoietic stem cell transplantation	8	5	3	60%

CLINICAL ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	295	289	6	2%
	Follow-up visits	2,860	2,755	105	4%
Day Hospital consultations		393	379	-14	-4%
Anticoagulation consultations		503	379	-124	-25%
Interconsultations		29	46	17	59%
Day Hospital chemotherapy activity		732	835	103	14%
Number of bone marrow biopsies		80	75	-5	-6%
Inpatient care	Number of discharges	34	36	-2	-6%
	Bed days	187	204	-17	-8%
	Average length of stay	5.5	5.2	0.3	6%

RADIATION ONCOLOGY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Leoncio Arribas Alpuente

CLINICAL LEADS

Marisa Chust Vicente

Enrique J. García Miragall

José Luis Guinot Rodríguez

ATTENDING PHYSICIANS

Ángel J. Acosta Rojas

Sandra Canós Puente

Manuel Casaña Giner

Yasmina Murria Pérez

Mónica Núñez Baez

Carmen Pesudo Ayet

Oriana A. Prato Carreño

Paula Santamaría García

Miguel A. Santos Olías

Berta Sanvictor Beneito

RESIDENT PHYSICIANS

Mónica Caballero Pascual

Carla Calvo Alós

Daniela Cediél Polo

Marina Coll Álvarez

Marta Rodríguez Lozal

CONSULTANT IN NEUROSURGERY

José V. Piquer Belloch

ACTIVITY INDICATOR DATA

ACTIVITY INDICATORS

			2025	2024	Diff.	Dev. %
Outpatient consultations	Valencia	First visits	2,953	2,680	273	10%
		Follow-up visits	12,764	12,014	750	6%
	Alcoy	First visits	392	356	36	10%
		Follow-up visits	1,709	1,642	67	4%
	Cuenca	First visits	208	377	-169	-45%
		Follow-up visits	704	1,092	-388	-36%
Inpatient care	Average number of beds		9.7	9.1	0.6	7%
	Number of discharges		270	354	-84	-24%
	Bed days		1,493	1,359	134	10%
	Average length of stay		5.5	4	1.5	38%
	Occupancy rate		29.3%	40.5%	-11.2%	-28%
	Turnover rate		26.2	37.5	-11.3	-30%

RADIOTHERAPY ACTIVITY

	2025	2024	Diff.	Dev. %
External beam radiotherapy	575	494	81	16%
Special techniques	2,347	2,446	-99	-4%
Brachytherapy	235	259	-24	-9%
TOTAL	3,157	3,199	-42	-1%
Radiosurgery	30	24	6	25%

RADIATION ONCOLOGY IN ALCOY

ACTIVITY INDICATOR DATA

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
First visits	392	356	36	10%
Follow-up visits	1,709	1,642	67	4%

RADIOTHERAPY ACTIVITY

	2025	2024	Diff.	Dev. %
External beam radiotherapy	64	61	3	5%
Special techniques	316	309	7	2%
TOTAL	380	370	10	3%

RADIATION ONCOLOGY IN CUENCA

ACTIVITY INDICATORS

ACTIVITY INDICATORS

	2024	2024	Diff.	Dev. %
First visits	208	377	-169	-45%
Follow-up visits	704	1,092	-388	-36%

RADIOTHERAPY ACTIVITY

	2025	2024	Diff.	Dev. %
External beam radiotherapy	40	74	-34	-46%
Special techniques	161	239	-78	-33%
TOTAL	201	313	-112	-36%

RADIATION ONCOLOGY IN VALENCIA

ACTIVITY INDICATOR DATA

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
First visits		2,953	2,680	273	10%
Follow-up visits		12,764	12,014	750	6%
Inpatient care	Average number of beds	9.7	9.1	1	7%
	Number of discharges	270	354	-84	-24%
	Bed days	1,037	1,359	-322	-24%
	Average length of stay	5.5	4	1.5	38%
	Occupancy rate	29.30%	40.50%	-11%	-28%
	Turnover rate	26.2	37.5	-11.3	-30%

RADIOTHERAPY ACTIVITY

		2025	2024	Diff.	Dev. %
External beam radiotherapy		471	359	112	31%
Special techniques		1,870	1,898	-28	-1%
Brachytherapy		235	259	-24	-9%
TOTAL		2,576	2,516	60	2%
Radiosurgery		30	24	6	25%

NEUROSURGERY

ACTIVITY INDICATORS

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
First visits	36	11	25	227%
Follow-up visits	104	36	68	189%
Subtotal	140	47	93	198%
Interconsultations	2	2	0	0%
Number of procedures	8		8	

EAR, NOSE AND THROAT (ENT)

HUMAN RESOURCES

HEAD OF DEPARTMENT

Juan Bosco Vendrell Marqués

CLINICAL LEAD

Eduardo Ferrandis Perepérez

ATTENDING PHYSICIANS

Simón Brotons Durbán

Ángel Plá Mocholí

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	497	468	29	6%
	Follow-up visits	4,297	4,142	155	4%
Number of procedures		295	257	38	15%
Inpatient care	Average number of beds	4.9	4.7	0.2	4%
	Number of discharges	312	246	66	27%
	Bed days	1,037	969	68	7%
	Average length of stay	3.3	3.8	-0.5	-13%
	Occupancy rate	83.50%	56.10%	27.4%	49%
	Turnover rate	63.9	54.4	9.5	17%

MEDICAL PHYSICS AND RADIATION PROTECTION

HUMAN RESOURCES

HEAD OF DEPARTMENT

Vicente Crispín Contreras

CLINICAL LEADS

Víctor González Pérez

Carmen Guardino de la Flor

MEDICAL PHYSICISTS

Víctor de los Dolores Alemany

Víctor González González

Mireia Hernández Trujillo

RESIDENT MEDICAL PHYSICISTS

Alberto Angulo Santos

Mireia Pallarés Ripollés

Daniel Pérez Enrique

Clara Solla Bartual

DOSIMETRISTS

Enrique Folgado Sales

Ana Martínez Baste

Daniel Torrecillas Plaza

QUALITY CONTROL

- Quality control of diagnostic imaging equipment and associated radiation protection:
 - 5 CT scanners
 - 1 fluoroscopy unit
 - 1 digital fluoroscopy unit
 - 2 general radiography units
 - 2 portable X-ray units
 - 2 mammography units
 - 2 digital mammography units
 - 1 bone densitometer
- Quality control of Nuclear Medicine equipment:
 - SPECT-CT gamma camera
 - 2 dose calibrators
 - PET-CT scanner
 - Metabolic therapy (radiation protection discharge)
- Quality control of Radiotherapy and Radiation Protection equipment:
 - 5 linear accelerators
 - 2 high-dose-rate brachytherapy units
- Monitoring and control of more than 100 staff with personal dosimeters.

ACTIVITY INDICATORS

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
Treatment plans for new linac patients	2,449	3,102	-653	-21%
High-complexity treatment planning	2,629	3,102	-473	-15%
Treatment plans for new brachytherapy patients	235	259	-24	-9%
Metabolic therapy treatments	46	31	19	61%
Radiosurgery procedures	30	24	6	25%

RADIOLOGY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Eugenio Sánchez Aparisi

CLINICAL LEADS

Estanislao Arana Fernández de Moya

Ana Marhuenda Fluixá

ATTENDING PHYSICIANS

Josep Asensi Pérez

Carlos M. Baracaldo Silva

María Barrios Benito

Carlos Deltoro González

Rosa M.^a Ferrer Meneu

Isabel Martín García

Paula Pelechano Gómez

Jesús Santos Cores

EQUIPMENT

- PACS with 3- and 5-megapixel colour workstations
- 2 MRI scanners (1.5 T)
- 2 CT scanners
- 1 conventional radiography system
- 2 GE TMRX portable X-ray units
- 5 ultrasound systems
- 1 remote fluoroscopy unit
- 1 vascular C-arm
- 1 Siemens Cios C-arm
- 1 full-field digital mammography unit
- 1 full-field digital mammography unit with tomosynthesis
- 2 mammography units
- 1 mammotome system
- 1 post-processing system
- 1 densitometer (Lunar model)
- 2 RadioQx C-arms

ACTIVITY INDICATOR DATA

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
CT scans	28,399	27,006	1,393	5%
MRI	5,102	4,781	321	7%
ULTRASOUNDS	11,705	11,437	268	2%
DOPPLER	335	324	11	3%
MAMMOGRAMS	5,885	5,625	260	5%
CONVENTIONAL AND CONTRAST- ENHANCED RADIOGRAPHY	8,716	8,019	697	9%
INTERVENTIONAL RADIOLOGY	3,602	3,543	59	2%
INTRAOPERATIVE FLUOROSCOPY	273	240	33	14%
DENSITOMETRY	2,656	2,388	268	11%
TOTAL	66,673	63,363	3,310	5%

ONCOLOGY WELL-BEING UNIT

HUMAN RESOURCES

ONCOLOGY WELL-BEING UNIT COORDINATOR

Elena Oliete Ramírez

PHYSICAL ACTIVITY AND ONCOLOGY

María Elena García Roca

José Noguesserola Micó

PHYSIOTHERAPY

Elisa Bañuls Sendra

Salvador Gea Mahiques

Juan B. Portolés Simeó

NUTRITION

Bianca T. Muresan Oltean

Iulia Scorojanu

MENTAL HEALTH UNIT

PSYCHIATRY

María del Cerro Arastey

PSYCHOLOGY

Ana García-Conde Benet

Pilar Llombart Fuertes

Rocío Romero Retes

PHYSICAL ACTIVITY

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025
Outpatient consultations	First visits	467
	Follow-up visits	2,043
Inpatient consultations		18

PHYSIOTHERAPY

ACTIVITY INDICATORS

ACTIVITY INDICATORS					
		2025	2024	Diff.	Dev. %
Lymphoedema Unit	Sessions	1,906	1,310	596	45%
Outpatient consultations	Sessions	3,381	3,174	207	7%
Transcutaneous electrical nerve stimulation (TENS)	Sessions	80	74	6	8%
Shockwave therapy (ESWT)	Sessions	217	165	52	32%
Inpatient care	Sessions	1,887	2,100	-213	-10%

NUTRITION

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	920	323	597	185%
	Follow-up visits	1,701	645	1,056	164%
Inpatient consultations		179	83	96	116%

MENTAL HEALTH UNIT

ACTIVITY INDICATORS

PSYCHIATRY

ACTIVITY INDICATORS

		2025
Outpatient consultations	First visits	299
	Follow-up visits	548
Inpatient consultations		199
Telephone consultations		98

GROUP INTERVENTION

	2025
GROUP SESSIONS	15

PSYCHO-ONCOLOGY

ACTIVITY INDICATORS

		2025	2024	Diff.	Dev. %
Outpatient consultations	First visits	717	454	263	58%
	Follow-up visits	2,492	2,325	168	7%
	Grief counselling	102	79	23	29%
Inpatient consultations		252	299	-47	-16%
Psychological consultations for family members		110	149	-39	-26%
Telephone consultations		98	91	7	8%

GROUP INTERVENTION

	2025	2024	Diff.	Dev. %
GROUP SESSIONS	341	319	22	7%

CLINICAL DOCUMENTATION AND ADMISSIONS UNIT (CDAU)

HUMAN RESOURCES

HEAD OF DEPARTMENT

Rodrigo Muñoz Balada

ATTENDING PHYSICIAN

Francisco José Pascual Plá

HEAD OF CLINICAL DOCUMENTATION

M.^a José Castro Boix

HEAD OF ADMISSIONS

Aránzazu Llavata Mayordomo

INFORMATION SYSTEMS MANAGEMENT

Jesús Martínez Esteso

ADMISSIONS AREA

ADMISSIONS AREA

		2025	2024	Diff.	Dev. %
Appointment records		158,503	144,265	14,238	10%
Emergency department records	ED admissions	8,698	8,253	445	5%
	Emergency admissions	2,024	1,944	80	4%
Day Hospital activity records		26,763	24,199	2,564	11%
Laboratory activity records	Haematology and biochemistry	81,745	77,582	4,163	5.4%
	Microbiology	45,258	35,653	9,605	27%
Radiology activity records		70,909	69,181	1,728	2%
Nuclear Medicine activity records		5,024	4,168	856	21%
Inpatient activity records	Admissions	6,716	6,440	276	4%
	Discharges	6,724	6,422	302	5%
Hospital at home activity records	Admissions	512	574	-62	-11%
	Discharges	527	555	-28	-5%

CLINICAL DOCUMENTATION AREA

CLINICAL DOCUMENTATION AREA					
		2025	2024	Diff.	Dev. %
REPROGRAPHY	No. of patients	4,692	4,376	316	7%
	Total no. of studies	9,921	9,455	466	5%
	Avg. monthly patients	391	365	26	7%
	Avg. monthly studies	827	788	39	5%
DIGITISATION	Total no. of documents	49,221	48,764	457	1%
	Total no. of images	130,575	137,502	-6,927	-5%
	Avg. monthly documents	4102	4,064	38	1%
	Avg. monthly images	10,881	11,459	-577	-5%
ACCREDITATION	No. of digital records/day	738	1,021	-283	-28%
DOCUMENTATION	No. of records	12,554	10,249	2,305	22%
	Delivered in person	1,871	2,012	-141	-7%
	Delivered electronically	10,683	8,237	2,446	30%
EMERGENCY DEPARTMENT CODING	Total episodes	8,557	8,109	448	6%
	% coded episodes	83%	100%	-17	-17%

		2025	2024	Diff.	Dev. %		
C O D I N G	MBDS for inpatients	Total episodes	6,444	6,112	332	5%	
		% coded episodes	100	100	0	0%	
		Average diagnoses	13.43	12.27	1.16	9%	
		Average procedures	7.67	7.62	0.05	1%	
		Diagnosis	% coded	100%	100%	0	0%
			0				
			1	14	21	-7	-33%
			2	50	82	-32	-39%
			3	115	131	-16	-12%
			4	156	219	-63	-29%
	5		206	234	-28	-12%	
	+5	5,903	5,425	478	9%		
	Procedures	% coded	100%	100%	0	0%	
		0	37	31	6	19%	
		1	50	131	-81	-62%	
		2	211	392	-181	-46%	
		3	665	534	131	25%	
		4	780	572	208	36%	
		5	585	419	166	40%	
	+5	4,116	4,033	83	2%		
MBDS for ambulatory surgery	Total episodes	1,483	1,208	275	23%		
	% coded episodes	100%	100%	0	0%		
	Average diagnoses	8.49	7.33	1.16	16%		
	Average procedures	4.79	4.63	0.16	3%		
	Diagnosis	% coded	100%	100%	0	0%	
		0					
		1	58	69	-11	-16%	
		2	115	109	6	6%	
		3	134	122	12	10%	
		4	130	121	9	7%	
		5	122	127	-5	-4%	
	+5	925	660	265	40%		
	Procedures	% coded	100%	100%	0	0%	
		0	3	9	-6	-67%	
1		28	26	2	8%		
2		63	48	15	31%		
3		344	320	24	8%		
4		384	316	68	22%		
5		187	145	42	29%		
+5	474	344	130	38%			

EMERGENCY DEPARTMENT (ED)

HUMAN RESOURCES

COORDINATOR

Francisco José Pascual Plá

ATTENDING PHYSICIANS

José J. Cabrera Hernández

Natalia Celis Gómez

Janet Contreras Samamé

María Josefina Donoso

José Julio Ferrando Pastor

Anaxímenes A. Lugo Dorante

Analía Ninacuri Sevilla

Israel Pérez Lafarge

Josefa Samper Hiraldo

ACTIVITY INDICATOR DATA

ACTIVITY INDICATORS

	2025	2024	Diff.	Dev. %
ED visits	8,602	8,139	463	6%
Admissions from the ED	2,024	1,944	80	4%
Deaths	5	1	4	400%
ED visits per day	23.6	22.2	1.4	6%
Admission rate from the ED	23.5%	23.9%	0.2%	1%
72-hour ED revisits	803	757	46	6%
72-hour revisit rate	9.3%	9.3%	0%	0%

UROLOGY

HUMAN RESOURCES

HEAD OF DEPARTMENT

Juan L. Casanova Ramón-Borja

CLINICAL LEADS

Manuel Beamud Cortés

Argimiro Collado Serra

José Domínguez Escrich

Álvaro Gómez-Ferrer Lozano

ATTENDING PHYSICIANS

Juan Colombas Vives

Pedro de Pablos Rodríguez

Ángel García Cortés

Cristina Gutiérrez Castañé

Javier A. Hernández Falcón

José A. López González

Augusto Wong Gutiérrez

PHYSIOTHERAPIST

Alicia Palop Moscardó

ACTIVITY INDICATORS

ACTIVITY INDICATORS

		2025	2025	Diff.	Dev. %
Outpatient consultations	First visits	1,482	1,381	101	7%
	Follow-up visits	15,253	15,364	-111	-1%
Urodynamic studies		132	98	34	35%
Perineal electrostimulation		2,226	1,627	599	37%
Prostate cancer early detection programme	First visits	435	437	-2	0%
	Follow-up visits	3,857	3,589	268	7%
Day Hospital chemotherapy		2,937	2,310	627	27%
Outpatient cystoscopies		2,282	2,044	238	12%
Transrectal prostate biopsy		2	9	-7	-78%
Number of procedures		1,890	1,798	92	5%
Inpatient care	Avg. no. of available beds	16.5	15.8	1	4%
	Number of discharges	2,103	1,989	114	6%
	Bed days	4,938	4,933	5	0%
	Average length of stay	2.3	2.5	0	-8%
	Occupancy rate	82.0%	84.9%	-2.9%	-3%
	Turnover rate	127.6	126.3	1.3	1%

NURSING

HUMAN RESOURCES

DIRECTOR OF NURSING

Nuria Casani Turégano

DEPUTY DIRECTOR OF NURSING

Paula D. Solá Guzmán

NURSE SUPERVISORS

Laboratory	Gemma Maestre García
Operating Theatres	Gema García Rodrigo
Surgical Services	Julia Coll Rodríguez
	Ana Martí Llorca
Intensive Care Unit	Carmen Hernández Ferrando
Medical Oncology	Ricardo Roca Almela
Day Hospital	M. ^a Teresa Navarro Pradas
Radiology	Esteban Mesas Plaza
Radiation Oncology	Sonia Gimeno Page

QUALITY

HUMAN RESOURCES

QUALITY MANAGER

Catalina Trenor Escuín

CERTIFICATIONS

- ISO 9001:2015 Quality Management Systems. Scope:
 - Clinical Analysis and Microbiology Laboratory
 - Pathology Department
 - Transfusion Service
 - Medical Physics and Radiological Protection Department
 - Radiation Oncology Department
 - Nuclear Medicine Department
 - Emergency Department
- ISO 14001:2015 Environmental Management Systems.
- EBU (European Board of Urology) certification as an benchmark international centre in specialised training in bladder and prostate tumours.
- High-level Spanish National Security Framework (ENS) certification.

ACCREDITATIONS

- OECI (Organisation of European Cancer Institutes) accreditation as a Cancer Centre.
- ESMO (European Society for Medical Oncology) accreditation as a centre of excellence in comprehensive care for cancer patients and palliative care patients.
- ISO 20387 accreditation for biobank activities.
- ISO 15189:2023 accreditation.
 - Molecular Biology Laboratory
 - Pathology Department

RECOGNITIONS

- Qh recognition for excellence in healthcare quality from the Spanish Institute for the Development and Integration of healthcare (IDIS)
- World's Best Hospital by *Newsweek* magazine.



SCIENTIFIC REPORT

4.



FUNDACIÓN
INSTITUTO VALENCIANO
DE ONCOLOGÍA

PATHOLOGY

ARTICLES IN INTERNATIONAL JOURNALS

One-step nucleic acid amplification analysis of sentinel lymphatic nodes in endometrial cancer patients (EU-OSNA): a European multicenter diagnostic accuracy study
Kostun, J., Nowosielski, K., Jedryka, M.A., Hardisson, D., Restaino, S., Gatus, S., Novak, Z., Lacalle, A.S., López, S., Pešta, M., Zebalski, M., Lepka, P., Diestro, M.D., Vizzielli, G., Matias-Guiu, X., Echim, T., Camacho Urkaray, E.N., Rienda, I., Slunecko, R., Czekanski, A., Berjón, A., Mariuzzi, L., Velasco, A., Betenbuk, J., Merino, I.G., Padilla-Iserte, P., Stráník, P., Smoligová, V., Presl, J.
Cancer Medicine, 2025, 18 (14): e71268
10.1002/cam4.71268 40981404 12451817

Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification
Moro, R., Mayo-Martínez, F., García-Casado, Z., Aguerralde-Martín, M., Traves, V., Manrique-Silva, E., Requena, C., Elder, D.E., Nagore, E.
Actas Dermosifiliogr., 2025, 117 (2), 104519
10.1016/j.ad.2025.104519 41352586

Correction: Can we rely on magnetic resonance imaging for prostate cancer detection and surgical planning? Comprehensive analysis of a large cohort of patients undergoing transperineal mapped biopsies
Diez, N.G., de Pablos-Rodríguez, P., Sánchez-Mateos Manzaneque, D., Martín García, M.I., Gómez, P.P., Benito, M.B., Calatrava Fons, A., Aliaga Patiño, J., Boronat Catalá, J., Gómez-Ferrer Lozano, A., Gutiérrez, A.W., Cortés, Á.G., Backhaus, M.R., Casanova Ramón Borja, J., Beamud Cortés, M., Domínguez Escrig, J.L., García, A.C.
World J Urol., 2025, 43 (1), 164
10.1007/s00345-025-05534-3 40072605

Sentinel lymph node detection in early ovarian cancer: the role of indocyanine green as a single tracer
Lago, V., Rey, I., Arnáez, M., Padilla-Iserte, P., Matute, L., Gurrea, M., López, S., Montero, B., De Vera, T.D., Domingo, S.
Int J Gynecol Cancer, 2025, 35 (6), 101826
10.1016/j.ijgc.2025.101826 40347521

The prognostic impact of the tumor immune microenvironment in synovial sarcoma: an immunohistochemical analysis using digital pathology and conventional interpretation
Medina Ceballos, E., Giner, F., Machado, I., Heras Morán, B., Espino, M., Navarro, S., Llombart Bosch, A.
J Pers Med., 2025, 15 (5), 169
10.3390/jpm15050169 40423041 12113210

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group
Fernández-Díaz, N., Mateos-González, M., Pertejo-Fernández, A., Cacho-Lavín, J.D., Juan-Fita, M.J., Chirivella-González, I., Arruti-Ibarbia, M., Fernández-

Calvo, O., Fernández-Núñez, N., Méndez-Vidal, M.J., Lázaro-Quintela, M., Molina-Díaz, A., Del Pozo-Alonso, N., Etxaniz-Ulazia, O., García-Acuña, S.M. Betancor, Y.Z., Azueta-Etxebarria, A., Calatrava-Fons, A., Lombardía-Rodríguez, H., Alarcón-Molero, L., Etxegarai-Ganboa, L., Antón-Cameselle, A., Bello-Giz, J.A., Neira-De Paz, C.M., Cabaleiro, T., González-Serrano, T., Ortiz-Rey, J.A., Sacristán-Lista, F., García-Rubín, S., Ortega, E., Carrato-Moñino, C., Aguín-Losada, S., León-Mateos, L., García-González, J., Pinto-Marín, Á., Durán, I., López-López, R., Anido-Herranz, U., Ruiz-Bañobre, J. *BMC Cancer*, 2025, 25 (1), 1835
10.1186/s12885-025-15264-9 41316036 12664163

Towards defining follow-up strategies for patients with primary intermediate-risk non-muscle-invasive bladder cancer

Contieri, R., Martini, A., Beijert, I.J., Mertens, L.S., Hentschel, A.E., Bründl, J., Compérat, E.M., Plass, K., Rodríguez, O., Subiela Henríquez, J.D., Hernández, V., de la Peña, E., Alemany, I., Turturica, D., Pisano, F., Soria, F., Capoun, O., Bauerová, L., Pešl, M., Bruins, H.M., Runneboom, W., Herdegen, S., Breyer, J., Brisuda, A., Calatrava, A., Rubio-Briones, J., Seles, M., Mannweiler, S., Bosschieter, J., Kusuma, V.R.M., Ashabere, D., Huebner, N., Seisen, T., Claps, F., Masson-Lecomte, A., Liedberg, F., Cohen, D., Lunelli, L., Cussenot, O., Sheikh, S.E., Volanis, D., Côté, J.F., Rouprêt, M., Haitel, A., Shariat, S.F., Mostafid, A.H., Nieuwenhuijzen, J.A., Zigeuner, R., Domínguez-Escrig, J.L., Hacek, J., Zlotta, A.R. et al. *Eur Urol Oncol*, 2025, 8 (4), 977–985
10.1016/j.euo.2025.04.010 40399193

Integration of an OS-based machine learning score (AS score) and Immunoscore as ancillary tools for predicting immunotherapy response in sarcomas

Machado, I., López-Reig, R., Giner, E., Fernández-Serra, A., Requena, C., Llombart, B., Giner, F., Cruz, J., Traves, V., Lavernia, J., Llombart-Bosch, A., López-Guerrero, J.A. *Cancers*, 2025, 17 (15), 2551
10.3390/cancers17152551 40805246 12346403

EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism

Olmedo Pelayo, J., Granado Calle, E., Delgado Bellido, D., Lobo Selma, L., Jordan Pérez, C., Monteiro Amaral, A.T., Ehlers, A.C., Ohmura, S., García Domínguez, D.J., Mackintosh, C., Carcaboso, A.M., Alonso, J., Machado, I., Llombart Bosch, A., Scotlandi, K., Grünewald, T.G.P., Gómez Herreros, F., de Álava, E. *Oncogene*, 2025, 44 (38), 3537–3552
10.1038/s41388-025-03496-9 40721661

FET-rearranged myoepithelial tumors are clinically heterogeneous and epigenetically distinct from PLAG1-rearranged adnexal and salivary gland myoepithelial tumors

Michal, M., Malik, F., Mansour, B., Hattery, T., Dehner, C.A., Martinek, P., Hájková, V., Vanecek, T., Chrisinger, J.S.A., Machado, I., Klubícková, N., Sumathi, V.P., Ng, T., Warmke, L., Oon, M.L., Petersson, F., Argani, P., Gross, J.M., Michal, M., Antonescu, C.R., Dermawan, J.K. *Clin Cancer Res.*, 2025
10.1158/1078-0432.CCR-25-2426 41342886

Confocal microscopy for immediate analysis of prostate biopsies

Rodríguez Concha, C., De Pablos-Rodríguez, P., Calatrava Fons, A., Aliaga Patiño, J., Pelechano Gómez, P., Martín García, M.I., Boronat Catalá, J., Gómez-Ferrer Lozano,

A., Beamud Cortés, M., García Cortés, Á., Wong Gutiérrez, A., López González, J.A., Collado Serra, A., Domínguez-Escrig, J.L., Hassi Román, M., Casanova Ramón-Borja, J. *Minerva Urol Nephrol.*, 2025, 77 (1), 85–90
10.23736/S2724-6051.25.06102-6 40183185

Multicenter analysis of the surgical management and adjuvant therapy of patients with melanoma and a positive sentinel lymph node biopsy
Samaniego-González, E., Podlipnik, S., Ribero, S., Nagore, E., Boada, A., Cañueto, J., Paradela, S., de Unamuno, B., Rodríguez-Jiménez, P., Puig, S., Malveyh, J., Carrera, C., Rocuzzo, G., Requena, C., Manrique-Silva, E., Richarz, N., Ruiz-Villanueva, A., Traves, V., España-Fernández, S., Botella-Estrada, R., González-Morán, M.A., Tejera-Vaquerizo, A.
Actas Dermosifiliogr., 2025, 116 (3), T233–T244
10.1016/j.ad.2024.12.005 39725282

Neutrophil-to-lymphocyte ratio associated with worse melanoma specific-survival and distant metastasis free survival in localized (stage I and II) cutaneous melanoma: an observational retrospective study on 988 patients
Ciobotariu, I., Ortega-Berbel, L.A., Calderón-Mollinedo, A., Aguerralde-Martín, M., Requena, C., Moro, R., Manrique-Silva, E., Traves, V., Nagore, E.
Int J Dermatol., 2025, 64 (10), 1855–1861
10.1111/ijd.17920 40629553

Oncological outcomes of patients undergoing radical prostatectomy with extended versus indocyanine-guided lymphadenectomy: midterm follow-up of PersonalymPCa clinical trial
Anagua Melendres, J.F., de Pablos-Rodríguez, P., Martínez Osorio, C.A., Gómez-Ferrer Lozano, A., Cortés, M.B., Calatrava Fons, A., Aliaga Patiño, J., Román, M.H., Part, V.R., Gutiérrez, A.W., Casanova Ramón Borja, J., Backhaus, M.R.
Urol Int., 2025, 109, 1–7
10.1159/000548203 41264563

Primary visceral Ewing sarcoma (gastric and bladder) with KIT expression: a report of two patients and a differential diagnostic approach
Chaachou Charradi, A., Bagué, S., Medina, C.M., Lavernia, J., Claramunt, R., López-Guerrero, J.A., Navarro, S., Llombart-Bosch, A., Williamson, S.R., Machado, I.
Int J Surg Pathol., 2025, 33 (5), 1299–1316
10.1177/10668969241308205 39865727

Uterine myxoid mesenchymal tumor with a novel SS18::VEZF1 gene fusion, lacking worrisome histological features
Machado, I., Claramunt, R., López, S., Aliaga, J., Garrigós, E., Martín, I., Romero, I., Llombart-Bosch, A., López-Guerrero, J.A.
Genes Chromosomes Cancer, 2025, 64 (8), e70079
10.1002/gcc.70079 40878061 12394789

GLI1::FOXO4-rearranged kidney tumors: a potentially distinct renal subtype within the spectrum of GLI1-altered tumors?
Panca, T., Klubícková, N., Dashti, N.K., Machado, I., Llombart-Bosch, A., Linos, K., Mosaieby, E., Vanecek, T., Manáková, L., Michal, M.
Virchows Arch., 2025, 486 (4), 751–757
10.1007/s00428-024-03998-z 39688667

Prognostic value of whole lymph node molecular analysis in colorectal cancer: a prospective multicenter study

Liu, Q., López-Prades, S., Sáez de Gordo, K., Rodrigo-Calvo, M., Martín, J.R., Romo, A., Pinilla, I., Tarragona, J., Machado, I., Berenguel, M. del M., Maurel, J., Bravo, R., Camps, J., Archilla, I., Cuatrecasas, M.

Clin Exp Med., 2026, 26 (1), 34

10.1007/s10238-025-01936-0 41286178

Interobserver variability of histopathological assessment in pT1 colorectal carcinoma

Sáez de Gordo, K., Daca-Álvarez, M., Rodrigo-Calvo, M., Archilla, I., López-Prades, S., Aguirre, J.J., Alarcón-Molero, L., Jurado, M.C., Canosa, A., Giner, F., González-Lois, C., Jimeno, M., Jurado, I., Machado, I., Martínez-Ciarpaglini, C., Musulen, E., Naranjo, D., Papaleo, N., Peña, C., Rosiñol, Ò, Sánchez-Yuste, R., Vázquez Benítez, G.T., Pellisé, M., Cuatrecasas, M., EpiT1 Consortium

Histopathology, 2026, 88 (4), 868–880

10.1111/his.70043 41392996

Interobserver variability in the histopathological evaluation of melanoma: analysis of 60 cases

Sanz-Motilva, V., Martorell, A., Manrique-Silva, E., Terrádez-Mas, L., Requena, C., Traves, V., Sanmartín, O., Rodríguez-Peralto, J.L., Nagore, E.

Actas Dermosifiliogr., 2025, 116 (6), 583–588

10.1016/j.ad.2025.04.004 40187558

ARTICLES IN NATIONAL JOURNALS

Immunohistochemistry staining for DNA mismatch repair proteins in endoscopic biopsies and the corresponding surgical specimen in colorectal cancer

Martínez Lapiedra, C., García-Fadrique, A., García-Casado, M.Z., Navarro-Fos, S., Machado-Puerto, I.

Rev Esp Enferm Dig., 2025, 117 (2), 76–83

10.17235/reed.2024.10645/2024. 39421923

INTERNATIONAL CONFERENCES

XXIV Congress FEDPATMEX, Monterrey (Mexico), October 2025

Attendance

Machado Puerto, I.

Integration of an Overall Survival-Based Machine Learning Score and Immunoscore as an Ancillary Tool for Predicting Immunotherapy Response in Sarcomas (Abstract 308)

United States and Canadian Academy of Pathology (USCAP), Boston (MA), March 2025

Poster presentation

Machado, I., López-Reig, R., Fernández-Serra, A., Giner, F., Claramunt, R., Requena, C., Traves, V., Lavernia, J., Llombart, B., López-Guerrero, J.A., Llombart-Bosch, A.

Recent Molecular Alterations in Sarcomas: Do They Have Clinical Impact on Diagnosis, Prognosis, or Treatment?

XXIV Congress FEDPATMEX, Monterrey (Mexico), October 2025

Presentation

Machado Puerto, I.

Bone and Soft Tissue Pathology

United States and Canadian Academy of Pathology (USCAP), Boston, March 2025

Oral presentation

Machado Puerto, I.

Bone and Soft Tissue Pathology

United States and Canadian Academy of Pathology (USCAP), Boston, March 2025

Attendance

Machado Puerto, I.

Interobserver Variability of Histopathological Risk Factors for Lymph Node Metastasis in pT1 Colorectal Carcinoma

37th European Congress of Pathology, Vienna (Austria), September 2025

Poster presentation

Sáez de Gordo, K., Musulen, E., Daca-Álvarez, M., Rodrigo, M., Archilla, I., López-Prades, S., Aguirre, J.J., Alarcón-Molero, L., Jurado, M.C., Canosa, A., Giner, F., González-Lois, C., Jimeno, M., Jurado, I., Machado Puerto, I., Martínez-Ciarpaglini, C., Naranjo-Hans, D., Papaleo, N., Peña, C., Rosiñol, Ò., Sánchez-Yuste, R., Vázquez Benítez, G.T., Pellisé, M., Cuatrecasas, M.,

Superficial Epithelioid Neoplasm: How Should We Classify It? (Mesenchymal Neoplasm, Sarcoma, Benign, Malignant, Low- or High-Risk, or Uncertain Potential)

XXIV Congress FEDPATMEX, Monterrey (Mexico), October 2025

Presentation

Machado Puerto, I.

Prognostic Significance of Tumour Budding Bd0 Category in pT1 Colorectal Carcinoma With Immunohistochemical Confirmation

37th European Congress of Pathology, Vienna (Austria), September 2025

Poster presentation

Sáez de Gordo, K., Musulen, E., Rodrigo, M., Archilla, I., López-Prades, S., Ramonda, M., Daca-Álvarez, M., Jurado, I., Martínez-Ciarpaglini, C., Rosiñol, Ò., Aguirre, J.J., Papaleo, N., González-Lois, C., Sánchez-Yuste, R., Vázquez Benítez, G.T., Zucchiatti, A., Valerdez, N., Jurado, M.C., Machado Puerto, I., Pellisé, M., Cuatrecasas, M.

Thyroid Pathology as a Clue to PTEN Hamartoma Tumor Syndrome

37th European Congress of Pathology, Vienna (Austria), September 2025

Poster presentation

Azueta Etxebarria, A., Fernández de la Prieta, I., Aguirrezabal Marcotegui, L., Cuenca Alvarado, R.I., Calvo Torio, P., Fernández Ferrer, S., Castaños Bueno, M., Pérez de Arenaza Marquínez, J., Rodríguez Villar, D., Zac Romero, C., López Agulló, S.

NATIONAL CONFERENCES

Pre-Congress Course in Pathology (7th CEAM), Madrid (Spain), October 2025

Attendance

Mengual García, E.

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Attendance

Calatrava Fons, A.

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Attendance

López Agulló, S.

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Attendance

Machado Puerto, I.

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Attendance

Traves Zapata, V.

Could We Still Work Today Without Collaborating with Our Molecular Biologist?

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Presentation

Machado Puerto, I.

Clinical Case: Nodular Follicular Disease in a Patient Under 25 Years of Age

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Presentation

López Agulló, S.

Reviewer of Abstract Submissions

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Organiser / Coordinator role

Machado Puerto, I.

Mesenchymal Lesion of the Gastrointestinal Tract

32nd National Congress of the SEAP-IAP, San Sebastián (Spain), May 2025

Presentation

Machado Puerto, I.

COURSES

49th Meeting of the Spanish Group of Dermatopathology – November 2025

Attendance

Traves Zapata, V.

Anatomic Pathology: The Journey from the Operating Room Specimen Container to the Final Report

Speaker: Aliaga Patiño, J.

May 2025. Valencia (Spain)

Bone and Soft Tissue

Attendees: Machado Puerto, I.

April 2025. Barcelona

Breast Cancer Biomarkers

Attendees: López Agulló, S.

November 2025. Online

Breast Biomarkers Course

Attendees: López Agulló, S.

November 2025.

Gynaecological Pathology Course of the European Society of Pathology

Attendees: López Agulló, S.

November 2025. Ghent (Belgium)

Course on PD-L1 in Cervical Cancer

Attendees: Aliaga Patiño, J.

July 2025. Online

Course on PD-L1 in Cervical Cancer

Attendees: López Agulló, S.

August 2025. Online

Course on PD-L1 in Head and Neck Tumours

Attendees: Aliaga Patiño, J.

July 2025. Online

Course on PD-L1 in Head and Neck Tumours

Attendees: Pérez Sánchez, N.

July 2025. Online

Course on PD-L1 in Melanoma

Attendees: Padilla Esquivel, J.

January 2025. Online

Course on PD-L1 in Head and Neck Tumours

Attendees: Padilla Esquivel, J.

July 2025. Online

EScoP Course on GU Pathology

Attendees: Aliaga Patiño, J.

June 2025. Istanbul (Turkey)

EScoP Course on GU Pathology

Attendees: Pérez Sánchez, N.

June 2025. Istanbul (Turkey)

ICH Good Clinical Practice E6(R3)

Attendees: Machado Puerto, I.

August 2025. Online

The Prostate Cancer Masterclass

Attendees: Aliaga Patiño, J.

May 2025. Valencia (Spain)

The Prostate Cancer Masterclass

Attendees: Pérez Sánchez, N.

May 2025. Valencia (Spain)

The Prostate Cancer Masterclass

Speaker: Calatrava Fons, A.

May 2025. Valencia (Spain)

MASTER'S THESIS

Impact of Molecular Classification on Fertility-Sparing Treatment in Endometrial Cancer

Rey Juan Carlos University (Madrid), June 2025

López Barona, M.

AWARDS

Honourable Mention

Frontiers in Oncology

Machado Puerto, I.

Associate Editor (official appointment letter)

Online, December 2025

PEER REVIEW ACTIVITY

Reviewer Certificate

Diagnostic Pathology

Machado Puerto, I.

Reviewer Certificate

Discover Oncology

Machado Puerto, I.

Reviewer Certificate

Genes, Chromosomes and Cancer

Machado Puerto, I.

Reviewer Certificate

Histopathology

Machado Puerto, I.

Reviewer Certificate

Journal of Cutaneous Pathology

Machado Puerto, I.

Reviewer Certificate

npj Precision Oncology

Machado Puerto, I.

Reviewer Certificate

World Journal of Surgical Oncology

Machado Puerto, I.

ANAESTHESIA, RESUSCITATION, AND PAIN MANAGEMENT

NATIONAL CONFERENCES

4th MEETING OF THE VALENCIAN SOCIETY OF ANAESTHESIOLOGY, RESUSCITATION AND PAIN THERAPY

Valencia, January 2025
Attendance
Martínez Navarrete, MA.

6TH NATIONAL CONGRESS ON MULTIMODAL REHABILITATION March 2025
Attendance
Fraga Rodríguez, R.

VODCAST: FLUID THERAPY RETHINKING
June 2025
Attendance
Coret Moya, M.

10th MEETING OF THE SEDAR INTENSIVE CARE SECTION
10th MEETING OF THE MADRID INTENSIVE CARE SECTION February 2025
Attendance
Martínez Albaladejo, R.

COURSES

562nd ATLS COURSE – LA MALVARROSA HOSPITAL
Attendees: Saiz Gil, P.
January 2025. VALENCIA

ADVANCED LIFE SUPPORT COURSE
Attendees: Coret Moya, M.
February 2025. Valencia

CLINICAL SESSIONS

Review
BROAD-SPECTRUM ANTIBIOTICS 2025
Ortega Giménez, J.
January 2025

Review
BIBLIOGRAPHIC SESSION: DEXAMETHASONE, INTRATHECAL MORPHINE,
TRANEXAMIC ACID AND METHYLENE BLUE IN SEPTIC SHOCK
Sánchez Gil, V.
January 2025

Review

ANAESTHESIA IN NEUROSURGERY

Perolada Beaus, M.B. RESIDENT – CASTELLÓN

January 2025

Multidisciplinary

MULTIMODAL PREHABILITATION

Fraga Rodríguez, R., Bañuls Sendra, E., Scorojano, I.

January 2025

Review

THORACIC WALL NERVE BLOCKS IN BREAST SURGERY

Saiz Gil, P.

February 2025

Review

CARCINOMATOSIS GUIDELINES AND HIPEC

Kaplan Rubistein, R.

March 2025

Review

PATIENT BLOOD MANAGEMENT (PBM)

Uncio Veyrat, J.

April 2025

Review

PERIOPERATIVE PAIN MANAGEMENT IN PATIENTS WITH CANCER-RELATED PAIN

Farga Niños, B. RESIDENT (R3) – SAN JUAN DE ALICANTE UNIVERSITY HOSPITAL

April 2025

Review

WELL-BEING UNIT

Oliete Ramírez, E.

June 2025

Review

HEREDITARY ANGIOEDEMA

Abarca, P. RESIDENT – HOSPITAL DE CASTELLÓN

June 2025

Multidisciplinary

CPR AND PATIENT SAFETY SESSION

Sanchis Gil, V., García Galiana, E.

July 2025

Review

VASOPRESSOR MANAGEMENT IN SEPTIC SHOCK

VIATRIS LABORATORY

October 2025.

Review

PERIOPERATIVE MANAGEMENT OF CHRONIC MEDICATION

Saiz Gil, P.

November 2025

Review

PERIOPERATIVE ARRHYTHMIAS

Martínez Albaladejo, R.A.

November 2025

MOLECULAR BIOLOGY

ARTICLES IN INTERNATIONAL JOURNALS

Immunohistochemistry staining for DNA mismatch repair proteins in endoscopic biopsies and the corresponding surgical specimen in colorectal cancer
Martínez Lapedra, C., García-Fadrique, A., García Casado, M.Z., Navarro Fos, S., Machado Puerto, I.

Rev Esp Enferm Dig, 2025; 117(2):76–83
10.17235/reed.2024.10645/2024.39421923

Integration of an OS-based machine learning score (AS score) and Immunoscore as ancillary tools for predicting immunotherapy response in sarcomas

Machado, I., López-Reig, R., Giner, E., Fernández-Serra, A., Requena, C., Llombart, B., Giner, F., Cruz, J., Traves, V., Lavernia, J., et al.
Cancers 2025, 2025;17(15):103390

Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumours: the Greko II study (GETH12013-01)

García-Donas, J., Garrigós, L., Laínez, N., Santaballa, A., Redondo, A., Cueva, J.F., Rubio, M.J., Prieto, M., López-Guerrero, J.A., García-Casado, Z., Barquin, A., Grande, E., Alia, E.G., Sevillano, E., Bover, I., Grazioso, T.P., Sánchez-Escribano, R., Hurtado, A., Navarro, P., Rodríguez-Moreno, J.F.

Clin Transl Oncol, 2025;27(7):3223–3231
10.1007/s12094-024-03827-4 Epub 2024 Dec 30. PMID: 39738931

Uterine myxoid mesenchymal tumor with a novel SS18::VEZF1 gene fusion, lacking worrisome histological features

Machado, I., Claramunt, R., López, S., et al.
Genes, Chromosomes and Cancer 64, no. 8, 2025 ()
<https://doi.org/10.1002/gcc.70079>

INTERNATIONAL CONFERENCES

Integration of an Overall Survival-Based Machine Learning Score and Immunoscore as an Ancillary Tool for Predicting Immunotherapy Response in Sarcomas (Abstract No. 308)

UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY. Boston (Massachusetts), March 2025

Poster presentation

Machado, I., López-Reig, R., Fernández-Serra, A., Giner, F., Claramunt, R., Requena, C., Traves, V., Lavernia, J., Llombart, B., López-Guerrero, J.A., Llombart-Bosch, A.

Digital Transformation in Biobanking: The Implementation of e-Consent at the Valencian Institute of Oncology (IVO) Biobank

EUROPEAN BIOBANK WEEK 2025. Bologna, May 2025
Oral presentation

Cortell Granero, M.I., Llavata Mayordomo, A., Novella Cañadas, R., Martínez Estesó, J., López García, P., Pascual Pla, F.J., Muñoz Balada, R., López Guerrero, J.A.

Enhancing Biobank Practices: Insights from EQA Participation at the IVO Biobank EUROPEAN BIOBANK WEEK 2025. Bologna, May 2025

Oral presentation

Cortell Granero, M.I., Carretero Hinojosa, V., Ramírez Calvo, M., Mazcuñan Vitiello, T., Claramunt Alonso, R., López-Guerrero, J.A.

Five Years of Insights from the GEICO Registry (GEICO 81-T): a Virtual Gynecological Cancer Clinical Registry with Decentralized Biospecimen Collection EUROPEAN BIOBANK WEEK 2025. CLINICAL BIOBANKING · Bologna, May 2025

López-Guerrero, J.A., Marquina, G., De Juan, A., Churruca, C., Barretina-Ginesta, M.P., Pertejo, A., De Sande, C., Esteban, C., Herrero, A., Quindós, M., Caballero, C., Masvidal, M., Legerén, M., Martínez-del Prado, M.P., Romero, I., Iglesias-Campos, M., Sánchez-Lorenzo, L., Santaballa, A., Rubio, M.J., Gálvez Guerrero, F.

From Collection to Characterization: Overcoming Challenges in Extracellular Vesicles Biobanking

32ND CONGRESS OF THE SEAP-IAP. Lisbon, June 2025

Oral presentation

López-Guerrero, J.A.

Incidence of Germline BRCA1/2 Mutations in High-Grade Serous Epithelial Ovarian Cancer: Final Results of the GEICO60-O/BORNEO Study

ESMO. Berlin, October 2025

Poster presentation

Romero, I., López-Reig, R., Rubio, J.M., Márquez, R., Ramchandani, A., Redondo, A., Barretina-Ginesta, M.P., Yubero, A., de Sande, L.M., Gaba, L., Sánchez-Heras, A.B., Gálvez, F., Dotor, E., Mendizábal, E., Esteban, C., Cueva, J.F., Pérez-Segura, C., Guerra-Alfá, E.M., Fernández-Serra, A., López-Guerrero, J.A.

Optimizing an NGS Low-Pass-Based Method to Detect Genomic Instability as a PARP Inhibitor Predictive Biomarker in High-Grade Serous Ovarian Cancer

ASCO 2025. Chicago (Illinois), May 2025

Poster presentation

Romero, I., López-Reig, R., Fernández-Serra, A., Aliaga, J., López-Guerrero, J. A.

SLAP 2025.

LATIN AMERICAN CONGRESS OF ANATOMY. Santiago de Chile, November 2025

Oral presentation

López-Guerrero, J.A.

NATIONAL CONFERENCES

Changes in the Classification of Synchronous Ovarian and Endometrial Tumours (TSEO) Based on Molecular Analysis

SEOM. Madrid, November 2025

Poster presentation

Morales López, L., Romero, R., López, R., Fernández, A., Aliaga, J.

Incidence of Germline BRCA1/2 Mutations in High-Grade Serous Epithelial Ovarian Cancer: Final Results of the GEICO60-O/BORNEO Study
SEOM. Madrid, November 2025

Oral presentation

Romero, I., López-Reig, R., Rubio, M.J., Márquez, R., Ramchandani, A., Redondo, A., Barretina-Ginesta, M.P., Yubero, A., de Sande, L.M., Gaba, L., Sánchez-Heras, A.B., Gálvez, F., Dotor, E., Mendizábal, E., Alarcón, J., Bermejo, M.J., Fariñas-Madrid, L., Quindós, M., Fernández-Serra, A., López-Guerrero, J.A.

New Technologies in Massive Sequencing: Oxford Nanopore

SLAP 2025. LATIN AMERICAN CONGRESS OF ANATOMY. San Sebastián, 2025

Oral presentation

López-Guerrero, J.A.

COURSES

15th GIDO Meeting: Lung Cancer – Advances, Realities and New Challenges in a Comprehensive Approach

Valencia, March 2025

Claramunt Alonso, R.

Molecular Diagnosis in NSCLC

Valencia, June 2025

Claramunt Alonso, R.

Practical Application of Biomarkers in Lung Cancer – Learning Genomics Online webinar

Attendees: Claramunt Alonso, R.

February 2025. Madrid

Basic Aspects of Clinical Research in Gynaecological Oncology. Creation and Maintenance of Registries and Biobanks in Gynaecological Cancer

Speaker: López-Guerrero, J.A.

2025.

Determination of ESR1 Mutations in Liquid Biopsy

Speaker: López-Guerrero, J.A.

November 2025. Valencia

1st RVB Meeting: Biobanks and Citizen Participation. Your Rights, Our Responsibility: What You Need to Know Before Donating

Speaker: López-Guerrero, J.A.

November 2025. Valencia

Impact of Preanalytical Variables in the Characterization of Extracellular Vesicles in Biofluids

Speaker: López-Guerrero, J.A.

2025. Madrid

Masterclass in Uro-Oncology: Prostate Cancer

Speaker: Fernández Serra, A.

Valencia, May 2025

MicroRNAs: Basis and Application in Non-Haematological Solid Neoplasms

Speaker: López-Guerrero, J.A.

2025.

Molecular Tumor Board 4: Breast Cancer

Speaker: López-Guerrero, J.A., Gavila, J., Mengual, E.

2025.

New Technologies in Laboratory Diagnosis. Online

Speaker: López-Reig, R.

2025.

Genomic Platforms

Speaker: López-Guerrero, J.A.

April 2025. Valencia

Online Masterclass: Navigating Endocrine Resistance in Advanced and Metastatic Breast Cancer – The Critical Role of Biomarker Analysis

Attendees: Claramunt Alonso, R.

September 2025. Madrid

Online Webinar: ETA eConference – Differentiated Thyroid Cancer

Attendees: Claramunt Alonso, R.

June 2025. Valencia

Online Webinar: NGS for the Study of Biomarkers in Lung Cancer

Attendees: Claramunt Alonso, R.

March 2025.

DOCTORAL THESES

Genetic Mutations of Factor VIII and Their Possible Association with Clinical Manifestations, Functional Activity and the Development of Inhibitors in a Cohort of Colombian Patients with Haemophilia

Sarmiento Doncel, S.

Catholic University of Valencia and CES University, 2025

Supervised by: López-Guerrero, J.A., Peláez-Sánchez, R.G.

CLINICAL SESSIONS

The Diagnostic Utility of FISH in Sarcoma Diagnosis: Is There a Role Beyond Next-Generation Sequencing

Claramunt Alonso, R.

October 2025.

GENERAL SURGERY

ARTICLES IN INTERNATIONAL JOURNALS

SURGICAL DIAGNOSIS AND TREATMENT OF ISOLATED PANCREATIC METASTASES:
A REPORT OF FOUR CASES

Trallero Anoro, M., Carbonell Castelló F., Caballero Soto, M., Campos Máñez, J., Vento
Maggio, G., Izquierdo Moreno, A., Fuster Diana, C.

REVISTA VENEZOLANA ONCOLOGÍA, 2025;37(4):288–295

INTERNATIONAL CONFERENCES

15th PSOGI INTERNATIONAL CONGRESS ON PERITONEAL SURFACE MALIGNANCIES
15TH PERITONEAL SURFACE ONCOLOGY GROUP INTERNATIONAL CONGRESS.
BARCELONA, OCTOBER 2025

Attendance

Caballero Soto, M.

NATIONAL CONFERENCES

7th SPANISH BREAST CONGRESS. Madrid, October 2025

Attendance

Fuster Diana, C., Vento Maggio, G., Lucas Hueso, A.

14th MEETING OF BREAST UNITS AND UNIT COORDINATORS

SPANISH SOCIETY OF SENOLOGY AND BREAST PATHOLOGY. Madrid, March 2025

Attendance

Vento Maggio, G.

2nd AEPCIMA CONGRESS. Málaga, May 2025

Attendance

Vento Maggio, G., Fuster Diana, C., Ríos Agudo, A., Sanz Navarro, E.

2nd AEPCIMA CONGRESS. Málaga, May 2025

Oral presentation

Vento Maggio, G., Fuster Diana, C., Ríos Agudo, A., Sanz Navarro, E.

SKIN- AND NIPPLE-SPARING MASTECTOMY: EXPERIENCE, INDICATIONS AND OUT-
COMES OVER 5 YEARS AT THE VALENCIAN INSTITUTE OF ONCOLOGY

2nd AEPCIMA CONGRESS. Málaga, May 2025

Oral presentation

Vento Maggio, G.

SCIENTIFIC PROGRAM AGAINST CANCER: SCIENCE AND CARE SEOM 2025

Madrid, November 2025

Presentation

Fuster Diana, C.

IMMEDIATE PREPECTORAL BREAST RECONSTRUCTION WITH POLYURETHANE IMPLANTS: EXPERIENCE AND EARLY OUTCOMES IN THERAPEUTIC AND RISK-REDUCING MASTECTOMIES

7th SPANISH BREAST CONGRESS. Madrid, October 2025

Poster presentation

Vento Maggio, G., Fuster Diana, C., Ríos Agudo, A., Maisto, V., Pérez Pérez, T., Caballero Soto, M., Sanz Navarro, E.

INTRAOPERATIVE STENT-VAC AS PROPHYLAXIS FOR DEHISCENCE IN IVOR LEWIS OESOPHAGECTOMY

25th NATIONAL SURGERY MEETING. Valladolid, November 2025

Poster presentation

Campos Mánhez, J., Trallero Anoro, M., Martínez Lapiedra, C., Izquierdo Moreno A., Carbonell Castelló, F., Fuster Diana, C.

24th NATIONAL MEETING OF HEPATOBILIOPANCREATIC SURGERY AND TRANSPLANTATION OF THE SPANISH ASSOCIATION OF SURGEONS

24th NATIONAL MEETING OF HEPATOBILIOPANCREATIC SURGERY. Barcelona, October 2025

Attendance

Carbonell Castelló, F.

25th NATIONAL SURGERY MEETING

25th NATIONAL SURGERY MEETING. Valladolid, November 2025

Poster presentation

Ríos Agudo, A.

25th NATIONAL MEETING OF THE SPANISH ASSOCIATION OF SURGEONS: SURGERY- INNOVATE, LEARN, CURE

25th NATIONAL MEETING OF THE SPANISH ASSOCIATION OF SURGEONS. Valladolid, November 2025

Attendance

Trallero Anoro, M., Ríos Agudo, A.

25th NATIONAL MEETING OF THE SPANISH ASSOCIATION OF SURGEONS: SURGERY- INNOVATE, LEARN, CURE

25th NATIONAL MEETING OF THE SPANISH ASSOCIATION OF SURGEONS. Valladolid, November 2025

Poster presentation

Campos Mánhez, J.

28th NATIONAL CONGRESS OF COLOPROCTOLOGY. Murcia, May 2025

Attendance

Izquierdo Moreno, A.

DIPLOMA – SKIN- AND NIPPLE-SPARING MASTECTOMY: EXPERIENCE, INDICATIONS AND OUTCOMES OVER 5 YEARS AT THE VALENCIAN INSTITUTE OF ONCOLOGY
SKIN- AND NIPPLE-SPARING MASTECTOMY

2nd AEPCIMA CONGRESS. Málaga, May 2025

Oral presentation

Vento Maggio, G. , Sanz Navarro, E. , Maisto, V., Ríos Agudo, A., Caballero Soto, M., Pérez Pérez, T., Gutiérrez, C., Fuster Diana, C.

Vento Maggio, G.

COURSES

DE-ESCALATION IN BREAST CANCER SURGERY: PRESENT AND FUTURE

Picassent, February 2025

Presentation

Ríos Agudo, A.

COLORECTAL SURGEON-LED PROCEDURE REFINEMENT

Attendees: Izquierdo Moreno, A.

Amsterdam, April 2025

How to Start Managing Basic Artificial Intelligence Applications in Healthcare

Attendees: Trallero Anoro, M.

August 2025. Online

How to Improve Clinical Decision-Making with Artificial Intelligence

Attendees: Trallero Anoro, M.

August 2025. Online

PRACTICAL ABDOMINAL WALL COURSE

Attendees: Carbonell Castelló, F.

June 2025. Madrid

8th ADVANCED COURSE IN VASCULAR AND NERVE MICROSURGERY

Attendees: Ríos Agudo, A., Fuster Diana, C.

Vitoria, November 2025

ZARAGOZA HPB MEETING AND UEMS HPB PREPARATORY COURSE

Attendees: Caballero Soto, M.

Zaragoza, September 2025

CLINICAL SESSIONS

Multidisciplinary

MORBIDITY AND MORTALITY

Carbonell Castelló, F.

January 2025
Multidisciplinary
GASTRIC CANCER
Campos Máñez, J.
July 2025

Multidisciplinary
AEPICIMA CONGRESS SUMMARY
Ríos Agudo, A.
September 2025

Multidisciplinary
PROCTOLOGY CONGRESS SUMMARY
Izquierdo Moreno, A.
September 2025

Multidisciplinary
THROMBOEMBOLIC PROPHYLAXIS
Caballero Soto, M.
November 2025

Multidisciplinary
SURGERY IN OLIGOMETASTATIC DISEASE IN PANCREATIC AND OESOPHAGOGAS-
TRIC CANCER

Trallero Anoro, M.
November 2025

Multidisciplinary
MELANOMA. UPDATE
Pérez Pérez, T.
November 2025

Multidisciplinary
SOUND AND INSEMA STUDY AT IVO
Maisto, V.
December 2025

Multidisciplinary
HEPATOBIILIARY CONGRESS
Carbonell Castelló, F.
December 2025

Multidisciplinary
SESPM CONGRESS
Vento Maggio, G.
December 2025

THORACIC SURGERY

ARTICLES IN INTERNATIONAL JOURNALS

Persistence of indocyanine green one week after percutaneous injection into pulmonary nodules

Arrarás Martínez, M., de Aguiar Quevedo, K., Barrios Benito, M.

Arch Bronconeumol. 2025;S0300-2896(25)00384-9

10.1016/j.arbres.2025.10.014 41198529

The International Association for the Study of Lung Cancer staging project: the database and proposal for the revision of the staging of pulmonary neuroendocrine carcinoma in the forthcoming ninth edition

Ming Sound, T., Rosenthal, A., Nicholson, A.G., Detterbeck, F., Eberhardt, W.E.E., Lievens, Y., Lim, E., Matilla, J.M., Yatabe, Y., Filosso, P.L., Beyruti, R., Nishimura, K.K., Travis, W.D., Uyiosa Osarogiagbon, R., Rami-Porta, R., Rusch, V., Asamura, H., Members of the IASLC Staging and Prognostic Factors Committee, the Advisory Boards, and Participating Institutions

J Thorac Oncol. 2025;20(7):856–870

10.1016/j.jtho.2025.01.013 39864546

NATIONAL CONFERENCES

58th SEPAR CONGRESS. Bilbao, June 2025

Attendance

Martínez Pérez, E.

5th MASTERCLASS IN UNIPORTAL THORACIC SURGERY. PUERTA DE MAR UNIVERSITY HOSPITAL

<https://www.i3neteventos.es/portfolio/v-masterclas> Online, February 2025

Attendance

Arrarás Martínez, M.

15th CONGRESS OF THE SPANISH SOCIETY OF THORACIC SURGERY. Alicante, May 2025

Attendance

Arrarás Martínez, M.

COURSES

4th MEETING ON PULMONARY HYPERTENSION AND 6th MEETING ON RIGHT VENTRICULAR DYSFUNCTION

Valencia, March 2025

Attendance

Martínez Pérez, E.
2nd INTERHOSPITAL MEETING OF PULMONOLOGY IN THE VALENCIAN COMMUNITY
Valencia, October 2025

Attendance

Martínez Pérez, E.

Presentation

Cruz Chamorro, D. and Luna Pardo, C.

7th ONLINE PNEUMONIA MEETING. November 2025

Attendance

Martínez Pérez, E.

INNOVATION MEETING BY INTUITIVE

Madrid, January 2025

Attendance

Arrarás Martínez, M.

OBSERVERSHIP IN ROBOTIC SURGERY

Barcelona, October 2025

Attendance

Arrarás Martínez, M.

5th UPDATE MEETING IN ONCOLOGY FOR PRIMARY CARE 2025

Valencia, November 2025.

Presentation

Martínez Pérez, E.

3rd INTERHOSPITAL MEETING OF PULMONOLOGY IN THE VALENCIAN COMMUNITY

Castellón, December 2025

Attendance

Martínez Pérez, E.

Presentation

Cruz Chamorro, D. and Luna Pardo, C.

TRAINING PLACEMENT IN THE PULMONOLOGY DEPARTMENT OF LA FE HOSPITAL:
RESPIRATORY FUNCTION TESTING LABORATORY

Valencia, November 2025.

Attendance

Martínez Pérez, E.

DERMATOLOGY

ARTICLES IN INTERNATIONAL JOURNALS

Association of MC1R variants with melanoma risk and interaction with sun exposure: an M-SKIP project

Stefanaki, I., D'Ecclesiis, O., Vignati S., Gaeta, A., Kypreou, K., Caini, S., Gandini, S., Nagore, E., Sera, F., Botta, F., Newton-Bishop, J.A., Polsky, D., Lazovich, D., Kanetsky, P., Puig, S., Gruis, N., Landi, M.T., Fargnoli, M.C., Stratigos, A., Guida, G., Ghiorzo, P., Menin, C., García-Borrón, J.C., Little, J., Nan, H., Raimondi, S.
J Eur Acad Dermatol Venereol. 2025;39(7):e568–e571
10.1111/jdv.20380 39425518

Avelumab to treat Merkel cell carcinoma: real-life experience in a dedicated oncology centre

Ríos-Viñuela, E., García-Vázquez, M., Juan, M.J., Nagore, E., Requena, C., Sanmartín, O., Llombart, B.
Actas Dermosifiliogr. 2025;116(1):T81–T86
10.1016/j.ad.2024.10.017 39395689

Comparison of nonacral cutaneous lentiginous melanomas according to solar elastosis grade: support for the new World Health Organization classification

Moro, R., Mayo-Martínez, F., García-Casado, Z., Aguerralde-Martín, M., Traves, V., Manrique-Silva, E., Requena, C., Elder, D.E., Nagore, E.
2025
10.1016/j.ad.2025.104519 41352586

Comparison of nonacral cutaneous lentiginous melanomas according to the degree of solar elastosis: support for the new World Health Organization classification

Moro, R., Mayo Martínez, F., García Casado, Z., Aguerralde Martín, M., Traves, V., Manrique Silva, E., Requena, C., Elder, D.E., Nagore, E.
Actas Dermosifiliogr. 2025;117(2)
10.1016/j.ad.2025.104519 41352586

Cutaneous AL-type amyloidomas as a variant of primary cutaneous marginal zone lymphoma: a series of 30 patients

García González, S., García García, M., Miguel Miguel, C., Córdoba Iturriagagoitia, A., Yanguas Bayona, J.I., Nájera Botello, L., Cabeza Martínez, R., Santos-Briz Terrón, A., Torre Castro, J., Sánchez Martínez, E., Rodríguez Pinilla, S.M., Hillen, U., Requena Caballero, C., Cerroni, L., Martínez Cisneros, S.P., Lezcano Biosca, V., Carracedo Vega, E., Díaz de la Pinta, F.J., Prieto-Torres, L.
Am J Dermatopathol. 2025;47(11):846–856
10.1097/DAD.00000000000003124 40905400

Dermoscopy findings of adverse nail effects in cancer patients: observational study of 140 patients

Laso Leizcano, C., Gavillero, A., Navarro Campoamor, L., García Lozano, T., Nagore E.
Actas Dermosifiliogr., 2025 ()

10.1016/j.ad.2025.104540 41371397

Dermoscopy findings of adverse nail effects in cancer patients: observational study of 140 patients

Laso Leizcano, C., Gavillero, A., Navarro Campoamor, L., García Lozano, T., Nagore Enguádanos, E.

Actas Dermosifiliogr., 2025 ()

10.1016/j.ad.2025.104540 41371397

From bench to bedside: exploring the role of sCD25 in melanoma and lung cancer among sleep apnea patients

Díaz García, E., Alfaro, E., Pérez Moreno, P., López Fernández, C., García Sánchez, A., Martínez García, M.A., Mañas, E., Cano Pumarega, I., Casitas, R., Campos Rodríguez, F., Sánchez de la Torre, M., Nagore, E., Martorell Calatayud, A., Hernández Blasco, L., Pastor, E., Abad Capa, J., Montserrat, J.M., Cabriada Nuño, V., Corral Peñafiel, J., Arias, E., Mediano, O., Somoza González, M., Dalmau Arias, J., Almendros, I., Troncoso Acevedo, F., Gotera Rivera, C., Pérez Warnisher, T., Peces Barba, G., Seijo, L.M., Gozal, D., García Río, F., Cubillos Zapata, C.

Pulmonology. 2025;31(1)

10.1080/25310429.2025.2590870 41396725

From bench to bedside: exploring the role of sCD25 in melanoma and lung cancer among sleep apnea patients

Díaz García, E., Alfaro, E., Pérez Moreno, P., López Fernández, C., García Sánchez, A., Martínez García, M.A., Mañas, E., Cano Pumarega, I., Casitas, R., Campos Rodríguez, F., Sánchez de la Torre, M., Nagore, E., Martorell Calatayud, A., Hernández Blasco, L., Pastor E., Abad Capa, J., Montserrat, J.M., Cabriada Nuño, V., Corral Peñafiel, J., Arias, E., Mediano, O., Somoza González, M., Dalmau Arias, J., Almendros, I., Troncoso Acevedo, F., Gotera Rivera, C., Pérez Warnisher, T., Peces Barba, G., Seijo, L.M., Gozal, D., García Río, F., Cubillos Zapata, C.

Pulmonology. 2025;31(1)

10.1080/25310429.2025.2590870 41396725

Immune checkpoint biomarkers galectin-9 and TIM-3 predict melanoma and lung cancer mortality in obstructive sleep apnea

Díaz-García, E., Alfaro, E., Pérez-Moreno, P., López-Fernández, C., García-Sánchez, A., Martínez-García, M.A., Mañas, E., Cano-Pumarega, I., Casitas, R., Campos-Rodríguez, F., Sánchez-de-la-Torre, M., Nagore, E., Martorell-Calatayud, A., Hernández-Blasco, L., Pastor, E., Abad-Capa, J., Montserrat, J.M., Cabriada-Nuño, V., Corral-Peñafiel, J., Arias, E., Mediano, O., Somoza-González, M., Dalmau-Arias, J., Almendros, I., Troncoso-Acevedo, F., Gotera-Rivera, C., Pérez-Warnisher, T., Peces-Barba, G.M., Seijo, L.M., Gozal, D., García-Río, F., Cubillos-Zapata, C.

2025 S0300-2896 (25)

10.1016/j.arbres.2025.03.018 40287376

Immune checkpoint biomarkers galectin-9 and TIM-3 predict melanoma and lung cancer mortality in obstructive sleep apnea

Díaz García, E., Alfaro, E., Pérez Moreno, P., López-Fernández, C., García Sánchez, A., Martínez García, M.A., Mañas, E., Cano Pumarega, I., Casitas, R., Campos Rodríguez, F., Sánchez de la Torre, M., Nagore, E., Martorell Calatayud, A., Hernández Blasco, L., Pastor, E., Abad Capa, J., Montserrat, J.M., Cabriada Nuño, V., Corral-Peñafiel, J., Arias, E., Mediano, O., Somoza González, M., Dalmau Arias, J., Almendros, I., Troncoso Acevedo, F., Gotera Rivera, C., Pérez Warnisher, T., Peces Barba, G., Seijo, L.M., Gozal, D., García Río, F., Cubillos Zapata, C.

Arch Bronconeumol. 2025 Dec;61(12):735-748.

10.1016/j.arbres.2025.03.018 40287376

Interobserver variability in the histopathological evaluation of melanoma: analysis of 60 cases

Sanz-Motilva, V., Martorell, A., Manrique-Silva, E., Terradez-Mas, L., Requena, C., Traves, V., Sanmartín, O., Rodríguez-Peralto, J.L., Nagore, E.

Actas Dermosifiliogr. 2025;S0001-7310(25)

10.1016/j.ad.2025.04.004 40187558

Microsatellitosis of cutaneous melanomas in wide local excision specimens after excisional biopsy

Vargas-Mora, P., González-Cuevas, R., Requena, C., Manrique-Silva, E., Traves, V., Nagore, E.

J Eur Acad Dermatol Venereol. 2025 ()

10.1111/jdv.20653 40123285

Mohs micrographic surgery in immunosuppressed vs immunocompetent patients: results of a prospective nationwide cohort study (REGESMOHS, Spanish registry of Mohs surgery)

Abril-Pérez, C., Mansilla-Polo, M., Escutia-Muñoz, B., Sanmartín, O., Garcés, J.R., Rodríguez-Prieto, M.A., Ruiz-Salas, V., de Eusebio-Murillo, E., Miñano-Medrano, R., González-Sixto, B., Artola-Igarza, J.L., Alfaro-Rubio, A., Redondo, P., Delgado-Jiménez, Y., Sánchez-Schmidt, J.M., Allende-Markixana, I., Alonso-Pacheco, M.L., García-Bracamonte, B., de la Cueva-Dobao, P., Navarro-Tejedor, R., Ciudad-Blanco, C., Carnero-González, L., Vázquez-Veiga, H., Cano-Martínez, N., Serra-Guillén, C., Vilarrasa, E., Sánchez-Sambucety, P., López-Estebarez, J.L., Flórez-Menéndez, Á., Martorell-Calatayud, A., Gil, P., Morales-Gordillo, V., Toll, A., Ocerin-Guerra, I., Mayor-Arenal, M., Suárez-Fernández, R., Sainz-Gaspar, L., Descalzo, M.A., García-Doval, I., Botella-Estrada, R.

J Eur Acad Dermatol Venereol. 2025;39(2):426–434.

10.1111/jdv.20103 38733285

Multicenter analysis of the surgical management and adjuvant therapy of patients with melanoma and a positive sentinel lymph node biopsy

Samaniego-González, E., Podlipnik, S., Ribero, S., Nagore, E., Boada, A., Cañueto, J., Paradela, S., de Unamuno, B., Rodríguez-Jiménez, P., Puig, S., Malveyh, J., Carrera, C., Rocuzzo, G., Requena, C., Manrique-Silva, E., Richarz, N., Ruiz-Villanueva, A., Traves, V., España-Fernández, S., Botella-Estrada, R., González-Morán, M.A., Tejera-Vaquerizo, A.

Actas Dermosifiliogr., 2025, 116 (3), T233–T244

10.1016/j.ad.2024.12.005 39725282

Neutrophil-to-lymphocyte ratio associated with worse melanoma-specific survival and distant metastasis-free survival in localized (stage I and II) cutaneous melanoma: an observational retrospective study

Ciobotariu, I., Ortega-Berbel, L.A., Calderón-Mollinedo, A., Aguerralde-Martín, M., Requena, C., Moro, R., Manrique-Silva, E., Traves, V., Nagore, E.

Int J Dermatol. 2025;64(10):1855–1861

10.1111/ijd.17920 40629553

Paraneoplastic dermatomyositis: a 25-patient series from a cancer center.

Requena, C., Sánchez-Romero, E., Nagore, E., Sanmartín, O.

Actas Dermosifiliogr., 2025 ()

10.1016/j.ad.2025.02.012 39938778

Photodynamic diagnosis correlation with mapping biopsies in extramammary Paget's disease

Mayo Martínez, F., Llombart Cussac, B., Moro, R.

J Eur Acad Dermatol Venereol. 2025.

10.1111/jdv.20783 40497560

Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach

Muñoz Couselo, E., Cañueto, J., Jerviz Guía, V., López López, A.M., Bermejo Segú, J.O., García Castaño, A., Puig Sardá, S., Sanmartín Jiménez, O., Soria Rivas, A., Gratal, P., Pardo, M.T., Rogado, A., Berrocal Jaime, A.

Clin Transl Oncol. 2025

10.1007/s12094-024-03826-5 39699741

Response to sonidegib in advanced basal cell carcinomas by histological subtype: a real-world cohort

Jiménez-Sánchez, A., Muñoz Moreno-Arrones, Ó., Béa Ardebol, S., Mayo Martínez, F., Pérez Pastor, G., Torres Navarro, I., Bonfill Ortí, M., Ruiz Salas, V., Masferrer, E., Martos Cabrera, L., Deza, G., Fernández de Misa Cabrera, R., Feal, C., Turrión Merino, L., Toll, A., Abril Pérez, C., Botella Estrada, R., Yébenes, M., Galiano Mejías, S., Jiménez Gallo, D., Ferrandiz Pulido, C., Florez, A., Hernández Hernández, N., Rios Buceta, L., Sanmartín, O., Ciudad Blanco, C., Jaka, A., Just-Sarobé, M., Conde Taboada, A., Mayor Arenal, M., Vargas Laguna, E., Alcaraz León, I., Leal, L., Medina Montalvo, S., Polo, I., Hernández Marín, B., Soria, A., Delgado Jiménez, Y., Rodríguez Jiménez, P.

Int J Dermatol. 2025

doi: 10.1111/ijd.17896. 40468572

Secondary intention healing time of postoperative surgical cancer skin wounds with a biosynthetic porcine type I collagen dressing: a 306-patient retrospective observational study

Gavillero Martín, A., Juliá Roca, M., Serra Guillén, I., Rodríguez Hernández, A., Manrique Silva, E., López Sundh, A.E., Nagore, E.

Actas Dermosifiliogr., 2025

10.1016/j.ad.2025.02.022 40015452

Stromal lipid species dictate melanoma metastasis and tropism.

Gurung, S., Budden, T., Mallela, K., Jenkins, B., von Kriegsheim, A., Manrique, E., Millán-Esteban, D., Romero-Camarero, I., Amaral, F., Craig, S., Durao, P., Pozniak, J., Stennett, L., Smith, D., Ashton, G., Baker, A., Zeng, K., Fruhwirth, G., Sanz-Moreno, V., Marques, J., Koulman, A., Marine, J.C., Somervaille, T.C.P., Motta, L., Gaudy-Marqueste, C., Nagore, E.

Cancer Cell. 2025;S1535-6108(25)

10.1016/j.ccell.2025.04.001. 40280124

Study of risk factors for the presence of interdigital nevi of the feet

Sánchez-García, V., Senent-Valero, M., Mexía Belda, B., Nagore, E., Bañuls, J.

Actas Dermosifiliogr., 2025;116(8):830–836

10.1016/j.ad.2025.06.005 40562167

Survival prognostic factors in patients with melanoma and unidentifiable sentinel lymph node: a case series of 72 patients

Ciobotariu, I., López Pardo, M., Mas Lucas, M.I., Manrique Silva, E., Requena, C., Traves, V., Moro, R., Nagore, E.

Int J Dermatol. 2025 ()

10.1111/ijd.17833 40488329

The pigmented hard palate: a long-term outcome of imatinib

Mayo-Martínez, F., Requena, C., Llombart, B.

Actas Dermosifiliogr., 2025 S0001-7310 (25)

10.1016/j.ad.2025.02.017. 39746652

Tumor microRNA signatures associate with stage II/III melanoma patient outcomes

Wiggins, J.M., Zhang, Q., Zhang, Y., Vand-Rajabpour, F., Hanniford, D., He, L., Lu, Y., Kenney, J.M., Sadeghi, K.D., Argibay, D., Orlow, I., Busam, K.J., Lezcano, C., Lee, T.K., Luo, L., Gorlov, I.P., Amos, C., Ernstoff, M.S., Seshan, V.E., Cust, A.E., Wilmott, J., Scolyer, R.A., Mann, G.J., Reiner, A., Kostrzewa, C.E., Nagore, E., Funchain, P., Ko, J., Edmiston, S.N., Conway, K., Googe, P.B., Ollila, D.W., Lee, J.E., Rees, J.R., Thompson, C.L., Gerstenblith, M., Bosenberg, M., Gould Rothberg, B.E., Osman, I., Saenger, Y., Reynolds, A.Z., Boyce, T., Holmen, S., Yan, S., Brunsgaard, E., Bogner, P., Kuan, P.F., Thomas, N.E., Begg, C.B., Shen, R., Berwick, M., Shao, Y., Polsky, D., Hernando, E.

Clin Cancer Res., 2025

10.1158/1078-0432.CCR-24-3785 41114662

Tumor miRNA signatures associate with outcomes of patients with stage II/III melanoma

Wiggins, J.M., Zhang, Q., Zhang, Y., Vand-Rajabpour, F., Hanniford, D., He, L., Lu, Y., Kenney, J.M., Sadeghi, K.D., Argibay, D., Orlow, I., Busam, K.J., Lezcano, C., Lee, T.K., Luo, L., Gorlov, I.P., Amos, C., Ernstoff, M.S., Seshan, V.E., Cust, A.E., Wilmott, J., Scolyer, R.A., Mann, G.J., Reiner, A., Kostrzewa, C.E., Nagore, E., Funchain, P., Ko, J., Edmiston, S.N., Conway, K., Googe, P.B., Ollila, D.W., Lee, J.E., Rees, J.R., Thompson, C.L., Gerstenblith, M., Bosenberg, M., Gould Rothberg, B.E., Osman, I., Saenger, Y., Reynolds, A.Z., Boyce, T., Holmen, S., Yan, S., Brunsgaard, E., Bogner, P., Kuan, P.F., Thomas, N.E., Begg, C.B., Shen, R., Berwick, M., Shao, Y., Polsky, D., Hernando, E.

Clin Cancer Res., 2025;31(24):5225–5236

10.1158/1078-0432. 41114662

INTERNATIONAL CONFERENCES

ATHENS, October 2025

Attendance

Mayo Martínez, F.

11th WORLD CONGRESS OF MELANOMA – 21st EADO CONGRESS Athens, April 2025

Presentation

Nagore Enguádanos, E.

AAD ANNUAL MEETING. ORLANDO, FLORIDA, March 2025

Attendance

Llombart Cussac, B.

EADV CONGRESS. Paris, September 2025

Presentation

Nagore Enguídanos, E.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February 2025

Moderator

Serra Guillén, C.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. Valencia, February 2025

Organiser / Coordinator role

Llombart Cussac, B.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. Valencia, February 2025

Organiser / Coordinator role

Sanmartín Jiménez, O.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. Valencia, February 2025

Organiser / Coordinator role

Manrique Silva, E.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. Valencia, February 2025

Organiser / Coordinator role

Mayo Martínez, F.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. Valencia, February 2025

Organiser / Coordinator role

Nagore Enguídanos, E.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. Valencia, February 2025

Organiser / Coordinator role

Requena Caballero, C.

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. Valencia, February 2025

Organiser / Coordinator role

Serra Guillén, C.

Update on the management of cutaneous squamous cell carcinoma

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February 2025

Moderator

Sanmartín Jiménez, O.

Key points in the diagnosis of subungual melanocytic lesions

XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February

2025
Moderator
Requena Caballero, C.

Advances in the management of cutaneous lymphomas
XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February
2025
Moderator
Llombart Cussac, B.

New prognostic biomarkers in cutaneous squamous cell carcinoma
XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February
2025
Moderator
Sanmartín Jiménez, O.

Overdiagnosis in melanoma
XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February
2025
Moderator
Nagore Enguítanos, E.

Sun Pharma internal team meeting
Glasgow, August 2025
Presentation
Moro, R.

Systemic treatment of basal cell carcinoma
XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February
2025
Moderator
Mayo Martínez, F.

Unmet needs and strategies in actinic keratosis management: insights from the UK
XII INTERNATIONAL SYMPOSIUM ON ADVANCES IN DERMATO-ONCOLOGY. February
2025
Moderator
Sanmartín Jiménez, O.

NATIONAL CONFERENCES

3rd CONGRESS OF HIDRADENITIS SUPPURATIVA. Madrid, November 2025
Attendance
Lorenz Dolz, J.

36 GEDOC. Valencia, February 2025
Moderator
Sanmartín Jiménez, O.

36 GEDOC Meeting, February 2025

Presentation

Mayo Martínez, F., Moro, R., Serra Guillén, C., Llombart Cussac, B., Requena Caballero, C., Nagore Enguídanos, E., Mascarell Escrivá, L., Sanmartín Jiménez, O.

36 GEDOC VALENCIA. February 2025

Organiser / Coordinator role

Sanmartín Jiménez, O.

37 GEDOC Barcelona. November 2025

Organiser / Coordinator role

Sanmartín Jiménez, O.

37 GEDOC Barcelona. November 2025

Moderator

Sanmartín Jiménez, O.

AEDV 2025. Valencia, May 2025

Organiser / Coordinator role

Nagore Enguídanos, E.

AEDV 2025. Valencia, May 2025

Organiser / Coordinator role

Requena Caballero, C.

Meeting of experts on long-term melanoma survivors. Madrid, March 2025

Presentation

Nagore Enguídanos, E.

19th NATIONAL MEETING OF DERMATOLOGY RESIDENTS. October 2025

Attendance

Lorenz Dolz, J.

How would you manage oncologic dermatology and dermatologic surgery? Case No. 3

AEDV 2025. Valencia, May 2025

Presentation

Serra Guillén, C.

How would you manage oncologic dermatology and dermatologic surgery?

AEDV 2025. Valencia, May 2025

Organiser / Coordinator role

Sanmartín Jiménez, O.

Actas Dermo-Sifiliográficas

19th NATIONAL MEETING OF DERMATOLOGY RESIDENTS. Barcelona, October 2025

Nagore Enguídanos, E.

Therapeutic update in extramammary Paget disease: how to treat each case

AEDV 2025. Valencia, May 2025

Presentation

Mayo Martínez, F.

AEDV Board working groups
AEDV 2025. Valencia, May 2025
Organiser / Coordinator role
Serra Guillén, C.

Advances and challenges in oncologic dermatologic surgery
37 GEDOC Barcelona. November 2025
Moderator
Serra Guillén, C.

Skin cancer: management of patients with locally advanced basal cell carcinoma
19th NATIONAL MEETING OF DERMATOLOGY RESIDENTS. Barcelona, October 2025
Presentation
Sanmartín Jiménez, O.

Cutaneous squamous cell carcinoma of the scalp with bone involvement: risk factors, management and prognosis. Multicenter retrospective study of 19 Spanish hospitals
37 GEDOC, November 2025
Presentation
Sanmartín Jiménez, O.

Problem case No. 2
AEDV 2025. Valencia, May 2025
Presentation
Requena Caballero, C.

Dermatopathology cases. Case No. 4
AEDV 2025. Valencia, May 2025
Presentation
Sanmartín Jiménez, O.

Mohs surgery in uncommon skin cancer: when is it indicated?
AEDV 2025. Valencia, May 2025
Presentation
Moro, R.

Mohs surgery in uncommon skin cancer: when is it indicated?
AEDV 2025. Valencia, May 2025
Presentation
Moro, R.

Immediate Mohs surgery vs delayed Mohs surgery
36 GEDOC VALENCIA. February 2025
Presentation
Serra Guillén, C.

Oncologic reconstructive surgery from the perspective of functionality and the importance of aesthetics
36 GEDET Meeting. Madrid, September 2025
Moro, R.

GEDOC clinical cases. Case No. 6
37 GEDOC Barcelona. November 2025
Oral presentation
Nagore Enguádanos, E.

Reading man flap on the scalp: multicenter experience
37 GEDOC Barcelona. November 2025
Mayo Martínez, F.

Double hatchet flap for reconstruction of surgical scalp defects
GEDOC Barcelona. November 2025
Oral presentation
Díez Santandreu, A.

Lateral lobulated flaps: reconstructive solutions in oncologic dermatologic surgery
37 GEDOC Barcelona. November 2025
Oral presentation
Lorenz Dolz, J.

SCIENTIFIC COMMITTEE
AEDV 2025. Valencia, May 2025
Organiser / Coordinator role
Nagore Enguídanos, E.

SCIENTIFIC COMMITTEE
AEDV 2025. Valencia, May 2025
Organiser / Coordinator role
Sanmartín Jiménez, O.

Oral communications in oncology II
36 GEDOC. Valencia, February 2025
Moderator
Llombart Cussac, B., Requena Caballero, C.

Technical considerations in Mohs surgery
36 GEDOC VALENCIA. February 2025
Presentation
Moro, R.

Working group coordinators. Dermato-oncology and surgery
AEDV 2025. Valencia, May 2025
Organiser / Coordinator role
Sanmartín Jiménez, O.

When molecular biology is truly helpful: experience in uncommon skin cancer
37 GEDOC Barcelona. November 2025
Requena Caballero, C.

Dermato-oncology
37 GEDOC Barcelona. November 2025
Moderator
Sanmartín Jiménez, O.

Extramammary Paget disease: key features and management recommendations
36 GEDOC. Valencia, February 2025
Moderator
Mayo Martínez, F.

Multicenter observational study on the outcomes of the "dog ear" flap technique in dermatologic surgery

37 GEDOC, November 2025

Presentation

Mayo Martínez, F.

Impact of delayed sentinel lymph node biopsy on nodal metastatic burden and prognosis in patients with melanoma and positive sentinel lymph node

37 GEDOC Barcelona. November 2025

Oral presentation

Nagore Enguídanos, E.

Neutrophil-to-lymphocyte ratio as a prognostic biomarker in cutaneous squamous cell carcinoma Retrospective study

36 GEDOC, February 2025

Oral presentation

Diéz Santandreu, A., Manrique Silva, E., Nagore Enguídanos, E., Lorenz Dolz, J., Serra Guillén, C., Llombart Cussac, B., Requena Caballero, C., Mayo Martínez, F., Sanmartín Jiménez, O.

Immunotherapy in advanced cutaneous squamous cell carcinoma: retrospective study and experience at our center

36 GEDOC, February 2025

Oral presentation

Nagore Enguídanos, E., Llombart Cussac, B., Sanmartín Jiménez, O.

AEDV Board of Directors. Editorial management of the journal *Actas*

AEDV 2025. Valencia, May 2025

Organiser / Coordinator role

Nagore Enguídanos, E.

Best of the year published in *Actas*

AEDV 2025. May 2025

Presentation

Nagore Enguídanos, E.

Lentigo maligna and lentigo maligna melanoma treated with Mohs micrographic surgery with paraffin sections: a single-center retrospective study

37 GEDOC Barcelona. November 2025

Oral presentation

Moro, R.

Benign melanocytic lesions

June 2025

Presentation

Requena Caballero, C.

Malignant melanocytic lesions

June 2025

Presentation

Requena Caballero, C.

Melanoma

36 GEDOC. Valencia, February 2025

Moderator

Nagore Enguídanos, E.
Educational session
36 GEDOC. Valencia, February 2025

Moderator
Nagore Enguídanos, E.
Educational session. Cutaneous tumour committee. Clinical cases
37 GEDOC Barcelona. November 2025

Moderator
Sanmartín Jiménez, O.

MODULE II: BASAL CELL CARCINOMA
3rd COURSE IN SKIN CANCER FOR RESIDENTS (R3). Barcelona, February 2025
Sanmartín Jiménez, O.

MODULE V: OTHER TUMORS: update in Merkel tumor
3rd COURSE IN SKIN CANCER FOR RESIDENTS (R3). Barcelona, February 2025
Llombart Cussac, B.

MODULE V: OTHER TUMORS, MERKEL UPDATE
3rd COURSE IN SKIN CANCER FOR RESIDENTS (R3). Barcelona, February 2025
Llombart Cussac, B.

New molecules in oncology. Key points to identify new adverse effects
AEDV 2025. May 2025
Presentation
Sanmartín Jiménez, O.

Organizing resources in screening within prevention campaigns. Use of AI
Valencia, May 2025
Presentation
Nagore Enguídanos, E.

Current role of lymph node dissection in patients with melanoma and positive sentinel lymph node: multicenter analysis of clinical practice in our setting and its impact
36 GEDOC, February 2025
Oral presentation
Nagore Enguídanos, E.

Role of surgery in melanoma in the new era of neoadjuvant therapy
XVI SYMPOSIUM GEM. La Coruña, June 2025
Presentation
Nagore Enguídanos, E.

Immunohistochemical profile and survival analysis in perianal extramammary Paget disease
37 GEDOC, November 2025
Presentation
Llombart Cussac, B.

ACTINIC KERATOSES AND FIELD CANCERIZATION: therapeutic approach and clinical guidelines
3rd COURSE IN SKIN CANCER FOR RESIDENTS (R3). Barcelona, February 2025
Serra Guillén, C.

Drug reactions

June 2025

Presentation

Sanmartín Jiménez, O.

Review of treatment with imatinib in dermatofibrosarcoma protuberans

36 GEDOC, February 2025

Oral presentation

Nagore Enguítanos, E., Serra Guillén, C., Llombart Cussac, B., Requena Caballero, C., Mayo Martínez, F., Sanmartín Jiménez, O.

Tumours of the epidermis. Adnexal tumours

4th HYBRID COURSE (R2) IN DERMATOPATHOLOGY

Presentation

Sanmartín Jiménez, O.

Tumours of the epidermis.

June 2025

Presentation

Sanmartín Jiménez, O.

Mesenchymal tumours

4th HYBRID COURSE (R2) IN DERMATOPATHOLOGY

Presentation

Llombart Cussac, B.

COURSES

Euromelanoma Workshop 2025

Brussels, November 2025

Nagore Enguítanos, E.

EADO Brainstorming Meeting

Rome, November 2025

3rd COURSE IN SKIN CANCER FOR RESIDENTS (R3)

Attendees: Díez Santandreu, A.

February 2025. Barcelona

10th ADVANCED COURSE ON DERMOSCOPY

Attendees: Karkut, A.

May 2025. Barcelona

Update on the Treatment of Actinic Keratoses and Field Cancerization

Speaker: Serra Guillén, C.

October 2025. Madrid

Refresher Course on Skin Cancer

Speaker: Serra Guillén, C.

October 2025. Madrid

INTRODUCTORY COURSE IN DERMATOPATHOLOGY WITH CLINICOPATHOLOGICAL

CORRELATION

Attendees: Córcoles Jannone, B.

September 2025. Madrid

PRE-CONGRESS COURSE: UPDATE IN DERMATOPATHOLOGY

Speaker: Requena Caballero, C.

November 2025. Valencia

PRE-CONGRESS COURSE: UPDATE IN DERMATOPATHOLOGY

Speaker: Sanmartín Jiménez, O.

November 2025. Valencia

ALL THAT IS NEW UNDER THE SUN

Speaker: Serra Guillén, C.

Palma de Mallorca, June 2025

UNDERGRADUATE THESIS SUPERVISION

Biomarkers in advanced cutaneous squamous cell carcinoma

Iranzo Murillo, N.

June 2025

Sanmartín Jiménez, O.

Clinicopathological, immunohistochemical and genetic study of a series of desmoplastic melanoma cases

Martínez Valsangiacomo, M.

June 2025

Requena Caballero, C.

Immunotherapy in the treatment of advanced cutaneous squamous cell carcinoma

García Pérez, M.

June 2025

Sanmartín Jiménez, O.

Scalp localisation as a poor prognostic factor for basal cell carcinoma

Arriete Pascual, Y.

June 2025

Requena Caballero, C.

DOCTORAL THESES

Endocrinological comorbidities in patients with hidradenitis suppurativa

Valencia, July 2025

Supervised by: Sanmartín Jiménez, O.

CLINICAL SESSIONS

Cutaneous manifestations of Lyme borreliosis

Lorenz Dolz, J.

March 2025

Cutaneous manifestations of Borrelia infection

Lorenz Dolz, J.

March 2025

Cutaneous infiltration in non-Hodgkin lymphoma

Lorenz Dolz, J.

January 2025

Cutaneous metastasis from breast carcinoma

Lorenz Dolz, J.

2025

Darier disease

Córcoles Jannone, B.

April 2025

Histiocytoid Sweet syndrome

Córcoles Jannone, B.

May 2025

Locally advanced Merkel cell carcinoma

Córcoles Jannone, B.

December 2025

Pyoderma gangrenosum

Córcoles Jannone, B.

October 2025.

Dermatological manifestations of endocrine diseases

Córcoles Jannone, B.

November 2025

Infections in the immunocompromised patient

Lorenz Dolz, J.

2025

Sexually transmitted infections

Lorenz Dolz, J.

November 2025

Cutaneous wounds

Díez Santandreu, A.

July 2025

Fixed drug eruption

Díez Santandreu, A.

March 2025

PHARMACY

NATIONAL CONFERENCES

ANALYSIS OF DRUG INTERACTIONS USING ARTIFICIAL INTELLIGENCE: ARE WE APPROACHING ITS USE AS A WORKING TOOL?

70th National Congress of Hospital Pharmacy. Málaga, October 2025

Poster presentation

Martínez Albaladejo, P., Mengual Barroso, M.R., Ricoy Sanz, I., Llopis Alemany, A., Benet Giménez, I., Gómez Perales, A., Bernabéu Castellá, S., Andrés Blasco, C.

ANALYSIS OF MEDICATION REQUESTS IN SPECIAL SITUATIONS: DATA AND TRENDS IN ONCO-HAEMATOLOGY

Toledo, November 2025

Poster presentation

Martínez Albaladejo, P., Llopis Alemany, A., Pastor Climente, I., Bernabéu Castellá, S., Benet Giménez, I., Monroy Ruiz, M., Colomer Nieves, Y., Andrés Blasco, C.

ESTABLISHMENT OF AN EMERGENCY ACTION PROTOCOL: EXPERIENCE FOLLOWING THE DANA

70th National Congress of Hospital Pharmacy. Málaga, October 2025

Oral presentation

Martínez Albaladejo, P., Llopis Alemany, A., Ricoy Sanz, I., Benet Giménez, I., Bernabéu Castellá, S., Pastor Climente, I., Colomer Nieves, Y., Andrés Blasco, C.

MANAGEMENT OF ALERTS FOR MEDICAL PRODUCTS: RESULTS FROM THE IMPLEMENTATION OF A NOTIFICATION REGISTRY

70th National Congress of Hospital Pharmacy. Málaga, October 2025

Poster presentation

Pastor Climente, I., Martínez Albaladejo, P., Bernabéu Castellá, S., Gómez Perales, A., Andrés Blasco, C.

CHAPTERS OF BOOKS

Does the New European Health Data Space Respect the Principle of Patient Autonomy?: Methodological Proposal for the Design of a Validation Tool

People-Centred Digital Technology for Ethical and Sustainable Business Practices

Fayos Fernández, A., Andrés Blasco, C.J., IGI Global Scientific Publishing. August, 2025

10.4018/979-8-3373-0385-7.ch006

COURSES

CODIFIR: Digital Competencies for Hospital Pharmacists

Attendees: Martínez Albaladejo, P. Online, 2025

Evidence for Clinical Practice Course

Attendees: Martínez Albaladejo, P.

Online, 2025

MASTER'S IN HEALTH AND SOCIAL CARE RESEARCH

Attendees: Martínez Albaladejo, P.

2025. Online

GYNAECOLOGY

INTERNATIONAL CONFERENCES

Masterclass in Gynaecological Oncology 2025

Georgia, October 2025

Attendance

Díaz Sierra, C., Herrero Roselló, D., Martínez Gomá, R.

NATIONAL CONFERENCES

Congress of the Valencian Society of Gynaecology and Obstetrics (SOGCV)

Gandía, February 2025

Attendance

Piñero Sánchez, O.

COURSES

9th Multidisciplinary Refresher Course in Gynaecological Tumours

Madrid, March 2025

Attendance

Piñero Sánchez, O.

Da Vinci certification

Attendees: Díaz Sierra, C.

February 2025. Badalona

Course on Robotic Surgery: Malignant Hysterectomy and Pelvic Lymphadenectomy

Attendees: Garrigós Llabata, E.

Strasbourg, May 2025

Da Vinci Course

Attendees: Badía Agustí, P.

February 2025. Barcelona

Robotic Surgery PROCTOR Training

Speaker: Piñero Sánchez, O.

Valladolid, April 2025

Malignant Hysterectomy Procedure Refinement

Attendees: Garrigós Llabata, E.

November 2025. Barcelona

Continuing Education Master's in Medical and Surgical Pelvic Floor Pathology (6th edition)

Attendees: Martínez Gomá, R.

Alicante, May 2025

Robotic Surgery PROCTOR Mentoring

Speaker: Piñero Sánchez, O.

Murcia, February 2025

GASTROENTEROLOGY UNIT

NATIONAL CONFERENCES

47th SEED National Congress of the Spanish Society of Digestive Endoscopy
SEED. Valencia, November 2025
Attendance
Maia de Alcántara, F.

47th SEED National Congress of the Spanish Society of Digestive Endoscopy
SEED. Valencia, November 2025
Attendance
Martínez de Juan, F.

47th SEED National Congress of the Spanish Society of Digestive Endoscopy
SEED. Valencia, November 2025
Attendance
Martínez Lapiedra, C.

COURSES

16th Advanced Endoscopy Meeting
Madrid, September 2025
Attendance
Martínez Lapiedra, C.

Update on the Management and Treatment of Pancreatic Cancer
Speaker: Martínez de Juan, F.
Torrevieja, May 2025

Advanced Endoscopy Training (Use of Lumen-Apposing Metal Stents)
Attendees: Martínez de Juan, F.
Valencia, September 2025

CLINICAL LABORATORY AND MICROBIOLOGY

NATIONAL CONFERENCES

19th National Congress of Clinical Laboratory Medicine. November 2025
Attendance
Pérez Ballester, P.

19th National Congress of Clinical Laboratory Medicine. Valencia, November 2025
Attendance
Cervantes García, S.

19th National Congress of Clinical Laboratory Medicine. Valencia, November 2025
Attendance
Guaita Martínez, M.

COURSES

Beckman Coulter User Meeting 2025
Madrid, October 2025
Attendance
Guaita Martínez, M.

5th Conference on External Quality Assurance Programmes
Online, October 2025
Attendance
Sánchez Yepes, M.

5th Conference on External Quality Assurance Programmes
Online, October 2025
Attendance
Cervantes García, S.

The Challenge of Analytical Interferences in the Clinical Laboratory: Approach to the Pre-Analytical, Analytical and Post-Analytical Phases
Attendees: Cervantes García, S.
Valencia, November 2025

8th Multidisciplinary and International Sepsis Code Meeting
Attendees: Guaita Martínez, M.
Online, March 2025

8th Edition Interhospital Clinical Sessions on Hepatitis 2024–2025
Attendees: Olmos Arenas, R.
Online, December 2025

Organic Acidaemias

Spanish Society of Laboratory Medicine

Attendees: Cervantes García, S.

Online, December 2025

Refresher Course on Antiphospholipid Syndrome: From the Clinic to the Laboratory

Attendees: Cervantes García, S.

Valencia, September 2025

Refresher Course on Antiphospholipid Syndrome: From the Clinic to the Laboratory

Attendees: Pérez Ballester, P.

Valencia, September 2025

Refresher Course on Antiphospholipid Syndrome: From the Clinic to the Laboratory

Attendees: Sánchez Yepes, M.

Valencia, September 2025

Application of Molecular Diagnostic Techniques to the Diagnosis of Imported Diseases

Attendees: Olmos Arenas, R.

Online, November 2025

Approach to the Patient with Bleeding

Attendees: Guaita Martínez, M.

Online, May 2025

Clinical Cases in Haematological Biology

Attendees: Sánchez Yepes, M.

Online, January 2025

Clinical Cases in Autoimmunity

Spanish Society of Laboratory Medicine

Attendees: Cervantes García, S.

Online, November 2025

Clinical Cases in Autoimmunity

Spanish Society of Laboratory Medicine

Attendees: Sánchez Yepes, M.

Online, November 2025

How to Create Artificial Intelligence Assistants for Different Use Cases (USV)

Attendees: Guaita Martínez, M.

Online, August 2025

How to Improve Patient Monitoring and Follow-up Using Artificial Intelligence (USV)

Attendees: Guaita Martínez, M.

Online, August 2025

How to Improve Clinical Decision-Making Using Artificial Intelligence (USV)

Attendees: Guaita Martínez, M.

Online, August 2025

Between Evidence and Uncertainty: Lipoprotein (a) Today and Other Factors for Assessing Overall Cardiovascular Risk

Attendees: Cervantes García, S.
Online, November 2025

Between Evidence and Uncertainty: Lipoprotein (a) Today and Other Factors for Assessing Overall Cardiovascular Risk

Attendees: Sánchez Yepes, M.
Online, November 2025

Automated Mass Spectrometry: A Step Further Towards the Laboratory of the Future

Attendees: Guaita Martínez, M.
Barcelona, April 2025

The Importance of the Laboratory in Clinical Diagnosis

Attendees: Cervantes García, S.
Online, May 2025

The Importance of the Laboratory in Clinical Diagnosis

Attendees: Sánchez Yepes, M.
Online, May 2025

Inclusion of the Kappa Index in the New McDonald Criteria for the Diagnosis of Multiple Sclerosis

Attendees: Pérez Ballesteros, P.
Online, December 2025

Inclusion of the Kappa Index in the New McDonald Criteria for the Diagnosis of Multiple Sclerosis

Attendees: Sánchez Yepes, M.
Online, December 2025

Introduction to Emergencies in a Clinical Laboratory

Attendees: Cervantes García, S.
Online, October 2025

Introduction to Emergencies in a Clinical Laboratory

Attendees: Sánchez Yepes, M.
Online, October 2025

Management of *C. difficile* Infection

Attendees: Olmos Arenas, R.
Online, November 2025

Mechanisms of Action of Cefepime/Enmetazobactam

Attendees: Olmos Arenas, R.
Online, November 2025

Hepatic Pathology and Its Relationship with Oxidative Stress

Attendees: Cervantes García, S.
Online, October 2025

Hepatic Pathology and Its Relationship with Oxidative Stress

Attendees: Sánchez Yepes, M.
Online, October 2025

Pre-Analytical Phase 4.0 in the Current and Future Clinical Laboratory
Spanish Society of Laboratory Medicine
Attendees: Cervantes García, S.
Online, November 2025

Pre-Analytical Phase 4.0 in the Current and Future Clinical Laboratory
Spanish Society of Laboratory Medicine
Attendees: Sánchez Yepes, M.
Online, November 2025

Requirements of UNE-EN ISO 15189
Attendees: Olmos Arenas, R.
Madrid, March 2025

Requirements of UNE-EN ISO 15189
Attendees: Sánchez Yepes, M.
Madrid, March 2025

Biennial Meeting on Aspergillosis in Critically Ill Patients
Attendees: Olmos Arenas, R.
Online, May 2025

Inter-Hospital Sessions
Attendees: Sánchez Yepes, M.
Online, May 2025

A Practical Approach to Analytical Quality
Attendees: Cervantes García, S.
Online, June 2025

A Practical Approach to Analytical Quality
Attendees: Sánchez Yepes, M.
Online, June 2025

INTERNAL MEDICINE

NATIONAL CONFERENCES

Oncogeriatrics: Wellbeing and Quality of Life at All Stages
4th Congress of Cancer Survivors "Full of Life" October Murcia, 2025
Presentation
Parra Gómez, L.

27th National Congress of SEIMC. Málaga, May 2025
Attendance
Egido González, A.

COURSES

1st CONFERENCE ON RARE IMMUNO-HAEMATOLOGICAL DISEASES
MADRID, February 2025
Attendance
Cañado Gómez, Y.

4th CONFERENCE ON PULMONARY HYPERTENSION AND 6th CONFERENCE ON
RIGHT VENTRICULAR DYSFUNCTION
Conference of SEOM on Oncogeriatrics 2025
28th National Congress of SEIMC. Valencia, March 2025
Attendance
Parra Gómez, L.

Conference of SEOM on Oncogeriatrics
Conference of SEOM on Oncogeriatrics. Madrid, May 2025
Attendance
Parra Gómez, L., Cañado Gómez, Y.

5th Refresher Conference on Oncology for Primary Care
Prescription and Description in the Oncology Patient
Valencia, November 2025.
Presentation
Parra Gómez, L.

7th Annual Pneumonia Conference. Critical Patient Infection Study Group (GEIPC)
Online, November 2025
Attendance
Parra Gómez, L., Egido González, A.

More Than COPD 4th Meeting
Madrid, February 2025
Attendance
Parra Gómez, L.

Designing, Testing and Implementing the New IRAS and PROAS Agenda
GEIRAS Scientific Meeting
Madrid, December 2025
Egido González, A.

Communication and Clinical Interview Skills

Attendees: Parra Gómez, L., October 2025. Online

THEORETICAL-PRACTICAL REFRESHER COURSE IN DIABETES. 18th EDITION

Attendees: Cañado Gómez, Y. January 2025. Online

Online Course on Metabolic Dysfunction-Associated Steatotic Liver Disease. What the Internist Should Know

Attendees: Parra Gómez, L.

March 2025. Online

I Online Course on SEMI Decision

Decision-Making in Internal Medicine

Attendees: Parra Gómez, L.

February 2025. Online

Permanent Training Master's in Advanced Clinical Care in Infectious Diseases (3rd Edition)

Attendees: Egido González, A.

September 2025. Online

14th Refresher Course on Infectious Pathology and Antimicrobials for Clinical Use

Attendees: Parra Gómez, L.

February 2025. Online

DIRECTION OF MASTER'S DISSERTATION

Algorithm 1. Management of Opportunistic Viral Infection in the Immunocompromised Patient: Patients with Solid Organ Tumours

Egido González, A.

Barcelona (online), September 2025

Marco, A.

Algorithm 2. Management of Gastrointestinal Conditions in the Haematopoietic Transplant Patient

Egido González, A.

Barcelona (online), September 2025

Marco, A.

Algorithm 3. Diagnosis and Treatment of Pneumonia in the Immunocompromised Patient

Egido González, A.

Barcelona (online), September 2025

Marco, A.

Management of Infections in the Immunocompromised Patient. Development of Three Diagnostic Algorithms

Egido González, A.

Barcelona (online), September 2025

Marco, A.

SESSIONS WITH THE MEDICAL ONCOLOGY SERVICE

Multidisciplinary

Session on Morbidity in the Oncology Patient, Diagnosis, Approach and Controversies

May 2025

NUCLEAR MEDICINE

INTERNATIONAL CONFERENCES

EUROPEAN CONGRESS OF NUCLEAR MEDICINE. Barcelona, May 2025
Attendance
Asensio Valero, L.

EUROPEAN CONGRESS OF NUCLEAR MEDICINE. Barcelona, May 2025
Attendance
Tajahuerce Romera, M.

NATIONAL CONFERENCES

EUROPEAN CONGRESS OF NUCLEAR MEDICINE. Valladolid, May 2025
Attendance
Cardona Cardona, V.M.

COURSES

PRECEPTORSHIP IN NETs FOR NUCLEAR MEDICINE
Speaker: Asensio Valero, L.
March 2025. Valencia

CLINICAL SESSIONS

Review
PET/CT IN BREAST CANCER
February 2025

Review
DTC TREATMENT IN NUCLEAR MEDICINE
March 2025

Review
PSMA IN DIAGNOSIS AND THERAPY
March 2025

Review
PSMA PET + CT-U (PROTOCOL)
April 2025

NEUROLOGY

ARTICLES IN INTERNATIONAL JOURNALS

Clinical and radiological features of pseudoprogression in brain tumours treated with immune checkpoint inhibitors

Ibáñez-Juliá, M.J., Bataller, L., Cabello-Murgui, F.J., Nguyen-Them, L., Alentorn, A., Torres-Martínez, A., Mazón-Momparler, M., Gironés-Sarrió, R.
Journal of Neurology, 2025;174(3):779–788.

<https://doi.org/10.1007/s11060-025-05091-0> 40426008 12263762

Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathies

Muelas, N., Carretero-Villarroy, N., Martí, P., Azorín, P., Frasquet, M., Poyatos-García, J., Portela, S., Martínez-Vicente, L., Argente-Escrig, H., Sivera, R., Vázquez-Costa, J.F., Tárrega, M., Más-Estellés, F., Vílchez, R., Bataller, L., Aller, E., Diago, L., Fores-Toribio, L., Sevilla, T., Vílchez, J.J.

Journal of Neurology, 2025;272(1):97

<https://doi.org/10.1007/s00415-024-12821-3> PMID: 39775307

Teaching video neuroimage: upper eyelid nystagmus as a manifestation of wernicke encephalopathy

Benlloch, C., Bataller, L., Górriz, D., Pérez, V., Sivera, R.
Neurology, 2025;105 e214311

<https://doi.org/10.1212/wnl.0000000000214311> 41100785

NATIONAL CONFERENCES

41st Meeting of the Valencian Society of Neurology. Illustrious Official College of Physicians of Valencia. February 2025

Bataller Alberola, L.

76th Annual Meeting of the Spanish Society of Neurology. Seville, November 2025
Moderator

Bataller Alberola, L.

COURSES

INNEBI. Meeting on Biomarkers in Neurology. Hospital La Fe (Valencia), October 2025

Attendance

Bataller Alberola, L.

MEDICAL ONCOLOGY

ARTICLES IN INTERNATIONAL JOURNALS

A cross-sectional analysis from a real-world cohort of microsatellite instability colorectal cancer (MSI-CRC) patients with metastatic disease from the Spanish RETTU registry

Melián Sosa, M.

JOURNAL OF CLINICAL ONCOLOGY, 2025;43:178

10.1200/JCO.2025.43.4_suppl.178

A real-world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations

Garde Noguera, J. et al.

2025

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

Climent Durán, M.A. et al.

EUROPEAN JOURNAL OF CANCER, 2025

10.1016/j.ejca.2025.115293. 39923274

Association of PD-1, LAG-3 and TIM-3 expression on intratumoural CD8 T-cells with response to atezolizumab in a real-world evidence biomarker study for advanced urothelial carcinoma patients

Climent Durán, M.A. et al.

Oncolmmunology, 2025

10.1080/2162402X.2025.2538687

Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC

Juan Fita, M.J. et al.

FUTURE ONCOLOGY, 2025;21(8):991–1003

doi: 10.1080/14796694.2025.2468569. PMID: 40029138

Bladder preservation with Durvalumab plus Tremelimumab and concurrent radiotherapy in patients with localized muscle-invasive bladder cancer (IMMUNOPRESERVE): A Phase II SOGUG Trial

Juan Fita, M.J. et al.

CLINICAL CANCER RESEARCH, 2025;31(4):659–666

doi: 10.1158/1078-0432 PMID: 39957401

CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions

Gavilá Gregori, J.

2025;27(9):3819–3826

10.1007/s12094-025-03896-z 40146417

Clinical and transcriptomic characterization of metastatic hormone-sensitive prostate cancer patients with low PTEN expression

Climent Durán, M.A. et al.

2025 ()

10.3390/ijms26136244.40650023 PMID: PMC12249740

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study

Hernando Meliá, C. et al.

ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY, 2025;8.

10.1016/j.esmorw.2025.100123

Deciphering the transcriptomic landscape of early HR+/HER2-low breast cancer in very young women

Hernando Meliá, C. et al.

Cancer Communications (London), 2025

10.1002/cac2.70019

Do patients with HER2+ MBC and their HCPs speak the same language? Perceptions and uses of chronic disease and metastatic treatment arising from the EtnobreastHER2 study

Gavilá Gregori, J.

PATIENT EDUCATION AND COUNSELING, 2025

10.1016/j.pec.2025.109289 40768920

Effectiveness and safety of cabozantinib treatment in patients with advanced renal cell carcinoma in Spanish and Portuguese real-world practice: the SOGUG-SPRWEC study

Juan Fita, M.J. et al.

CLINICAL GENITOURINARY CANCER, 2025

doi: 10.1016/j.clgc.2025.102402 PMID: 40830022

Efficacy of anti-PD1 therapy in PD1-high mRNA tumours across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLT1-1904 ACROPOLI trial

Gavilá Gregori, J.

ESMO OPEN, 2025

10.1016/j.esmoop.2025.105838.41033278 PMID: PMC12514499

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: primary results

Hernando Meliá, C. et al.

European Journal of Cancer, 2025;25(217)

10.1016/j.ejca.2024.115219 39779447

Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor-positive advanced breast cancer: systematic review and network meta-analysis

Hernando Meliá, C. et al.

Cancer Treatment Reviews, 2025

Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumour and D842V-PDGFR mutation

Aguilar Andino, H. et al.

THE ONCOLOGIST, 2025;30(5)

doi.org/10.1093/oncolo/oyaf062

Expert opinion on current treatment alternatives in patients progressing from metastatic castration-sensitive prostate cancer after receiving treatment intensification

Juan Fita, M.J.

CLINICAL GENITOURINARY CANCER, 2025

doi: 10.1016/j.clgc.2025.102338 PMID: 40252319

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial

Gavilá Gregori, J.

ESMO OPEN, 2025

10.1016/j.esmoop.2025.105309 40532361 PMC12212146

First-line pembrolizumab plus lenvatinib for advanced non-clear cell renal cell carcinoma: updated results from the phase 2 KEYNOTE-B61 trial

Climent Durán, M.A. et al.

European Urology, 2025;88(6):614–624

10.1016/j.eururo.2025.05.019 Epub 2025 Jul 24

Immune-based combinations in intermediate-poor risk patients with non-clear cell renal carcinoma: results from the ARON-1 study

Juan Fita, M.J. et al.

EUROPEAN UROLOGY FOCUS, 2025

doi: 10.1016/j.euf.2025.05.020 PMID: 40738794

Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: a Spanish, multicentre, observational study

Climent Durán, M.A. et al.

Clinical and Translational Oncology, 2025;27(5):2220–2231

10.1007/s12094-024-03744-6

Impact of prior chemotherapy on response to second-line pembrolizumab in urothelial cancer: exploratory analysis of the phase 3 KEYNOTE-045 trial

Climent Durán, M.A. et al.

European Urology, 2025;88():462–471

10.1016/j.eururo.2024.07.015

Information needs and barriers to patient-centred care in oncology: EtnobreastHER2, an ethnographic study with HER2+ MBC patients and their healthcare providers

Gavilá Gregori, J.

FRONTIERS IN MEDICINE, 2025

10.3389/fmed.2025.1592380. 41210878 PMCID: PMC12590183

Involvement of the microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer

Hernando Meliá, C. et al.

MOLECULAR MEDICINE, 2025
10.1186/s10020-025-01163-z

Latent representation of H&E images retains biological information in a breast cancer cohort

Gavilá Gregori, J.

PLOS ONE, 2025;20(9)

10.1371/journal.pone.0329221. 40997111 PMC12463230

Multicentre, observational retrospective-prospective study to evaluate real-world data of avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma. SOGUG-AVELUMAB RW

Juan Fita, M.J. et al.

CLINICAL AND TRANSLATIONAL ONCOLOGY, 2025

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

Juan Fita, M.J. et al.

FRONTIERS IN ONCOLOGY, 2025

doi: 10.3389/fonc.2025.1605282 PMID: 40786505

NUTRIGETNE Group. Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-2109) study

Melián Sosa, M. et al.

THE ONCOLOGIST, 2025;30

10.1093/oncolo/oyae343 39998905 PMC11853595

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

Garde Noguera, J. et al.

2025

Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

Garde Noguera, J. et al.

2025

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumours: the phase 2 TUXEDO-3 trial

Garde Noguera, J. et al.

2025

Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older frail patients with metastatic renal cell carcinoma: the SOGUG-CABOMAYOR study

Climent Durán, M.A. et al.

Journal of Geriatric Oncology, 2025

10.1016/j.jgo.2025.102340

Adjuvant chemotherapy versus chemoimmunotherapy for patients with resected stage IB-IIIa non-small cell lung cancer (NADIM ADJUVANT): phase III randomized study
Sandiego Contreras, S. et al.
SEOM, 2025

Real-world experience on the use of nivolumab monotherapy for advanced renal cell carcinoma: a multicentre retrospective cohort study in Spain
Juan Fita, M.J. et al.
BMC CANCER, 2025
doi: 10.1186/s12885-025-15264-9 PMID: 41316036

Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETTU gastrointestinal registry
Melián Sosa, M. et al.
ESMO Real World Data and Digital Oncology, 2025;7:100116

Retifanlimab in advanced penile squamous cell carcinoma: the phase 2 ORPHEUS study
Climent Durán, M.A. et al.
European Urology, 2025;88(5):278–286
10.1016/j.euo.2024.04.021

SEOM-SOGUG clinical guideline for urothelial cancer
Climent Durán, M.A. et al.
Clinical and Translational Oncology, 2025;27(11):4142–4159
10.1007/s12094-025-04045-2

The impact of the therapeutic decision of massive gene sequencing (NGS) in plasma from patients with advanced non-small cell lung cancer (NSCLC)
Garde Noguera, J. et al.
2025

The spatial landscape of cancer hallmarks reveals patterns of tumour ecological dynamics and drug sensitivity
Climent Durán, M.A.
CELL REPORTS, 2025;44(2)
10.1016/j.celrep.2024

Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance for advanced urothelial cancer: the phase II DISCUS trial
Climent Durán, M.A. et al.
Annals of Oncology, 2025
10.1016/j.annonc.2025.10.011.

Effects of a targeted concurrent training program on exercise adherence in female breast cancer survivors: a randomized controlled trial
Oliete Ramírez, E. et al.
Healthcare, 2025;13(4):429

ARTICLES IN NATIONAL JOURNALS

Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real-world data from 772 patients

Juan Fita, M.J.

Climent Durán, M.A. et al.

ACTAS UROLÓGICAS ESPAÑOLAS, 2025;49(5):501742

doi: 10.1016/j.acuroe.2025.501742 PMID: 40097098

Long disease course in a patient with BRCA1+ ovarian cancer: from initial response to resistance and multiorgan involvement

Ugalde Catarinella, T., Romero Noguera, I., Morales López, L., Nácher Arroyo, L., Ramos López, C.

18TH SEOM CLINICAL CASE COMPETITION, 2025

Intestinal obstruction in advanced colon cancer, locally advanced disease, progression or cure?

Ugalde Catarinella, T., Melián Sosa, M., Morales López, L., Nácher Arroyo, L., Ramos López, C., Navarro López, A.

18TH SEOM CLINICAL CASE COMPETITION, 2025;728–731

INTERNATIONAL CONFERENCES

Oral presentation: Elacestrant Alone or in Combination with Triptorelin in Premenopausal Women with ER+/HER2- Early Breast Cancer: Primary Analysis From The Phase 2 SOLT1-2104 PremiÈRe Trial

SAN ANTONIO BREAST CANCER SYMPOSIUM (USA), DECEMBER 2025

Oral presentation

Hernando Melián, C.

2L after IO?

TRANSPYRENEAN ONCOLOGY SYMPOSIUM. MONTPELLIER, MARCH 2025

Presentation

Romero Noguera, I.

A Cross-Sectional Analysis from a Real-World Cohort of Microsatellite Instability Colorectal Cancer (MSI-CRC) Patients with Metastatic Disease from the Spanish RETTU Registry

ASCO GI Chicago, January 2025

Poster presentation

Melián Sosa, M. et al.

APrediction Tool for Malnutrition and Sarcopenia in Patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENS):

results from NUTRIGETNE (GETNE-2109) study

ESMO, BERLIN, OCTOBER 2025

Oral presentation

Melián Sosa, M. et al.

Abstract B033. Petosemtamab (MCLA-158) Monotherapy or With Chemotherapy in Metastatic Colorectal Cancer: Preliminary Antitumour Activity and Safety Data from a Phase 2 Study

ACRC, BOSTON, November 2025

Poster presentation

Melián Sosa, M.

Abstract poster PS7-08: Results from SERENA-1 Parts K/L: A Phase 1 Study of Next-Generation Oral SERD Camizestrant (AZD9833) in Combination with Ribociclib in Women with ER-Positive, HER2-Negative

ASCO CHICAGO, June 2025

Poster presentation

Hernando Meliá, C.

ADC and Immunotherapy: Stronger Together?

FIT-Cancer 11

Presentation

Guerrero Zotano, A.

Belzutifan in RCC and VHL disease

6TH EDI CLINICAL OBSERVATION PROGRAM FOR GU CANCER. BARCELONA, July 2025

Presentation

Juan Fita, M.J.

BREAST CANCER EARLY STAGE

ESMO CONGRESS 2025. BERLIN, October 2025

Presentation

Gavilá Gregori, J.

CLINICAL CASES.

ADVANCES IN IMMUNOTHERAPY, LATEST RESULTS IN INVEST. PANAMA, September 2025

Presentation

Juan Fita, M.J.

Characterization of Locally Advanced Rectal Cancer (LARC) Patients in Spanish TTD-RETUD Registry

ESMO, BERLIN, OCTOBER 2025

Poster presentation

Melián Sosa, M. et al.

Deintensification Strategies in Responding Patients / PARP Inhibition: TREATMENT FOR ALL?

IV TRENDING TOPICS IN GU CANCERS. SANTA CRUZ DE TENERIFE, March 2025

Presentation

Lorente Estellés, D.

DISCUS: A Phase II Study Comparing 3 Versus 6 Cycles of Platinum-Based Chemotherapy prior to Maintenance Avelumab in Advanced Urothelial Cancer

ESMO CONGRESS 2025. BERLIN, October 2025
Oral presentation
Climent Durán, M.A. et al.

Discussion of MINI ORALS 76MO, 77MO, 78MO
VIENNA, June 2025
Oral presentation
Romero Noguera, I.

Efficacy and Safety of Rucaparib in Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer after Crossover from Physician's Choice Therapy on TRITON3
ESMO, BERLIN, OCTOBER 2025
Poster presentation
Juan Fita, M.J.

First-line Futibatinib + Cetuximab
EUROPEAN LUNG CANCER CONGRESS 2025. PARIS, March 2025
Oral presentation
Sandiego Contreras, S.

First-line Therapies for mRCC, How to Choose?
6TH EDI CLINICAL OBSERVATION PROGRAM FOR GU CANCER. BARCELONA, July 2025
Presentation
Juan Fita, M.J.

GCIG AUTUMN MEETING: Education Committee
GCIG GYNECOLOGIC CANCER GROUP. BERLIN, October 2025
Presentation
Romero Noguera, I.

IMPACT OF IMMUNOTHERAPY ON THE MANAGEMENT OF FIRST-LINE ADVANCED RENAL CANCER
ADVANCES IN IMMUNOTHERAPY, LATEST RESULTS IN IMMUNO. PANAMA, September 2025
Presentation
Juan Fita, M.J.

INCIDENCE OF GERMLINE BRCA1/2 MUTATIONS IN HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER
ESMO CONGRESS 2025. BERLIN, November 2025
Poster presentation
Romero Noguera, I.

Influence of Oncotype DX Testing on Real-World Outcomes in Early-Stage Breast Cancer
ESMO CONGRESS 2025. BERLIN, October 2025
Poster presentation
Hernando Meliá, C.

Interim Results from the NADIM ADJUVANT Phase III Trial
IASLC WCLC 2025. BARCELONA, September 2025
Oral presentation
Sandiego Contreras, S. et al.

Ki67 AFTER PREOPERATIVE ENDOCRINE THERAPY: IMPACT ON SYSTEMIC
TREATMENT DECISIONS AND CONFIDENCE AMONG MEDICAL ONCOLOGISTS FOR
PATIENTS WITH LUMINAL EARLY BREAST CANCER
ESMO BREAST CANCER, Munich, May 2025
Poster presentation
Hernando Meliá, C. and Guerrero Zotano, A.

THE EVIDENCE LINE
SAN ANTONIO BREAST CANCER 2025. SAN ANTONIO (USA), December 2025
Moderator
Hernando Meliá, C.

Lactate Dehydrogenase as a Predictive Biomarker to Anti-Epidermal Growth Factor
Receptor Therapy in RAS/BRAF Wild-Type Left-Sided Metastatic Colorectal Cancer. A
GEMCAD Study
ESMO, BERLIN, OCTOBER 2025
Poster presentation
Melián Sosa, M. et al.

LBA109-DISCUS: A PHASE II STUDY COMPARING 3 VERSUS 6 CYCLES OF PLATINUM-
BASED CHEMOTHERAPY PRIOR TO MAINTENANCE AVELUMAB IN ADVANCED
UROTHELIAL CANCER
ESMO CONGRESS 2025. Berlin, 2025
Oral presentation
Climent Durán, M.A. et al.

MAINTENANCE WITH AVELUMAB IS THE BEST OPTION FOR FIRST-LINE mUC
6TH ANNUAL UC COURSE. MADRID, May 2025
Presentation
Climent Durán, M.A.

ADVANCED BLADDER CANCER PANEL (MODERATOR)
GUARD INTERNATIONAL SYMPOSIUM. MADRID, June 2025
Presentation
Juan Fita, M.J.

MEMBER OF THE BOARD OF DIRECTORS
16TH GEICAM INTERNATIONAL SYMPOSIUM. MADRID, March 2025
Organiser / Coordinator role
Hernando Meliá, C.

New Drugs in Metastatic Prostate Cancer
6TH EDI CLINICAL OBSERVATION PROGRAM FOR GU CANCER. BARCELONA, July
2025
Presentation
Lorente Estellés, D.

NEW GUIDES IN THE MANAGEMENT OF BLADDER CANCER
2ND MULTIDISCIPLINARY MEETING TO DISCUSS GAPS IN BLADDER CANCER
BARCELONA, July 2025

Presentation
Climent Durán, M.A.

NGS, Not Always Necessary
16TH GEICAM INTERNATIONAL SYMPOSIUM. MADRID, March 2025

Presentation
Guerrero Zotano, A.

NEW APPROACHES IN THE ADJUVANT MANAGEMENT OF BREAST CANCER IN HR+,
HER2- PATIENTS AT RISK OF RECURRENCE
3RD REFRESHER CONFERENCE: A NEW LOOK AT CANCER IN WOMEN. COLOMBIA,
January 2025

Presentation
Gavilá Gregori, J.

Optimizing an NGS Low-Pass-Based Method to Detect Genomic Instability as a PARP
Inhibitor Predictor in High-Grade Serous Ovarian Cancer
ASCO CHICAGO, June 2025

Poster presentation
Romero Noguera, I. et al.

OPTIMIZING TREATMENT SEQUENCING FOR EXTENDED QUALITY SURVIVAL IN UC
PATIENTS
MERCK SYMPOSIUM ONCOLOGY MEETING. EVORA (PORTUGAL), April 2025

Presentation
Juan Fita, M.J.

Optimizing Treatment Sequencing: Learnings from Real-World Evidence
MERCK VIBRANT TALKS 2025. LISBON, January 2025

Presentation
Juan Fita, M.J.

ORGAN-SPECIFIC TRANSCRIPTOMIC SIGNATURES IN VISCERAL METASTASES OF
METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
ESMO CONGRESS 2025. BERLIN, October 2025

Poster presentation
Climent Durán, M.A. et al.

PARP Inhibitors in Prostate Cancer
6TH EDI CLINICAL OBSERVATION PROGRAM FOR GU CANCER. BARCELONA, July
2025

Presentation
Lorente Estellés, D.

Phase 1 Dose Escalation Results of the WEE1 Inhibitor, Azenosertib (A), in combination
with Encorafenib (E) and Cetuximab (C) in Patients (Pts) with Previously Treated
BRAF V600E Mutant Metastatic Colorectal Cancer

ASCO CHICAGO, June 2025
Poster presentation
Melián Sosa, M. et al.

Real-World Evidence of Adjuvant Pembrolizumab in Renal Cell Carcinoma (RCC) from a Spanish Registry: The ARENAL Trial from the GUARD Consortium
EMUC 2025, PRAGA, November 2025
Oral presentation
Juan Fita, M.J.

Real-World Efficacy of Trifluridine/Tipiracil and Bevacizumab Combination according to Baseline Prognostic Factors: The BeTAS Study
ASCO GI Chicago, January 2025
Oral presentation
Melián Sosa, M.

Real-World Efficacy of Trifluridine/Tipiracil and Bevacizumab Combination according to Baseline Prognostic Factors: the BeTAS study
ASCO CHICAGO, June 2025
Poster presentation
Melián Sosa, M. et al.

TALAPRO2. WHICH PATIENTS SHOULD WE TEST AND WHICH ARE CANDIDATES FOR TREATMENT
GUARD INTERNATIONAL SYMPOSIUM. MADRID, June 2025
Presentation
Lorente Estellés, D.

ADVANCED BLADDER CANCER WORKSHOP
GUARD INTERNATIONAL SYMPOSIUM. MADRID, June 2025
Presentation
Juan Fita, M.J.

ADVANCED PROSTATE CANCER WORKSHOP
GUARD INTERNATIONAL SYMPOSIUM. MADRID, June 2025
Presentation
Lorente Estellés, D.

TOP 2 COMMUNICATIONS FROM THE ONCOLOGIST'S POINT OF VIEW
POST-MUNDIAL GIDO. BARCELONA, October 2025
Oral presentation
Sandiego Contreras, S.

TRANSCRIPTOMIC PROFILE ASSOCIATED WITH CLINICAL OUTCOMES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
ESMO CONGRESS 2025. BERLIN, October 2025
Poster presentation
Climent Durán, M.A. et al.

Transcriptomic Insights into Cisplatin Resistance in Testicular Germ Cell Tumors:

Molecular Pathways and Tumor Microenvironment
Berlin, 2025
Poster presentation
Climent Durán, M.A.

TRANSCRIPTOMIC INSIGHTS INTO CISPLATIN RESISTANCE IN TESTICULAR GERM CELL TUMORS: MOLECULAR PATHWAYS AND TUMOR MICROENVIRONMENT
ESMO CONGRESS 2025. BERLIN, October 2025
Poster presentation
Climent Durán, M.A. et al.

TRIPLETS OR DOUBLETS IN MHSPC, THAT IS THE QUESTION
IV TRENDING TOPICS IN GU CANCERS. SANTA CRUZ DE TENERIFE, June 2025
Presentation
Juan Fita, M.J.

NATIONAL CONFERENCES

BEST OF ASCO 2025. VALENCIA, June 2025
Organiser / Coordinator role
Sandiego Contreras, S.

GUARD INTERNATIONAL SYMPOSIUM. VALENCIA, June 2025
Organiser / Coordinator role
Climent Durán, M.A.

SEOM 2025, MADRID, November 2025
Oral presentation
Lorente Estellés, D.

IS ASCO 2025 CHANGING THE FUTURE OF RESEARCH IN GYNAECOLOGICAL TUMOURS?
19TH POST-ASCO MEETING ON GYNAECOLOGICAL TUMOURS. MADRID, June 2025
Presentation
Romero Noguera, I.

IS THERE PRECISION ONCOLOGY IN PROSTATE CANCER?
7TH CAMBADOS CONSENSUS FORUM ON GENITOURINARY TUMOURS. CAMBADOS, October 2025
Presentation
Lorente Estellés, D.

HAVE WE REACHED THE END OF PLATINUM-BASED CHEMOTHERAPY IN THE FIRST-LINE SETTING?
SOGUG 2025. 2ND BLADDER CANCER MEETING. MADRID, May 2025
Presentation
Juan Fita, M.J.

UPDATE ON THE MANAGEMENT OF HORMONE-SENSITIVE METASTATIC PROSTATE
CANCER: How and When Should Treatment Be Intensified?
SEOM 2025, MADRID, November 2025
Presentation
Lorente Estellés, D.

ADVANCED BLADDER CANCER: ACHIEVEMENTS AND CHALLENGES AHEAD
VII GO NORTE INTERNATIONAL GU DEBATES. LIMPIAS (CANTABRIA), October 2025
Presentation
Climent Durán, M.A.

BIOMARKERS IN PROSTATE CANCER
13TH GERMINAL SYMPOSIUM. MADRID, October 2025
Presentation
Lorente Estellés, D.

METASTATIC BREAST CANCER: PRESENTATION OF A CLINICAL CASE
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025
Presentation
Ramos López, C.

TRIPLE-NEGATIVE BREAST CANCER. EXPERT PANEL
SALAMANCA, May 2025
Presentation
Gavilá Gregori, J.

ADVANCED PROSTATE CANCER: MANAGEMENT OF HORMONE-SENSITIVE DISEASE
37TH ADVANCED COURSE IN MEDICAL ONCOLOGY. ALCALÁ DE HENARES, June 2025
Presentation
Lorente Estellés, D.

ADVANCED PROSTATE CANCER: MANAGEMENT OF CASTRATION-RESISTANT
DISEASE
37TH ADVANCED COURSE IN MEDICAL ONCOLOGY. ALCALÁ DE HENARES, June
2025
Presentation
Climent Durán, M.A.

PROSTATE CANCER AND GERMINAL TUMOURS
SEOM 2025, MADRID, November 2025
Moderator
Climent Durán, M.A.

LUNG CANCER WITH DRIVERS: PRESENTATION OF A CLINICAL CASE
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025
Presentation
Sandiego Contreras, S.

LUNG CANCER WITHOUT DRIVERS: PRESENTATION OF A CLINICAL CASE
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025

Presentation

Nácher Arroyo, LI.

CHARACTERISATION OF PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
(LARC) IN THE REGISTRO TTD-RETUD

SEOM 2025, MADRID, November 2025

Oral presentation

Melián Sosa, M.

UROTHELIAL CARCINOMA: NEW TREATMENT OPTIONS, NEW CHALLENGES

10TH ONCOPROMISES VS ONCOSAURS SYMPOSIUM. SANTANDER, June 2025

Moderator

Climent Durán, M.A.

MOLECULAR CLINICAL CASE 3: IMPACT OF MOLECULAR BIOLOGY ON THE
TREATMENT OF BASAL-LIKE METASTATIC BREAST CANCER

SEOM 2025, MADRID, November 2025

Presentation

Guerrero Zotano, A.

MULTIDISCIPLINARY COMMITTEE FOR UROTHELIAL TUMOURS: CURRENT AND
FUTURE MANAGEMENT

88TH NATIONAL CONGRESS OF UROLOGY. CÁDIZ, June 2025

Presentation

Juan Fita, M.J.

NSCLC WITH EGFRm: Advantages and Disadvantages of Using Targeted Therapy in
the 1st Line

ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025

Presentation

Garde Noguera, J.

mCRPC. Treatment Options. Present and Future

2025 URONCOR SYMPOSIUM. MADRID, June 2025

Presentation

Lorente Estellés, D.

THE ART OF CHOOSING YOUR FUTURE: DRAW YOUR OWN CANVAS

THE TROUPE. ADVANCING KNOWLEDGE IN HER2+ MBC. MÁLAGA, July 2025

Presentation

Hernando Meliá, C.

ADVANCED DISEASE: STATE OF THE ART AND AREAS OF NOVELTY / CONTROVERSY
13TH GERMINAL SYMPOSIUM. MADRID, October 2025

Moderator

Climent Durán, M.A.

AI IN ONCOLOGY: BASIC PRINCIPLES AND PATIENT-CENTRED CLINICAL PRACTICE

SEOM 2025, MADRID, November 2025

Presentation
Gavilá Gregori, J.

INCIDENCE OF GERMLINE BRCA 1/2 MUTATIONS IN HIGH-GRADE SEROUS EPITHELIAL OVARIAN CANCER: FINAL RESULTS OF THE BORNEO (GEICO600-0) STUDY

SEOM 2025, MADRID, November 2025

Oral presentation

Romero Noguera, I.

MANAGEMENT OF PATIENTS WITH NSCLC WITH PD-L1 EXPRESSION >1%
LUNG SUMMIT 2025. MADRID, June 2025

Presentation

Sandiego Contreras, S.

BEST SURGERY AND ADJUVANT THERAPY
38TH NATIONAL MEETING OF THE URO-ONCOLOGY GROUP. GIJÓN, April 2025

Presentation

Juan Fita, M.J.

WHAT IS NEW IN THE TREATMENT OF SCAC
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025

Presentation

Melián Sosa, M.

NEW APPLICATIONS OF GENOMIC PLATFORMS AND EMERGING PLATFORMS: FROM INDICATION TO TREATMENT SELECTION

20TH ONCOLOGICAL MILESTONES MEETING. MADRID, November 2025

Presentation

Guerrero Zotano, A.

NEW THERAPEUTIC STRATEGIES IN ADVANCED BREAST CANCER
SEOM 2025, MADRID, November 2025

Moderator

Guerrero Zotano, A.

NEW INVESTIGATIONAL THERAPEUTIC STRATEGIES IN PROSTATE CANCER. CAN WE IMPROVE THE DESIGN OF CTs?

16TH SCIENTIFIC SYMPOSIUM SOGUG. 2025 December

Presentation

Lorente Estellés, D.

NEW INVESTIGATIONAL TREATMENTS IN PROSTATE CANCER
13TH NATIONAL MEETING ON ADVANCES IN UROLOGICAL CANCER. GUADALAJARA, June 2025

Presentation

Lorente Estellés, D.

OPTIMISING THE MANAGEMENT OF LOCALISED HER2 BREAST CANCER
10TH ONCOPROMISES VS ONCOSAURS SYMPOSIUM. SANTANDER, June 2025

Presentation
Gavilá Gregori, J.

OPTIMISING THE WAY IMMUNOTHERAPY IS ADMINISTERED
ONCOFIR 2025. VALENCIA, February 2025

Presentation
Sandiego Contreras, S.

ROLE OF PARP INHIBITORS IN THE MANAGEMENT OF 1L mCRPC
27TH SYMPOSIUM ON REVIEWS IN CANCER. MADRID, February 2025

Presentation
Lorente Estellés, D.

Recurrence patterns after adjuvant pembrolizumab in localised clear cell renal cell carcinoma: real-world data in Spain

SEOM 2025, MADRID, November 2025

Oral presentation
Juan Fita, M.J.

PERIOPERATIVE TREATMENT IN MUSCLE INVASIVE BLADDER CANCER: A RAPIDLY
EVOLVING FIELD

IV GO NORTE INTERNATIONAL GU DEBATES. LIMPIAS (CANTABRIA), October 2025

Presentation
Juan Fita, M.J.

POSTER E-33: Impact of Stromal Modulation on Treatment with LAG-3-Targeted
Immunotherapy in Patients with Pancreatic Ductal Adenocarcinoma

SEOM 2025, MADRID, November 2025

Poster presentation
Melián Sosa, M.

BLADDER PRESERVATION

7TH MEETING ON NEW DEVELOPMENTS IN UROLOGICAL TUMOURS DURING 2024.
BARCELONA, January 2025

Presentation
Juan Fita, M.J.

MAIN DEVELOPMENTS BEYOND OTHER TARGETS.

NEW DEVELOPMENTS IN TARGETED THERAPY IN ADVANCED NSCLC. VALENCIA,
May 2025

Presentation
Sandiego Contreras, S.

REDEFINING THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA:
ADVANCING INDIVIDUALISATION

MERCK MEDICAL SYMPOSIUM. MADRID, December 2025.

Presentation
Juan Fita, M.J.

BREAST CANCER SESSION
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025
Moderator
Gavilá Gregori, J.

DIGESTIVE CANCER SESSION: PRESENTATION OF A CLINICAL CASE
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025
Presentation
Melián Sosa, M.

DIGESTIVE CANCER SESSION: PRESENTATION OF A CLINICAL CASE
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025
Presentation
Morales López, L.

GENITOURINARY CANCER SESSION: PRESENTATION OF A CLINICAL CASE
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025
Presentation
Juan Fita, M.J.

GENITOURINARY CANCER SESSION: PRESENTATION OF A CLINICAL CASE
ONCOLOGICAL CHALLENGE 16. VALENCIA, December 2025
Presentation
Morales López, L.

TRACK 1. Gastrointestinal Tumours
Best of ASCO'25. Online, June 2025
Moderator
Melián Sosa, M.

CURRENT TREATMENT OF PROSTATE AND KIDNEY CANCER
ONCOFIR 2025. VALENCIA, February 2025
Presentation
Juan Fita, M.J.

CURRENT TREATMENT OF DIGESTIVE TUMOURS
ONCOFIR 2025. VALENCIA, February 2025
Presentation
Melián Sosa, M.

CURRENT TREATMENT OF...
ONCOFIR 2025. VALENCIA, February 2025
Moderator
Climent Durán, M.A.

CURRENT TREATMENT OF BREAST CANCER
ONCOFIR 2025. VALENCIA, February 2025
Presentation
Gavilá Gregori, J.

FIRST-LINE TREATMENT IN PATIENTS WITH BRAF MUTATIONS, KRAS G12C MUTATIONS AND HER2+: WHERE DO WE STAND?

10TH GEMCAD SYMPOSIUM. BARCELONA, October 2025.

Presentation

Melián Sosa, M.

FIRST-LINE TREATMENT IN LACGT. BRENTUXIMAB VEDOTIN

18TH GOTEL COURSE. MÁLAGA, February 2025

Presentation

Melián Sosa, M.

Neoadjuvant Treatment with Chemotherapy or Hormone Therapy in Luminal HR+/HER2- Breast Cancer and Postmenopausal Women: 10-Year Results

SEOM 2025, MADRID, November 2025

Poster presentation

Nácher Arroyo, L., Morales López, L., Ugalde Catarinella, T., Ramos López, C., Navarro López, A., Blanch Tormo, S., Hernando Meliá, C., Melián Sosa, M., Sandiego Contreras, S., Gavilá Gregori, J., Guerrero Zotano, A.

A PRACTICAL VIEW (CLINICAL CASE)

MULTIDISCIPLINARY APPROACH TO LUNG CANCER. VALENCIA, May 2025

Moderator

Sandiego Contreras, S.

JOINING FORCES AGAINST GYNAECOLOGICAL CANCER: Innovative Perspectives in Immunotherapy

5TH GEICO TRANSLATIONAL MEETING. MADRID, June 2025

Organiser / Coordinator role

Romero Noguera, I.

15TH GIDO MEETING. VALENCIA, March 2025

Organiser / Coordinator role

Sandiego Contreras, S.

Care needs at home

SECPAL CONGRESS 2025. ZARAGOZA, September 2025

Poster presentation

Oliete Ramírez, E. et al.

Care needs in different disease sites

SECPAL CONGRESS 2025. ZARAGOZA, September 2025

Poster presentation

Oliete Ramírez, E. et al.

COURSES

THERAPEUTIC SEQUENCING: SECOND- AND THIRD-LINE TREATMENT

2ND UPDATE MEETING IN URO-ONCOLOGY: UPDATE 2025. MADRID, February 2025

Presentation

Juan Fita, M.J.

LOCAL BREAST CANCER

DEBATING CURRENT ISSUES IN BREAST CANCER. VALENCIA, January 2025

Presentation

Hernando Meliá, C.

INTERNAL GILEAD TRAINING MEETING. MADRID, January 2025

Presentation

Hernando Meliá, C.

CHALLENGES IN EARLY LUMINAL DISEASE

PRESENT AND FUTURE OF LUMINAL BREAST CANCER. VALENCIA, January 2025

Presentation

Blanch Tormo, S.

ENDOMETRIAL CANCER PANEL

MULTIDISCIPLINARY MANAGEMENT OF OVARIAN CANCER AND OTHER
GYNAECOLOGICAL TUMOURS

9TH HOSPITAL 12 DE OCTUBRE COURSE. MADRID, February 2025

Moderator

Romero Noguera, I.

DESCRIPTION OF MECHANISMS OF RESISTANCE TO iPARP

MSD MEETING (10 YEARS MAKING HISTORY TOGETHER). MADRID, February 2025

Presentation

Romero Noguera, I.

HER2-LOW: CHANGES IN THE BREAST CANCER TREATMENT PARADIGM. VALENCIA,
March 2025

Organiser / Coordinator role

Gavilá Gregori, J.

A DEEPER LOOK INTO HER2-LOW DETERMINATION

CHANGES IN THE BREAST CANCER TREATMENT PARADIGM. VALENCIA, March 2025

Presentation

Guerrero Zotano, A.

OPTIMISING FOLLOW-UP OF PATIENTS WITH PROSTATE CANCER: STRATEGIES AND
BEST PRACTICES

ANDRÓGENO PROJECT. MADRID, March 2025

Presentation

Juan Fita, M.J.

EARLY-STAGE DISEASE, NEOADJUVANT / ADJUVANT TREATMENT

SYSTEMIC TREATMENT OF BREAST CANCER UPDATE. TENERIFE, March 2025

Presentation

Hernando Meliá, C.

CORE DATA PRESENTATION AND DISCUSSION

FACE TO FACE MEETING AURORA MANUSCRIPT. FLORENCE, April 2025

Moderator

Guerrero Zotano, A.

THERAPEUTIC APPROACHES FOR DIFFERENT PATIENT PROFILES WITH OVARIAN
CANCER

PHARMA & EUROPEAN MEETING. ROME, April 2025

Presentation

Romero Noguera, I.

Rubraca 2LM, Long-Term Responder

PHARMA & EUROPEAN MEETING. ROME, April 2025

Presentation

Romero Noguera, I.

4th Challenge Summit in Prostate Cancer. Madrid, May 2025

Oral presentation

Juan Fita, M.J.

THERAPEUTIC STRATEGIES IN ADVANCED FIRST-LINE DISEASE: CURRENT
PERSPECTIVE AND INITIAL MANAGEMENT

THERAPEUTIC STRATEGIES IN ADVANCED DISEASE. BARCELONA, June 2025

Moderator

Romero Noguera, I.

A FURTHER STEP FOR THE BENEFIT OF THE PATIENT

4TH ADVANCES IN TARGETED THERAPY IN LUNG CANCER MEETING. ALICANTE,
May 2025

Moderator

Sandiego Contreras, S.

AEACP DIALOGUES. ONLINE, May 2025

Presentation

Sandiego Contreras, S.

NEW DEVELOPMENTS IN LUNG CANCER. VALENCIA, May 2025

Presentation

Sandiego Contreras, S.

THE ROLE OF PARP INHIBITORS IN FIRST-LINE THERAPY FOR OVARIAN CANCER

SPEAKER TOUR COLOMBIA. COLOMBIA, May 2025

Presentation

Romero Noguera, I.

Beyond QT in Recurrent or Metastatic Cervical Cancer

PODCAST

THERAPEUTIC STRATEGIES IN ADVANCED DISEASE. Online, June 2025

Oral presentation

Romero Noguera, I.

Profiling Patients Eligible or Not Eligible for T-DXd

T-DXd in 1L in MBC. MADRID, June 2025

Presentation

Hernando Meliá, C.

LATEST DATA PRESENTED IN ENDOMETRIAL, CERVICAL AND OVARIAN CANCER GROUP INPUT MEETING. MADRID, June 2025

Presentation

Romero Noguera, I.

MULTIDISCIPLINARY DEBATE: TRIPLETS, DOUBLETS AND DE-INTENSIFICATION: EXPERT OPINION

ADVANCES IN PROSTATE CANCER ONCO-SUMMIT. MEXICO, September 2025

Presentation

Juan Fita, M.J.

RESIDENTS' WORKSHOP. HOW TO IMPLEMENT A TUMOUR BOARD IN YOUR PRACTICE?

ADVANCES IN PROSTATE CANCER ONCO-SUMMIT. MEXICO, September 2025

Presentation

Juan Fita, M.J.

TYPES OF CLINICAL TRIALS: beyond I, II, III and IV phases

HOW TO DESIGN A CLINICAL TRIAL IN GU TUMOURS? VALENCIA, September 2025

Presentation

Lorente Estellés, D.

METASTATIC DISEASE (CCR BLOCK)

EMPOWERG-II. MADRID, September 2025

Presentation

Melián Sosa, M.

THE IMPORTANCE OF SCREENING

5TH UPDATE MEETING IN MEDICAL ONCOLOGY FOR PRIMARY CARE. VALENCIA, September 2025

Organiser / Coordinator role

Melián Sosa, M.

ASTHENIA

5TH UPDATE MEETING IN MEDICAL ONCOLOGY FOR PRIMARY CARE. VALENCIA, September 2025

Presentation

Morales López, L.

ADVANCES TOWARDS PERSONALISED BREAST CANCER SCREENING

5TH UPDATE MEETING IN MEDICAL ONCOLOGY FOR PRIMARY CARE. VALENCIA, September 2025

Presentation

Hernando Meliá, C.

CANCER-RELATED CACHEXIA

5TH UPDATE MEETING IN MEDICAL ONCOLOGY FOR PRIMARY CARE. VALENCIA, September 2025

Presentation

Sandiego Contreras, S.

The First & Only Extended Adjuvant Option in Her2+ EBC
EXPANDING HER2 HORIZONS. TRIPOLI (LIBYA), September 2025
Presentation

Guerrero Zotano, A.

WELCOME AND INTRODUCTION

HOW TO DESIGN A CLINICAL TRIAL IN GU TUMOURS? VALENCIA, September 2025

Organiser / Coordinator role

Climent Durán, M.A.

TRANSLATING EVIDENCE INTO EXPERIENCE IN NEWLY DIAGNOSED OR RELAPSED
ADVANCED ENDOMETRIAL CANCER

AURORA MEETING. MADRID, October 2025

Moderator

Romero Noguera, I.

ESR1: WHEN AND HOW?

PRECISION ONCOLOGY IN BREAST CANCER.

TRANSLATIONAL MEETING. VALENCIA, September 2025

Presentation

Hernando Meliá, C.

PLATFORMS AND SIGNATURES IN BREAST CANCER. NEW CHALLENGES

PRECISION ONCOLOGY IN BREAST CANCER.

TRANSLATIONAL MEETING. VALENCIA, September 2025

Moderator

Gavilá Gregori, J.

HOW IS A CLINICAL TRIAL DESIGNED AND WHO TAKES PART IN ALL ITS PHASES?

16TH SEMINAR FOR JOURNALISTS. SALAMANCA, September 2025

Presentation

Gavilá Gregori, J.

IO-IO DOUBLETS IN PD-L1-NEGATIVE CANCER: EXPERIENCE OF A SPANISH CENTRE
ONCO MEET EXPERT LISBOA. November 2025

Presentation

Garde Noguera, J.

Oncological Nutrition in Breast, Gastrointestinal and Gynaecological Cancer

OFFICIAL COLLEGE OF DIETITIANS AND NUTRITIONISTS OF VALENCIA

CODINUCOVA CONFERENCE. VALENCIA, February 2025

Presentation

Ruiz Cordero, V.

ALK 1ST-LINE LUNG CANCER

LUNG CANCER CONFERENCE. VALENCIA, September 2025

Presentation

Ruiz Cordero, V.

DOUBLETS VS TRIPLETS

PROSTATE PRECEPTORSHIP. VALENCIA, December 2025

Presentation
Juan Fita, M.J.

PERSONALISED MEDICINE (AMPLITUDE, CAPITELLO, PSMAaddition)
PROSTATE PRECEPTORSHIP. VALENCIA, December 2025
Presentation
Climent Durán, M.A.

WHAT TRIALS AND NEW MOLECULES ARE COMING FOR PROSTATE CANCER?
PROSTATE PRECEPTORSHIP. VALENCIA, December 2025
Presentation
Lorente Estellés, D.

1ST UPDATE MEETING IN LUMINAL BREAST CANCER. DENIA, May 2025
Organiser / Coordinator role
Hernando Meliá, C.

WORKSHOP ON CLINICAL TRIAL DESIGN
PROMESA. DEVELOPING COMPETENCIES IN BREAST CANCER. IBIZA, May 2025
Presentation
Hernando Meliá, C.

Clinical Case of A Patient with HR+ HER2- Early Breast Cancer at High Risk of
Recurrence. MONARCH STUDY
NEXT GENERATION. VALENCIA, April 2025
Presentation
Hernando Meliá, C.

EDUCATIONAL PROJECT FOR PATIENTS WITH BREAST CANCER ONLINE. April 2025
Presentation
Hernando Meliá, C.

RIBOLEAGUE. VALENCIA, September 2025
Moderator
Hernando Meliá, C.

APPROACH TO TRODELVY IN METASTATIC BREAST CANCER
BEYOND THE CLINICAL TRIAL. VALENCIA, October 2025
Presentation
Hernando Meliá, C.

STRATEGIES TO IMPROVE FOLLOW-UP AND ADHERENCE
MULTIDISCIPLINARY APPROACH TO METASTATIC BREAST CANCER. VALENCIA,
November 2025
Presentation
Hernando Meliá, C.

BRAIN METASTASES
GIDO MEETING. VALENCIA, November 2025
Moderator
Sandiego Contreras, S.

NEW DEVELOPMENTS PRESENTED IN EARLY-STAGE NSCLC
16TH WCLC REVIEW MEETING. BARCELONA, October 2025

Presentation

Sandiego Contreras, S.

MANAGEMENT OF PATIENTS WITH MESOTHELIOMA AND THYMOMA
TIME3 KICKOFF. VALENCIA, November 2025

Presentation

Sandiego Contreras, S.

DAY TO DAY IN UROLOGICAL TUMOURS: NEEDS AND CHALLENGES
2ND MEETING ON THE APPROACH TO DRUGS IN GU TUMOURS. GIRONA, December
2025

Presentation

Lorente Estellés, D.

CUORE GIDO

Attendees: residents

September 2025. CANET DE BERENGUER

TRAINING ON 1L aUC
METASTATIC BREAST CANCER TRAINING MEETING

Organised by: MERCK

MADRID, September 2025

IMMUNE SYSTEM AND CANCER: BIOLOGICAL BASIS AND THERAPEUTIC
APPLICATIONS

MASTER'S DEGREE IN APPROXIMATE MOLECULARS IN HEALTH SCIENCES

Attendees: MASTER'S STUDENTS

VALENCIA, November 2025

Workshop 1: Management of the Multidisciplinary Committee in the Treatment of
Early-Stage Bladder Cancer

ONCO ACADEMY; NEXTGEN ONCOLOGY

Speaker: Juan Fita, M.J.

MADRID, June 2025

Physical Exercise in Oncology.

Training Course for the Design of Physical Activity And Healthy Exercise Programmes

Speaker: Oliete Ramírez, E.

October 2025. VALENCIA

Ethical Scenarios at the End of Life

Emergency Oncology Course for Residents

Speaker: Oliete Ramírez, E.

September 2025. VALENCIA

DIRECTION OF MASTER'S DISSERTATION

Advanced Prostate Cancer Master's Degree 2025–2026, Spanish Association of Urology. Chapter on Metastatic Castration-Resistant Prostate Cancer
Juan Fita, M.J.
SALAMANCA, 2025

AWARDS

Award
1st Prize for Healthcare Excellence in the Valencian Community. Awarded by the 8th Mediterranean TV Awards
Oliete Ramírez, E.
Palliative Care Category
VALENCIA, November 2025

CLINICAL SESSIONS

Multidisciplinary
JOURNAL CLUB: Dietary Interventions and Precision Nutrition in Cancer Therapy
Ugalde Catarinella, T., Bañón, S.
January 2025

Review
CONTINUOUS CARE, one year on
Oliete Ramírez, E.
February 2025

Multidisciplinary
MELANOMA RESEARCH AT IVO
Nagore Enguádanos, E.
February 2025

Multidisciplinary
MOLECULAR BIOLOGY: TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer
Ugalde Catarinella, T.
February 2025

Multidisciplinary
CASE MANAGER NURSE (Practical Aspects)
Landete Ballester, A.
January 2025

Multidisciplinary
MORBIDITY AND MORTALITY "New Toxicities of Bispecific Antibodies: CRS and ICAN.

Management Protocol and Experience" (No. MR T104519)
Ruiz Cordero, V.
January 2025

Review
POST-SAN ANTONIO 2025
Blanch Tormo, S.
March 2025

Multidisciplinary
ONCOGERIATRICS
Parra Gómez, L.
March 2025

Multidisciplinary
JOURNAL CLUB: Title: Efficacy and Safety of a Single Dose of Arexvy in Older Adults Aged 60 Years and Over
Cañado Gómez, Y., Ramos López C.
March 2025

Multidisciplinary
Title of Article: Functional Evaluation and Clinical Classification of BRCA2 Variants
Nature, 2025
García, Z.
March 2025

Multidisciplinary
Paraneoplastic Neurological Syndromes
Bataller Alberola, L.
March 2025

Review
BLADDER PRESERVATION
Climent Durán, M.A.
April 2025

Multidisciplinary
JOURNAL CLUB: Title: "Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial"
Guerrero Zotano, A., Ugalde Catarinella, T.
April 2025

Review
MORBIDITY AND MORTALITY. Title: "Ophthalmological Toxicity in Oncology Patients"
(No. MR 392953)
Yaya Tur, R., Nácher Arroyo, L.
April 2025

Multidisciplinary
JOURNAL CLUB. Title: "Ibrutinib Combined with Immunochemotherapy With or

Without Autologous Stem-Cell Transplantation Versus Immunochemotherapy and Autologous Stem-Cell Transplantation in Previously Untreated Mantle-Cell Lymphoma in Younger Patients"

Melián Sosa, M., Ugalde Catarinella, T.
May 2025

Review

MORBIDITY AND MORTALITY. Title: "CLINICAL CASE OF THROMBOTIC MICROANGIOPATHY" (No. MR 401506) Guest Speaker: Dr. Isidro Torregrosa (Nephrology, Hospital Clínico de Valencia)

Parra Gómez, L., Ramos López, C.
May 2025

Multidisciplinary

TITLE: Tumour-Infiltrating Clonal Haematopoiesis

Guerrero Zotano, A.
May 2025

Multidisciplinary

"Assessment of a Polygenic Risk Score in Screening for Prostate Cancer"

Romero Noguera, I., Ugalde Catarinella, T.
May 2025

Multidisciplinary

EARLY vs DEFERRED USE OF CDL4/6 INHIBITORS IN ADVANCED BREAST CANCER: CIRCULATING TUMOUR DNA ANALYSIS OF A RANDOMIZED PHASE 3 TRIAL

Ugalde Catarinella, T.
October 2025.

Multidisciplinary

"Treatment of HER2-Positive Metastatic Breast Cancer"

Blanch Tormo, S., Ramos López, C.
October 2025.

Multidisciplinary

"Adjustment of Therapeutic Effort: Protocol Proposal"

Morales López, L., Navarro López, A.
October 2025.

Multidisciplinary

"Treatment of HER2-Positive Metastatic Breast Cancer"

Blanch Tormo, S., Ugalde Catarinella, T.
October 2025.

Multidisciplinary

"Adjustment of Therapeutic Effort: Protocol Proposal"

Morales López, L., Navarro López, A.
October 2025.

Multidisciplinary
Transcriptomic Profiles and Benefit From Treatment in Metastatic Hormone-Sensitive Prostate Cancer
Lorente Estellés, D.
November 2025

Multidisciplinary
"Urothelial Carcinoma: eriooperative Treatment"
Climent Durán, M.A., Ugalde Catarinella, T.
November 2025

Multidisciplinary
"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer"
Melián Sosa, M., Nácher Arroyo, L.
November 2025

Multidisciplinary
"New Molecular Approaches"
Lorente Estellés, D.
November 2025

Review
"SERENA 6"
Guerrero Zotano, A., Ramos López, C.
December 2025

Multidisciplinary
"HIGHLIGHTS GU ESMO 2025"
Juan Fita, M.J.
December 2025

Multidisciplinary
POST-ASCO DIGESTIVE
Melián Sosa, M.
June 2025

Multidisciplinary
POST-ASCO GU
Juan Fita, M.J.
June 2025

Multidisciplinary
POST-ASCO LUNG
Sandiego Contreras, S.
June 2025

Multidisciplinary
POST-ASCO Head and Neck
Aguilar Andino, H.
June 2025

Multidisciplinary

"Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers"

Romero Noguera, I.

February 2025

Review

"Regarding a Paraneoplastic Syndrome"

Ramírez Bellóch, R. , Bataller Alberola, L., Morales López, L.

February 2025

Multidisciplinary

"Parenteral Nutrition in Palliative Care Patients"

Ruiz Ortega, P. , Nácher Arroyo, L.

February 2025

Review

JOURNAL CLUB. "Use of Apixaban in the Treatment of DVT in Oncology Patients"

February 2025

Multidisciplinary

Emerging Fusion-Driven and Other Molecular Alterations in Sarcomas: Do They Provide Meaningful Diagnostic, Prognostic, or Therapeutic Information?

Machado Puerto, I.

December 2025

Multidisciplinary

"HIGHLIGHTS GU ESMO 2025"

Juan Fita, M.J.

December 2025

Review

QOPI CRITERIA

Climent Duran, M.A.

December 2025

Multidisciplinary

"ONE YEAR AS A NURSE CASE MANAGER"

Landete Ballester, A.

December 2025

HOSPITAL AT HOME

COURSES

DOC Conference on Clinical Cancer Pain
Valencia, June 2025
Attendance
Mancheño Álvaro, A.

15TH INTERNATIONAL MEETING OF THE SPANISH SOCIETY OF PALLIATIVE CARE (SECPAL)
Zaragoza, September 2025
Attendance
Ruiz Ortega, P.

7TH MEETING OF THE ARAGONESE SOCIETY OF PALLIATIVE CARE (CUSIRAR)
Zaragoza, September 2025
Attendance
Ruiz Ortega, P.

7TH MEETING OF THE ARAGONESE SOCIETY OF PALLIATIVE CARE (CUSIRAR)
Zaragoza, September 2025
Attendance
Mancheño Álvaro, A.

15TH INTERNATIONAL MEETING OF THE SPANISH SOCIETY OF PALLIATIVE CARE (SECPAL)
Zaragoza, September 2025
Attendance
Mancheño Álvaro, A.

7TH MEETING OF THE ARAGONESE SOCIETY OF PALLIATIVE CARE (CUSIRAR)
Zaragoza, September 2025
Attendance
Díaz Castro, R.

WORKING TOGETHER FOR LIFE
13TH COMPREHENSIVE CARE IN PALLIATIVE CARE MEETING. CASTELLÓN,
November 2025
Wollstein Lara, C.

WORKING TOGETHER FOR LIFE
13TH COMPREHENSIVE CARE IN PALLIATIVE CARE MEETING. CASTELLÓN,
November 2025
Ruiz Ortega, P.

MANAGEMENT OF ONCOLOGY PATIENTS IN PRIMARY CARE
5TH VALENCIA MEETING. Valencia, November
Presentation
Ruiz Ortega, P.

Effective Communication of Sensitive News in Oncology
Attendees: Mancheño Álvaro, A.
February 2025. Valencia

UNDERGRADUATE THESIS SUPERVISION

Descriptive Study of the Characteristics of Oncology Patients Receiving Palliative Sedation at Home
Delgado Palencia, H.
Valencia, 2025
Martín Utrilla, S.

Nursing Care in Postoperative Feeding in Patients With Pancreatic Cancer
Guerrero Calvo, A.
Valencia, 2025
Martín Utrilla, S.

Advance Care Planning in End-of-Life Patients Belonging to the Hospital-at-Home Unit
Lerma Morgado, C.
Valencia, 2025
Martín Utrilla., S.

Descriptive Study of the Profile of the Main Caregiver of Oncology Patients in Home-Based Palliative Care
Castellanos Arias, A.
Valencia, 2025
Martín Utrilla, S.

Palliative Management of Refractory Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease
Camarasa García, E.
Valencia, 2025
Martín Utrilla., S.

Oncology Patients in Hospital-at-Home Units: A Multifactorial Study Related to Quality of Life
Rey Carmona, C.
Valencia, 2025
Martín Utrilla, S.

Polypharmacy in Oncology Patients Admitted to the Hospital-at-Home Unit at the End of Life
Ortega Martínez, M.

Valencia, 2025
Martín Utrilla., S.

Relevance of Palliative Sedation at Home in Patients With Colorectal Cancer
Martínez Aznar, L.
Valencia, 2025
Martín Utrilla, S.

Palliative Sedation at Home: A Systematic Review of the Experience of Nurses and Family Members
Fernández Núñez, P.
Valencia, 2025
Martín Utrilla, S.

DIRECTION OF MASTER'S DISSERTATION

Interventions to Treat Burnout in Nursing Professionals in the Area
Castillo Feltrer, L.
Valencia, 2025
Martín Utrilla, S.

DOCTORAL THESES

Pressure Injuries in Terminal Palliative Care Patients
Valencia, 2025
Supervised by: Pérez Bermejo, M., Palomar LLatas, F.

HAEMATOLOGY

INTERNATIONAL CONFERENCES

Impact of ASCT Consolidation and Rituximab Maintenance on Survival in Real-World Patients With Mantle Cell Lymphoma (MCL) in Spain. The GELTAMO-MCL-2022 Study

18TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA. Lugano, June 2025

Poster presentation

Marín-Niebla, A., Bastos, M., Pérez A., Cabirta, A., De la Cruz, F., Canelo, M., Jiménez-Ubieto, A., González de Villambrosía, S., Muntañola, A., Luzardo, H., Ríos-Herranz, E., De la Cruz, B., Córdoba, R., Saus Carreres, A., Martín, A., García-Noblejas, A., Grande, C., Prieto, P., Nicolás, C., Gutiérrez, A., Hernández-Rivas, JA., Sánchez-González, B., Alonso-Trillo, R., Donato, E., Villafuerte, P., García Belmonte, D., Verdesoto-Cozzarelli, S.R., Suárez, S., Parda de la Mano, E., Avaria, A. et al.

Real-World Evidence of Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma. Spanish Multicentre GELTAMO Study

18TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA. Lugano, June 2025

Poster presentation

Bento, L., Bastos-Oreiro, M., Gutiérrez, A., García, C., Cabero, A., Jiménez-Ubieto, A., González de Villambrosia, S., López, A., Browne, S., Sánchez, S., Fernández-Caldas, P., Villalobos, T., Navarro, B., Alarcón-Tomás, A., Pérez, S., Saus, A., Villafuerte, P., Donato, E., García-Belmonte, D., Rovira, J., Salazar, C. et al.

NATIONAL CONFERENCES

Evaluation of the Role of AHCT in the Era of Rituximab Maintenance in Mantle Cell Lymphoma (MCL) in Spain. The GELTAMO-MCL-2022 Study

Oviedo, October 2025

Poster presentation

Marín-Niebla, A., Bastos, M., Pérez, A., Cabirta, A., De la Cruz, F., Canelo, M., Jiménez-Ubieto, A., González de Villambrosía, S., Muntañola, A., Luzardo, H., Ríos-Herranz, E., De la Cruz, B., Córdoba, R., Saus Carreres, A., Martín, A., García-Noblejas, A., Grande, C., Prieto, P., Nicolás, C., Gutiérrez, A., Hernández-Rivas, J.A., Sánchez-González, B., Alonso-Trillo, R., Donato, E., Villafuerte, P., García Belmonte, D., Verdesoto-Cozzarelli, S.R., Suárez, S., Parda de la Mano, E., Avaria A., et al.

COURSES

Annual Meeting of the Valencian Haematology Association. Valencia, February 2025
Attendance

Avaria Navalón, A.

Annual Meeting of the Valencian Haematology Association. Valencia, February 2025
Attendance

Salazar Lozada, C.

GREMI Annual Meeting 2025. Valencia, February 2025
Attendance

Avaria Navalón, A.

GREMI Annual Meeting 2025. Valencia, February 2025
Attendance

Salazar Lozada, C.

HI Lymphoma and Myeloma

Attendees: Avaria Navalón, A.
November 2025. Madrid

HI Lymphoma and Myeloma

Attendees: Salazar Lozada, C.
November 2025. Madrid

Clinical-Pathological Update on the Diagnosis and Treatment of Malignant Haematological Diseases

Attendees: Avaria Navalón, A.
February 2025. Online

Clinical-Pathological Update on the Diagnosis and Treatment of Malignant Haematological Diseases

Attendees: Salazar Lozada, C.
February 2025. Online

UPDATE IN THE MANAGEMENT OF LYMPHOID NEOPLASMS

Attendees: Avaria Navalón, A.
March 2025. Online

UPDATE IN THE MANAGEMENT OF LYMPHOID NEOPLASMS

Attendees: Salazar Lozada, C.
March 2025. Online

Update in Chronic Myeloid Leukaemia

Attendees: Avaria Navalón, A.
September 2025. Online

Update in Chronic Myeloid Leukaemia

Attendees: Salazar Lozada, C.
September 2025. Online

CONCLUSIONS OF THE 66TH ASH ANNUAL MEETING AND EXPOSITION

Attendees: Avaria Navalón, A.
January 2025. Valencia

CONCLUSIONS OF THE 66TH ASH ANNUAL MEETING AND EXPOSITION

Attendees: Salazar Lozada, C.
January 2025. Valencia

HI Scientific Tour in Immunohaematology

Attendees: Avaria Navalón, A.
September 2025. Online

HI Scientific Tour in Immunohaematology

Attendees: Salazar Lozada, C.
September 2025. Online

2ND MANTLE CELL LYMPHOMA COURSE

Attendees: Salazar Lozada, C.
March 2025. Online

Prognosis and Treatment of Follicular Lymphoma in Multiple Relapses

Attendees: Avaria Navalón, A.
January 2025. Online

Prognosis and Treatment of Follicular Lymphoma in Multiple Relapses

Attendees: Salazar, C.
January 2025. Online

Zanubrutinib in Lymphoproliferative Disorders

Attendees: Avaria Navalón, A.
April 2025. Online

Zanubrutinib in Lymphoproliferative Disorders

Attendees: Salazar, C.
April 2025. Online

RADIATION ONCOLOGY

ARTICLES IN INTERNATIONAL JOURNALS

Prospective Registry Trial of Adjuvant High-Dose-Rate Brachytherapy in Unirradiated Head and Neck Cancer: 20-Year Data

García-Consuegra, A., Gimeno-Morales, M., Cambeiro, M., López-Picazo, J.M., Alcalde, J., Ramos, L.i., Tagliaferri, L., Guinot, J.L., Bussu, F., Moreno-Jiménez, M., Martínez-Monge, R.

2025

10.1002/hed.28131 40062517 PMC12248273

Response to "Refinements in Accelerated Partial Breast Irradiation: Toward Better Efficacy and Safety"

Guinot, J.L., Gutiérrez-Miguel, C., Meszaros, N.

2025

10.1016/j.radonc.2025.110722. 39870180

INTERNATIONAL CONFERENCES

HDR Brachytherapy of the Eyelid: A Tool for the Future

ESTRO Congress. Vienna, May 2025

Poster presentation

Vercher, M., Canos, S., Ros, B., Cediél, D., Coll, M., Pallarés, M., Angulo, A., Guardino, C., Santos, M., González-Pérez, V., Guinot, J.L., Arribas Alpuente, L.

Updated Recommendations of the GEC-ESTRO Breast Cancer Working Group Based on Clinical Evidence

ESTRO Congress. Vienna, May 2025

Oral presentation

Csaba, P., Gutiérrez Miguel, C., Ivanov, O., Smanyko, V., Stankiewicz, M., Martínez, I., Lössl, K., Guinot, J.L., Hannoun-Levi, J.M., Strnad, V.

NATIONAL CONFERENCES

Multidisciplinary Approach to Lung Cancer: Clinical Case 1

GIDO Group. Valencia, May 2025

Presentation

Arribas Alpuente, L.

The Key Role of Radiation Oncology in Non-Surgical Lung Cancer Patients

GIDO Group. Dénia, February 2025

Presentation

Arribas Alpuente, L.
Radiotherapy in Disseminated Prostate Cancer: When and Where?
Masterclass on Prostate Cancer. Valencia, May 2025
Presentation
Arribas Alpuente, L.

Radiotherapy in Lung Cancer in 2025
15th GIDO Meeting. Valencia, March 2025
Presentation
Arribas Alpuente, L.

Radiation Oncology in Breast Cancer
JMA Gynaecology Association Meeting. Cuenca, June 2025
Presentation
Guinot Rodríguez, J.L.

23RD CONSENSUS MEETING OF THE GEB SPANISH BRACHYTHERAPY GROUP
Pamplona, October 2025
Attendance
Núñez Baez, M.

COURSES

12th Review Meeting On Thoracic Pathology From The 2025 American Congress:
REVIEW OF COMMUNICATIONS AND NEW DEVELOPMENTS IN RADIOTHERAPY FOR
THORACIC NEOPLASMS
12th American Congress Meeting 2025. Valencia, June 2025
Presentation
Santamaría García, P.

Brain Metastases 2025. Clinical Case: Small-Cell Lung Cancer, Limited Stage Without
Brain Metastases at Diagnosis, Subsequently Developing 3 Lesions: Discussion of
HA-WBRT Plus Memantine, Role of Salvage Radiosurgery
Brain Metastases 2025. Clinical Case. Valencia, November 2025
Presentation
Chust Vicente, M.L.

Indications for Radiotherapy in Cutaneous Squamous Cell Carcinoma Valencia, May
2025
Presentation
Chust Vicente, M.L.

PROSTATE PERCEPTORSHIP □ Management of Locally Advanced Prostate Cancer:
Why and What For?
Management of Locally Advanced Prostate Cancer. Valencia, December 2025
Presentation
Sanvictor Beneito, B.

In-Person Meeting on the Evolution of the Management of Patients With CPHSm
Evolution of the Management of Patients With CPHSm Valencia, October 2025

Presentation

Sanvictor Beneito, B.
Comprehensive and Practical Brachytherapy
GEC-ESTRO Course
Organised by: Guinot Rodríguez, J.L.
Porto, June 2025

Practical Demonstration of Iodine-125 Seed Implants to a Doctor, a Nurse and a Medical Physicist from UPMC Hospital
Speaker: Nurse and Medical Physicist
Whitfield (Irlande), February 2025

ESTRO: Brachytherapy for Prostate Cancer
ESTRO: Brachytherapy
Attendees: Sanvictor Beneito, B.
Verona, October 2025

2nd Meeting on Brain Metastases
GIDO Group
Speaker: Arribas Alpuente, L.
November 2025. Valencia

4th Course on Oncological Emergencies for Residents
GIDO Group
Attendees: Resident Physicians
Canet de Berenguer, September 2025

Masterclasses in Prostate Cancer (IVO). Surgery vs Radiotherapy
Masterclasses in Prostate Cancer (IVO). Surg. vs RT.
Speaker: Sanvictor Beneito, B.
May 2025. Valencia

DOCTORAL THESES

Active Surveillance in Vestibular Schwannoma as a First Therapeutic Option
Arribas Graullera, M.
Valencia, December 2025
Supervised by: Arribas Alpuente, L.

CLINICAL SESSIONS

Breast Working Group
2025

Online Meetings of the Head & Neck and Skin Working Group
2025

EAR, NOSE AND THROAT (ENT)

INTERNATIONAL CONFERENCES

"The Future of Head and Neck Oncology Training: An International Challenge"
European Head and Neck Course 2025. Birmingham, December 2025

Presentation

Ferrandis Perepérez, E.

European Congress on Head and Neck Oncology. Amsterdam, March 2025

Oral presentation

Ferrandis Perepérez, E.

NATIONAL CONFERENCES

43rd ENT Congress of The Autonomous Communities of Valencia, Murcia and Castilla-La Mancha. May 2025.

Presentation

Ferrandis Perepérez, E.

76th National SEORL-CCC Congress. Madrid, October 2025

Oral presentation

Ferrandis Perepérez, E., Brotons Durbán, S.

8th LARYNGEAL CANCER FORUM. Barcelona, October 2025.

Presentation

Ferrandis Perepérez, E.

COURSES

New Developments in HPV-Positive Oropharyngeal Cancer

Valencia, February 2025

Plá Mocholí, A.

Oral Cavity Reconstruction

5th Meeting of The Logroño Oncology and Surgery Committee. January 2025

Presentation

Ferrandis Perepérez, E.

Current Management of Differentiated Thyroid Carcinoma

8th SAVORL AND CCC Meeting. Valencia, February 2025

Oral presentation

Brotons Durbán, S.

8th Valencian Society of Otorhinolaryngology and CCC Meeting

Valencia, February 2025

Attendance

Vendrell Marqués, J.B.

Nasal Pyramid Reconstruction

Online, January 2025

Presentation

Ferrandis Perepérez, E.

Differentiated Thyroid Carcinoma

CDT Expert Forum. Madrid, January 2025

Attendance

Brotos Durbán, S.

Thyroid Cancer Surgery: How Do I Do It?

Innovation Meeting in Thyroid Surgery. Marina Baixa H., March 2025

Presentation

Brotos Durbán, S.

8th Spring Meeting of the Oncology and Head and Neck Surgery Committee

Round Table on Oral Cavity

Bilbao, June 2025

Oral presentation

Ferrandis Perepérez, E.

Differentiated Thyroid Cancer. Online, June 2025

Oral presentation

Brotos Durbán, S.

Da Vinci Robot Accreditation

Attendees: Ferrandis Perepérez, E., Plá Mocholí, A.

September 2025. Barcelona

Robotic ENT Surgery (Da Vinci Accreditation)

Attendees: Ferrandis Perepérez, E., Plá Mocholí, A.

March 2025. Barcelona

2nd Course on Head and Neck Reconstruction

Speaker: Ferrandis Perepérez, E.

May 2025. Valencia

4th Course on Basic Oncology for ENT specialists

Speaker: Ferrandis Perepérez, E.

February 2025. Madrid

MEDICAL PHYSICS AND PROTECTION

ARTICLES IN INTERNATIONAL JOURNALS

A comparative cost-benefit analysis of electronic brachytherapy versus HDR IT-192 for exclusive vaginal cuff treatment in postoperative endometrial cancer

Lozares Cordero, S., González Pérez, V., Sánchez Casi, M., González González, T., Castillo Peña, P., Pallarés Ripollés, M., Herreros Martínez, A., Pellejero Pellejero, S. *Journal of Contemporary Brachytherapy*, 2025;17(3):160-167
10.5114/jcb.2025.152539 40697727

Head and neck and skin (HNS) GEC-ESTRO and BRAPHYQS working groups joint critical review of the use of Rhenium-188 in dermatology-oncology

Lozares-Cordero, S., Tur, P., Ballester, F., Bundschuh, R.A., González-Pérez, V., Jaber, R., Carlsson-Tedgren, Å., Tagliaferri, L., Siebert, F.A., Rembielak, A. *Clinical and Translational Radiation Oncology*, 2025;53:100991
10.1016/j.ctro.2025.100991

Quality control strategies for head and neck brachytherapy (interventional radiotherapy)

Fionda, B., Placidi, E., Rosa, E., Lancellotta, V., Vaccaro, M., Cornacchione, P., De Angeli, M., Scalise, S., Ciasca, G., Pastore, F., González-Pérez, V., Micciché, F., Massaccesi, M., Gambacorta, M.A., Galli, J., Bussu, F., de Spirito, M., Tagliaferri, L. *Journal of Contemporary Brachytherapy*, 2025;17(2):127-132
10.5114/jcb.2025.150065 40485915

INTERNATIONAL CONFERENCES

ALFIM 2025. La Antigua (Guatemala), March 2025

Attendance

González Pérez, V.

ESTRO 2025. Vienna, June 2025

Attendance

González Pérez, V.

Brachytherapy 2

ESTRO 2025. Vienna, May 2025

Moderator

González Pérez, V.

Development of Advanced Applicators for Electronic Brachytherapy in Cervical Cancer

ALFIM 2025. La Antigua (Guatemala), March 2025

Presentation

González Pérez, V.

Feasibility of Electronic Brachytherapy in Cervical Cancer: A Dosimetric Analysis of

Early-Stage Patients

ESTRO 2025. Vienna, May 2025

Poster presentation

Sergio Lozares, V., González-Pérez, N., Fuentemilla, A., Gandía, H.P., Expósito, S.

HDR Brachytherapy of the Eyelid: A Tool for the Future

ESTRO 2025. Vienna, May 2025

Poster presentation

Vercher, M., Tortajada, M.I., Canos, S., Santos, M.A., Cediél, D., Medina, R.A., Vico, M., Pallares, M., González-Pérez, V., Guinot, J.L., Arribas, L.

Physics Brachytherapy

ESTRO 2025. Vienna, May 2025

Moderator

González Pérez, V.

Reviewer of Abstracts for the ESTRO Congress in the Areas of Brachytherapy and Physics

ESTRO 2025. Vienna, May 2025

Review

González Pérez, V.

Reviewer of Abstracts At The 10th Latin American Congress, 2nd Ibero-American Congress And 4th International Symposium on Radiological Protection in Medicine La Antigua (Guatemala), March 2025

Review

González Pérez, V.

Treatment of Cervical Cancer With Brachytherapy: State of the Art and Future Perspectives

ALFIM 2025. La Antigua (Guatemala), March 2025

Presentation

González Pérez, V.

NATIONAL CONFERENCES

Comparison of Optimisation Methods in Radiosurgery for Multiple Metastases: HyperArc vs Conventional Techniques in Eclipse

9th SEFM-SEPR Joint Congress. Toledo, June 2025

Oral presentation

Ripollés Pallarés, M., Angulo Santos, A., Solla Bartual, C., Hernández Trujillo, M., González González, V., de los Dolores Alemany, V., Guardino de la Flor, C., Crispín Contreras, V.

Electronic Brachytherapy in Early-Stage Cervical Cancer: A Multicentre Study

9th SEFM-SEPR Joint Congress. Toledo, June 2025

Oral presentation

Lozares Cordero, S., González Pérez, V., Pellejero Pellejero, S., Fuentemilla Urío, N., Expósito, H.P., Gandía Martínez, A.

Innovation in Superficial Treatments with Open Radionuclides (Rhenium-188):
Optimisation of Dosimetry and Radiation Protection Using Monte Carlo Simulations
Toledo, June 2025

Oral presentation

Lozares Cordero, S., Vijande Asenjo, J., Tur, P., González Pérez, V., Rembielak, A.

Reirradiation Protocol in Lung Cancer: A Retrospective Study

Toledo, June 2025

Oral presentation

Angulo Santos, A., González Pérez, V., Chust Vicente, M., Vercher Ferrer, M., Cediell
Polo, D., Pallarés Ripollés, M., Solla Bartual, C., Crispín Contreras, V.

Dose Summation EBRT + BT

23rd SEOR-SEFM Brachytherapy Meeting Pamplona, October 2025

Presentation

González Pérez, V.

New Technologies Applied to Brachytherapy

23rd SEOR-SEFM Brachytherapy Meeting. Pamplona, October 2025

Moderator

González Pérez, V.

Oral Presentations in Brachytherapy

9th SEFM-SEPR Joint Congress. Toledo, May 2025

Moderator

González Pérez, V.

Simulation of a Monte Carlo Shielding on a Gynaecological Applicator for Dose
Modulation of Intensity in Electronic Brachytherapy in Cervical Cancer

9th SEFM-SEPR Joint Congress. Toledo, June 2025

Poster presentation

Pallarés Ripollés, M., González Pérez, V., Oliver Gil, S., Giménez Alventosa, V., Lozares
Cordero, S., Angulo Santos, A., Solla Bartual, C., Crispín Contreras, V.

23rd SEOR-SEFM Brachytherapy Meeting. Pamplona, October 2025

Attendance

González Pérez, V.

9th SEFM-SEPR Joint Congress. Toledo, May 2025

Attendance

González Pérez, V.

Member of the Scientific Committee and the Organising Committee of the 9th SEFM-
SEPR Joint Congress

9th SEFM-SEPR Joint Congress. Toledo, May 2025

Organiser / Coordinator role

González Pérez, V.

COURSES

5th RSEF/IFIMED Meeting on Medical Physics. Valencia, October 2025.

Crispín Contreras, V.

Organiser / Coordinator role

GEC-ESTRO Workshop 2025

Attendees: González Pérez, V.

Belgrade, November 2025

Master's Degree in Medical Physics at the University of Valencia, Faculty of Physics
2024-2025

Attendees: Postgraduate Students

Valencia, October 2025 (b-Learning)

Technique-Based Dose Delivery Optimization

Optimization Management of Early HPV

Speaker: Head & Neck ESTRO Focus Group

April 2025. Online

DIRECTION OF MASTER'S DISSERTATION

Design and Development of a Gynaecological Applicator in Cervical Cancer

Ripollés Pallarés, M.

Valencia, September 2025

González Pérez, V.

RADIOLOGY

ARTICLES IN INTERNATIONAL JOURNALS

A systematic review and meta-analysis on the diagnostic accuracy of artificial intelligence and computer-aided diagnosis of lumbar prolapsed intervertebral disc
Arana, E.

Neurosci Inform, 2025;5(4):100235
10.1016/j.neuri.2025.100235

Bone remodeling, not inflammation, as the predominant pathology in modic type 1 lesions of the lumbar spine

Kovacs, F., Arana, E.

Pain Med, 2025;10
10.1093/pm/pnaf142

Can we rely on magnetic resonance imaging for prostate cancer detection and surgical planning? Comprehensive analysis of a large cohort of patients undergoing transperineal mapped biopsies

Díez, NG., de Pablos-Rodríguez, P., Sánchez-Mateos Manzaneque, D., Martín García, M.I., Gómez, P.P., Benito, M.B., Calatrava Fons, A., Patiño, J.A., Boronat Catalá, J., Gómez-Ferrer Lozano, A., Gutiérrez, A.W., Cortés, A.G., Backhaus, M., Casanova Ramón Borja, J., Beamud Cortés, M., Domínguez Escrig, J.L., García, A.

World J Urol, 2025;12(1):164
10.1007/s00345-025-05534-3

Confocal microscopy for immediate analysis of prostate biopsies

Rodríguez Concha, C., de Pablos-Rodríguez, P., Calatrava Fons, A., Aliaga Patiño, J., Pelechano Gómez, P., Martín García, M.I., Boronat Catalá, J., Gómez-Ferrer Lozano, A., Beamud Cortés, M., García Cortés, A., Wong Gutiérrez, A., López González, J.A., Collado Serra, A., Domínguez-Escrig, J.L., Hassi Román, M., Casanova Ramón-Borja, J.

Minerva Urol Nephrol, 2025;77(1):85-90
10.23736/S2724-6051.25.06102-6 40183185

Do patients with lumbar spinal stenosis benefit from decompression of levels with adjacent moderate stenosis? A prospective cohort study from the NORDSTEN study

Kovacs, F., Arana Fernández de Moya, E.

Spine J, 2025;25(4):847
10.1016/j.spinee.2024.08.032 40107820.

Lumbar spine MRI reporting: AI caveats hamper its boost

Arana, E., Kovacs, F.

Eur J Radiol, 2025;183:111904
10.1016/j.ejrad.2024.111904 39740599.

The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy

Zhang, K., Teoh, J., Laguna, P., Domínguez-Escrig, J.L., Barret, E., Casanova Ramón-Borja, J., Muir, G., Bohr, J., Pelechano Gómez, P., de Reijke, T.M., Ng, C.F., Leung, C.H., Sánchez-Salas, R., de la Rosette, J.

BJU, 2025;136(1):120-127

10.1111/bju.16720 40183286

ARTICLES IN NATIONAL JOURNALS

Automated structural analysis of vertebrae using semantic segmentation and numerical methods

Gandía-Vañó, B., Nadal Soriano, E., Navaro-Jiménez, J.M., Arana, E., Ródenas García, J.J.

Anales de Ingeniería Mecánica, 2025;1(24)

10.63450/aim.1.283.2025

Radiological diagnosis of malignant spinal cord compression syndrome: Consensus document from SENR, SERAU, SERME and SERAM

Pérez Lara, A., Arana, E., Bello Báez, A., de Araujo Martins-Romeo, D.

Radiología (Engl Ed), 2025;67(3):384-394

10.1016/j.rxeng.2024.12.001 40412852

Local recurrence after radiotherapy or brachytherapy in prostate cancer: what to do? Comparative retrospective analysis between radical prostatectomy and salvage cryoablation

Martínez-Osorio, C., de Pablos-Rodríguez, P., Figueroa, N., Cortés, M., Castañé, C., Gómez-Ferrer, A., Gutiérrez, A., Pérez, Y., Beneito, B., Calatrava Fons, A., Aliaga, J., Cortés, Á., González, J.A., Rodríguez-Part, V., Pelechano Gómez, P., Borja, J.L.

Actas Urológicas Españolas, 2025

10.1016/j.acuro.2025.501914

NATIONAL CONFERENCES

Automated Structural Analysis of Vertebrae Using Semantic Segmentation and Numerical Methods

25th National Congress Of Mechanical Engineering. Santander, June 2025.

Oral presentation

Gandía-Vañó, B., Nadal Soriano, E., Navaro-Jiménez, J.M., Arana, E., Ródenas García, J.J.

Abdominal Complications in Oncology Patients Undergoing Treatment

Annual Meeting of the Valencian Society of Radiology (SRCV). Valencia, February 2025

Presentation

Pelechano Gómez, P.

Current Status of Imaging in Laryngeal Cancer
76th National Congress of ENT. Madrid, October 2025
Presentation
Arana Fernández de Moya, E.

Imaging Techniques in Skin Cancer
52nd NATIONAL CONGRESS OF DERMATOLOGY AND VENERELOGY. Valencia, May 2025
Presentation
Arana Fernández de Moya, E.

COURSES

11th Update Meeting on Breast Imaging. Madrid, February 2025
Attendance
Asensi Pérez, J.

Round Table – Clinical Cases "How Does AI Read It?"
2nd Training Meeting on Current Challenges in Prostate Cancer. Madrid, November 2025
Presentation
Pelechano Gómez, P.

13th ESUR Prostate MRI
Attendees: Pelechano Gómez, P.
Cambridge, June 2025

MANAGEMENT OF LOCALISED PROSTATE CANCER: Role of MRI in the Follow-Up of Patients on Active Surveillance and After Focal Therapy
Masterclass in Uro-Oncology: Prostate Cancer
Speaker: Pelechano Gómez, P.
May 2025. Valencia

PRESENT OF PROSTATE CANCER DIAGNOSIS: Should We Incorporate Artificial Intelligence?
Masterclass in Uro-Oncology: Prostate Cancer
Speaker: Pelechano Gómez, P.
May 2025. Valencia

Prostate MRI and Artificial Intelligence
Attendees: Pelechano Gómez, P.
November 2025. Online

Clinical Case Session: AI in Prostate Cancer
Attendees: Pelechano Gómez, P.
June 2025. Online

VIRADS Workshop: Clinical Applications and Training Course on Bladder MRI
Attendees: Pelechano Gómez, P.
Bilbao, October 2025

PEER REVIEW ACTIVITY

European Journal of Radiology
Arana Fernández de Moya, E.

European Radiology
Arana Fernández de Moya, E.

Neuroradiology
Arana Fernández de Moya, E.

PLOS One
Arana Fernández de Moya, E.

Radiology
Arana Fernández de Moya, E.

Spine
Arana Fernández de Moya, E.

CLINICAL DOCUMENTATION AND ADMISSIONS UNIT (CDAU)

NATIONAL CONFERENCES

ON PATIENT FALLS AND PRESSURE ULCERS: TRAINING AS A TOOL FOR PREVENTION
3RD ESSPPA Patient Safety Congress. Granada, June 2025

Poster presentation

Pascual-Plá F.J., Bosca-Mayans, M.R. Mancheño Álvaro, A. Martínez-Esteso, J. Trenor-Escuin, C. Arena, C.

INFORMATION SECURITY FOR CANCER PATIENTS, A KEY FACTOR IN QUALITY OF CARE: INFORMED CONSENT FOR PALLIATIVE SEDATION
3RD ESSPPA Patient Safety Congress. Granada, June 2025

Poster presentation

Pascual-Plá F.J., Bosca-Mayans, M.R. Mancheño-Álvaro, A. Martínez-Esteso, J. Trenor-Escuin, C. Muñoz-Balada, R.

COURSES

Empowerment and Equity: The Dual Gender Perspective in Healthcare

Online, March 2025

Attendance

Pascual Plá, F.J.

Conference on Aggressions Against Healthcare Professionals

Online, March 2025

Attendance

Pascual Plá, F.J.

AI Without Borders: Transforming Global Health Care

Online, April 2025

Attendance

Pascual Plá, F.J.

Microsoft Healthcare Day - SEDISA. Spanish Society of Healthcare Executives

Madrid, April 2025

Attendance

Pascual Plá, F.J.

11th Forum on the National Health System Information System: The New Era in Health Data Management

Online, April 2025

Martínez Esteso, J.

11th Forum on the National Health System Information System: The New Era in

Health Data Management
Online, April 2025
Pascual Plá, F.J.

Four Years of LORE: A Long Way to Go
Online, June 2025
Attendance
Pascual Plá, F.J.

Strategies, Experiences and Responsibilities in Preventing Surgical Site Infection
Valencia, October 2025
Attendance
Pascual Plá, F.J.

Designing the Future of Health Experience
Online, November 2025
Attendance
Pascual Plá, F.J.

Best Practices in Equality and the Environment
Attendees: Pascual Plá, F.J.
April 2025. Valencia

CIBERINFEC and Its Interactions With SEIMC_2025
Attendees: Pascual Plá, F.J.
March 2025. Online

Experience Management Everywhere
Attendees: Pascual Plá, F.J.
May 2025. Online

Patient Experience University: Your Pathway to Growth and Excellence
Attendees: Pascual Plá, F.J.
May 2025. Online

Reigniting the Human Experience: Strategies for Getting Back to Basics
Attendees: Pascual Plá, F.J.
April 2025. Online

Return on Human Experience: Eight Principles to Inspire Excellence in Healthcare
Attendees: Pascual Plá, F.J.
April 2025. Online

Rising Strong: Team Resilience Strategies
Attendees: Pascual Plá, F.J.
May 2025. Online

EMERGENCIES

COURSES

DOC Conference on Clinical Cancer Pain
Valencia, June 2025
Attendance
Pascual Plá, F.J.

Update on Invasive Fungal Infection
Attendees: Pascual Plá, F.J.
July 2025. Online

The Urgency of Breathing 2025
Attendees: Pascual Plá, F.J.
October 2025. Online

BEYOND IMMUNISATION: VACCINOLOGY COURSE
Attendees: Pascual Plá, F.J.
March 2025. Webinar:

Biennial Meeting on Aspergillosis in Critically Ill Patients
Attendees: Pascual Plá, F.J.
June 2025. Online

Advances in Depression Care: Enhancing Quality of Life With Rapid-Acting Therapeutics
Attendees: Pascual Plá, F.J.
March 2025. Webinar:

Non-Antimicrobial Alternatives Against Multidrug-Resistant Bacteria
Attendees: Pascual Plá, F.J.
April 2025. Webinar:

Effective Communication of Sensitive News in Oncology
Attendees: Pascual Plá, F.J.
February 2025. Valencia

Dengue Vaccine Effectiveness and Safety: What Do Real-World Data Tell Us?
Attendees: Pascual Plá, F.J.
March 2025. Webinar:

New Viruses, Old Challenges - West Nile Virus: Public Health Challenges and Control Strategies
Attendees: Pascual Plá, F.J.
June 2025. Online

An Updated Approach to the Management of Selected Infectious Processes Associated With Gram-Positive Pathogens
Attendees: Pascual Plá, F.J.
April 2025. Webinar

UROLOGY

ARTICLES IN INTERNATIONAL JOURNALS

A phase 2 randomized open-label study of oral Darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer
Gómez-Ferrer Lozano, A., Montorsi, F., Gandaglia, G., Barletta, F., Briganti, A., Bertrand, F., Tombal, B., Gómez-Veiga, F.
Eur Urol 2024, 2025
10.1016/j.euo.2025.01.012 39922738

Confocal microscopy for immediate analysis of prostate biopsies
de Pablos Rodríguez, P., Concha, C., Calatrava Fons, A., Aliaga Patiño, J., Pelechano Gómez, P., Martín García, M.I., Boronat Catalá, J., Gómez-Ferrer Lozano, A., Beamud Cortés, M., García Cortés, A., Wong Gutiérrez, A., López González, J.A., Collado Serra, A., Domínguez Escrig, J.L., Hassi Roma, M., Casanova Ramón Borja, J.
MINERVA UROLOGY AND NEPHROLOGY, 2025 77(5)
10.23736/S2724-6051.25.06102-6

Correction: Can we rely on magnetic resonance imaging for prostate cancer detection and surgical planning? Comprehensive analysis of a large cohort of patients undergoing transperineal mapped biopsies
De Pablos Rodríguez, P., Diez, N., Sánchez Mateos, D., Martín García, M.I., Pelechano Gómez, P., Barrios Benito, M., Calatrava Fons, A., Aliaga Patiño, J., Boronat Catalá, Juan., Gómez-Ferrer A., Wong Gutiérrez, A., García Cortés, A., Ramírez Backhaus, M., Casanova Ramón-Borja, J., Beamud Cortés, M., Domínguez Escrig, J.L., Coy García, A.
World Journal of Urology, 2025 43:164
10.1007/s00345-024-05233-5

Dynamic sentinel node biopsy in penile cancer: 25 years of experience at a tertiary oncology centre
Gómez-Ferrer Lozano, A., Rodríguez, C., Hassi, M., García, A., Calatrava, A., de Pablos Rodríguez, P., Casanova Ramón-Borja, J.L.,
2025
10.1016/j.acuroe.2025.501721 40107615 2025

Impact of the waiting list on oncological outcomes of radical prostatectomy in patients with intermediate- and high-risk prostate cancer
De Pablos Rodríguez, P., Guedes Oliva, P., Gómez-Ferrer, A., Beamud Cortés, M., Wong Gutiérrez, A., Gutiérrez Castañe, C., Calatrava Fons, A., Aliaga Patiño, J., García Cortés, A., Agustín López, J., Collado Serra, A., Rodríguez Part, V., Rodríguez Part, V., Casanova Ramón-Borja, J.
ACTAS UROLÓGICAS ESPAÑOLAS, 2025 50(1):5
10.1016/j.acuro.2025.501910

Oncological outcomes of patients undergoing radical prostatectomy with extended versus indocyanine-guided lymphadenectomy: mid-term follow-up person-allymph-Ca clinical trial

De Pablos Rodríguez, P., Ana Melendres, J.F., Martínez Osorio, C.A., Gómez-Ferrer Lozano, A., Beamud Cortés, M., Calatrava Fons, A., Patiño Aliaga, J., Hassi Roman, M., Rodríguez Part, V., Wong Gutiérrez, A., Casanova Ramón-Borja, J., Ramírez Backhaus, M.

Karger, 2025 16

10.1159/000548203

Oncological outcomes of primary prostate cancer patients treated with focal cryotherapy: does Gleason impact results?

Mate, K., de Pablos-Rodríguez, P., Burbano Herraiz, M., et al.

Research Square, 2025

10.21203/rs.3.rs-6285402/v1

Perioperative and oncological outcomes of distal ureterectomy for upper tract urothelial carcinoma (UTUC): a multicentre study in the European Association of Urology Non-muscle-invasive Bladder Cancer

Domínguez-Escrig, J.L., Soria, F., Liedberg, F., Stahl, E., Moschini, M., Pradere, B., D'Andrea, D., Teoh, J.Y., Capoun, O., Soukup, V., Bhavan, P., Birtle, A., Comérat, E.M., Mariappan, P., Van Rhijn, B., Baard, J., Seisen, T., Xylinas, E.N., Shariat, S.F., Gontero, P., Masson-Lecomte, A.

EUROPEAN UROLOGY ONCOLOGY, 2025 2588-9311(9)

doi.org 10.1016 j.euo.2025.12.002

Prostate-specific antigen response at six months predicts progression in metastatic hormone-sensitive prostate cancer treated with Apalutamide

De Pablos Rodríguez, P., Osorio, C.A., Sopeña Sutil, R., Vilaseca Cabo, A., Linares Espinos, E., Ramírez Backhaus, M., Gómez Rivas, J., Costa Planells, M., Martínez Breijo, S., Picola Brau, N., Domínguez Esteban, N., Muñoz Rodríguez, J., Sanchis Bonet, A., Guijarro Cascales, A., Beamud Cortés, M., Servian Vives, P., de la Morena Gallego, J.M., Pérez Marquez, M., García Sanz, M., Ramón Aleman, J., Zamora Horcajada, A., Rodríguez Part, V., Hassi Roman, M., Rodríguez Concha, C., Ríos González, E.,

Wiley, 2025 6

10.1002/pros.70040

PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signalling inhibitors

Martínez Corral, R., De Pablos Rodríguez, P., Bardella Altarriba, C., Vera Ballesteros, F.J., Abella Serra, A., Rodríguez Part, V., Martínez Corral, M.E., Picola Brau, N., López Abad, A., Gómez-Ferrer, A., Beamud Cortés, M., Suárez Novo, J.F., López González, P.A., García Puche, M., Álvarez Gracia, A.M., Pérez Fentes, D.

ELSEVIER, 2025 7

10.1016/j.urolone.2025.05.006 1078-1439

PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signalling inhibitors

Gómez-Ferrer Lozano, A., Martínez Corral, R., de Pablos Rodríguez, P., Bardella

Altarriba, C., Vera Ballesteros, F.J., Abella Serra, A., Rodríguez Part, V., Martínez Corral, M.E., Picola Brau, N., López Abad, A., Beamud Cortés, M., Suárez Novo, J.F., López González, P.A., García Puche, M., Álvarez García, A.M., Pérez Fentes, D.

Urol Oncol, 2025, 2025

10.1016/j.urolonc.202505.006 40441949

PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients: when is the optimal time point?

De Pablos Rodríguez, P., Martínez Corral, R., Pérez Fentes, D., Bardella Altarriba, C., Vera Ballesteros, F., Abella Serra, A., Antón Fuente, S., Martínez Corral, M.E., Picola Brau, N., López Abad, A., Gómez-Ferrer, A., Beamud Cortés, M., Suárez Novo, J.F., López González, P.A., García Puche, M., Álvarez Gracia, A.

ELSEVIER, 2025 7

10.1016/j.urolonc.2025.10.012

PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) PATIENTS: when is the optimal time point?

Gómez-Ferrer Lozano, A., Martínez Corral, R., Pérez Fuentes, D., Bardella Altarriba, C., Vera Ballesteros, F.J., Abella Serra, A., Antón Fuente, S., Martínez Corral, M.E., Picola Brau, N., López Abad, A., Beamud Cortés, M., Suárez Novo, J.F., López González, P.A., García Puche, M., Álvarez Gracia, A.M., de Pablos Rodríguez, P.

2025

10.1016/j.urolonc.2025.10.012 4126248

Use of Apalutamide in patients with metastatic hormone-sensitive prostate cancer diagnosed by conventional and next-generation testing: real-world data from 772 patients

De Pablos-Rodríguez, P., Roman, M., Mate, K., Zamora Horcajada, A., Guijarro Cascales, A., Sanchís Bonet, A., Vilaseca, A., Vázquez-Martul Pazos, D., Linares Espinós, E., Muñoz Rodríguez, J., De la Morena Gallego, J.M., Alemán, J.R., Gómez Rivas, J., Formisano, L., Juan Fita, M.J., Costa Planells, M., Domínguez Esteban, M., Pérez Marquez, M., García Sanz, M., García Esposito, N., Picola, N., Servian Vives, P., Sopena Sutil, R., Climent Durán, M.A., Ramírez Backhaus, M.

Actas Urológicas Españolas, 2025 50(1):8

10.1016/j.acuro.2025.501742

ARTICLES IN NATIONAL JOURNALS

Dynamic sentinel node biopsy in penile cancer: 25 years of experience at a tertiary oncology centre

De Pablos, P., C., Hassi, M., García, A., Calatrava, A., Casanova, J., Gómez-Ferrer, A. ACTAS UROLÓGICAS ESPAÑOLAS, 2025 501721(6)

10.1016/j.acuro.2025.501721

The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy

Domínguez Escrig, J., Zhang, K., Teoh, J., Laguna, P., Barret, E., Casanova

Ramón-Borja, J., Muir, G., Borh, J., Pelechano Gómez, P., de Reijke, T.M., Chi-Fai, N.

Chi-ho., L., Sánchez Salas, R., de la Rasette, J.
BJU INTERNATIONAL, 2025 8
10.1111 bju16720

INTERNATIONAL CONFERENCES

18TH Congress of the Ibero-American Society of Neurourology and Urogynaecology (SINUG). Vigo (Spain), November 2025

Attendance

Palop Moscardó, A.

Update on Bladder Cancer: Non-Muscle-Invasive. Muscle-Invasive
2025 EAU Guidelines Update - Renal, Bladder and Prostate. March 2025

Presentation

Domínguez Escrig, J.L.

Annual Meeting of the American Society of Clinical Oncology (ASCO)

Chicago, May 2025

Attendance

Gómez-Ferrer Lozano, A.

NATIONAL CONFERENCES

Robotic Group Meeting of the Spanish Association of Urology: Management of Sequelae Secondary to Lymphadenectomy in Urological Cancer

Bilbao, January 2025

Attendance

Gómez-Ferrer Lozano, A.

COURSES

6TH GIDO Meeting. Valencia, February 2025

Attendance

Palop Moscardó, A.

15TH GIDO MEETING on Lung Cancer: Advances, Realities and New Challenges in the Comprehensive Approach

Valencia, March 2025

Attendance

Palop Moscardó, A.

Physiotherapy in the Prevention and Treatment of Urinary Incontinence

Masterclass on Prostate Cancer. Valencia, May 2025

Presentation

Palop Moscardó, A.

Multidisciplinary Approach to Lung Cancer: A Practical Perspective

Valencia, May 2025

Attendance

Palop Moscardó, A.

Masterclass on Prostate Cancer

Paris, April 2025

Gómez-Ferrer Lozano, A.

Certificate at the Scientific Meeting "The Focal"

Attendees: Domínguez Escrig, J.

October 2025. Madrid

Robotic Cystectomy

Attendees: García Cortés, A.

Santander, June 2025

Robotic Cystectomy

Attendees: Gómez-Ferrer Lozano, A.

Santander, June 2025

Masterclass on Prostate Cancer

Speaker: Gómez-Ferrer Lozano, A.

February 2025.

Preceptorship in Prostate Cancer for Mexican Urologists

Speaker: Gómez-Ferrer Lozano, A.

June 2025. Valencia

Preceptorship in Prostate Cancer for Portuguese Urologists at IVO

Speaker: Gómez-Ferrer Lozano, A.

April 2025. Valencia

22nd AEU Urology Course for 5th-Year Residents

Speaker: Domínguez Escrig, J.

November 2025. Madrid

NURSING

NATIONAL CONFERENCES

28TH ANNUAL SVMN VALENCIA AND MURCIA MEETING. Elche, (Alicante), April 2025
Attendance
González García, S.

28TH ANNUAL SVMN VALENCIA AND MURCIA MEETING. Elche, (Alicante), April 2025
Attendance
Tormo Calabuig, V.

16th Nursing in Digestive Endoscopy Congress (AEEED)
Valencia, November 2025
Attendance
Gordo Caballero, S.

16th Nursing in Digestive Endoscopy Congress (AEEED)
Valencia, November 2025
Attendance
Picazo Ruiz, V.

16th Nursing in Digestive Endoscopy Congress (AEEED)
Valencia, November 2025
Attendance
Senent Noguera, A.

23rd ENT AND HEAD AND NECK SURGERY NURSING MEETING. Valencia, October 2025
Attendance
Coll Rodríguez, J.

23rd ENT AND HEAD AND NECK SURGERY NURSING MEETING. Valencia, October 2025
Attendance
Pérez Barros, P.

19th National Surgical Nursing Congress. Murcia, May 2025
Attendance
García Rodrigo, G.

76th National SEORL-CCC Congress
Madrid, October 2025
Attendance
García Rodrigo, G.

12th National Congress on Vascular Access and 1st International Congress on
Infusion Therapy
Pamplona, November 2025
Attendance
Fuentes Piquer, G.

ONCOLOGY WELL-BEING UNIT

ARTICLES IN INTERNATIONAL JOURNALS

ACCURACY OF THE "TIMED UP AND GO" TEST FOR PREDICTING LOW MUSCLE MASS IN A PREOPERATIVE PREHABILITATION PROGRAMME FOR COLORECTAL CANCER
Pérez-Santiago, L., Garzón-Hernández, L.P., Martín-Arévalo, J., Pla-Martí, V., Moro-Valdezate, D., Casado-Rodrigo, D., Riera-Cardona, M., Tarazona, N., Muresan, B.T., Wu Xiong, N.Y., Espí-Macías, A., García-Botello, S.
J Clin Med, 2025 14(6):2088
10.3390/jcm14062088.

NUTRITIONAL SUPPORT IN CANCER PATIENTS: PERCEPTION OF HEALTHCARE PROFESSIONALS AND PATIENTS
Morales Cerchiaro, A., Higuera, I., Maldonado, G.F., Canicoba, M., Sánchez-Migallón, J.M., Peiró, I., Domínguez, C., Ibarra, M., Salleras, N., Choulli, M., Muresan, B.T., Sendrós, M.J., Arribas, L., SENPE Working group
Nutr Hosp, 2025 42(3):602-609
10.20960/nh.05786

Unmet supportive care needs in cancer survivors in Spain: a multicentre cross-sectional study on prevalence and Sociodemographic and disease-related risk factors
Andreu, Y., Gil-Juliá, B., Picazo, C., García-Conde, A., Soto-Rubio, A.
Curr Oncol, 2025 32:524
10.3390/currncol32090524

CHAPTERS OF BOOKS

PART 10 - Continuous Care in Gynaecological Cancer: Chapter 114 - Communication in Oncology. Psychological Implications. Pages 715-719
Practical Manual of Gynaecological Oncology - 2ND Edition
García-Conde Benet, A.
Editorial Médica Panamericana. Madrid, 2025
9788411062213 (Print Version)

NATIONAL CONFERENCES

National Congress on Physical Exercise and Cancer
Castellón, 2025
Attendance
García Roca, M.E.

The Role of Radiofrequency in the Physiotherapy Management of Side Effects in Cancer Patients

7th Spanish Breast Congress. Madrid, October 2025
Presentation
Bañuls Sendra, E.

SEMiPyP Congress. Barcelona, February 2025
Attendance
Scorojanu, I.A.

6th National Congress on Multimodal Rehabilitation. Tarragona, March 2025
Attendance
Scorojanu, I.A.

COURSES

Well-Being in Cancer Patients Workshop
5TH Update Meeting on Oncology for Primary Care. Valencia, November 2025
Presentation
García-Conde, A., García, E., Gea, S., Scorojano, I.

5th Update Meeting on Oncology for Primary Care
Valencia, November 2025.
Presentation
García Roca, M.E.

5th Update Meeting on Oncology for Primary Care
Valencia, November 2025.
Presentation
del Cerro Arastey, M.

MEETING OF RESEARCHERS IN CANCER - CIUTAT D'ALCOI
Alcoy, May 2025
Organiser / Coordinator role
García Roca, M.E.

Communication With the Patient: What to Communicate and How to Communicate It
15TH GIDO Meeting on Lung Cancer Valencia, March 2025
Oral presentation
Romero Retes, R.

MULTIDISCIPLINARY APPROACH TO LUNG CANCER: A Practical Perspective
Valencia, May 2025
Attendance
Bañuls Sendra, E.

1st Nutrition Meeting of SVHaD. Valencia, January 2025
Attendance
Scorojanu, I.A.

1st Multidisciplinary Meeting on Surgical Prehabilitation in Frail Patients

Madrid, June 2025

Attendance

Scorojanu, I.A.

Meeting for Nutritionists: "Toxicities of Targeted Cancer Treatments and Their Nutritional Impact"

November 2025

Attendance

Scorojanu, I.A.

Update Meeting on Oncology for Primary Care Physicians

Valencia, November 2025.

Presentation

Scorojanu, I.A.

"One Ball One Hour" Meeting

Puerto de Sagunto, February 2025

Presentation

Scorojanu, I.A.

Training Course on Lymphology

Attendees: Bañuls Sendra, E.

February 2025.

1st Exercise and Nutrition in Cancer Course

Speaker: Scorojanu, I.A.

Valencia, November 2025

Approach to Eating Disorders in Clinical Practice

Attendees: Scorojanu, I.A.

Online, 2025

Advanced Course in Nutritional Ultrasound

Attendees: Scorojanu, I.A.

Málaga, October 2025

Physical Exercise for the Oncology Population Course

Speaker: García Roca, M.E.

Valencia, 2025

OncoHab360 Course: "Challenges in the Onco-Surgical Patient: Can We Anticipate Prehabilitation?"

Attendees: Scorojanu, I.A.

Madrid, February 2025

Training Programme on the Design of Physical Activity and Exercise Programmes in Oncology

Speaker: García Roca, M.E.

Valencia, 2025

University Master's Degree in Therapeutic Exercise in Oncology for Physiotherapists
Speaker: García Roca, M.E.
Valencia, 2025

University Master's Degree in Personal Training for Cancer Patients
Speaker: García Roca, M.E.
Valencia, 2025

Postgraduate Specialisation in Physical Activity and Oncology
Speaker: García Roca, M.E.
Castellón, 2025

Training Programme in Body Composition and Bioimpedance
Attendees: Scorojanu, I.A.
Online, 2025

DIRECTION OF MASTER'S DISSERTATION

Influence of Nutraceutical Use in the Prevention and Treatment of Breast Cancer
Valencia, June 2025
Muresan, B.T.

The Ketogenic Diet as a Complementary Nutritional Strategy in Pancreatic Cancer
Valencia, June 2025
Muresan, B.T.

Dietary and Nutritional Recommendations for the Prevention of Colon Cancer:
Literature Review
Valencia, June 2025
Muresan, B.T.

DOCTORAL THESES

Benefits of an Online Physical Exercise Programme, Delivered via Streaming and Supervised, in Patients With Breast Cancer During Oncological Treatment. A Clinical Trial
Defended by: García Roca, M.E.
Universitat Jaume I (Castellón), February 2025
Collado Boira, E.J., Hernándo Domingo, C.



VALENCIAN ONCOLOGY
INSTITUTE FOUNDATION

C/ Profesor Beltrán Báuena, 8 - 46009
Valencia - Tel: +34 96 111 40 00

www.ivo.es

